Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 1 of 176 
CONFIDENTIAL    
Title Page  
Protocol Title:  A Phase 1b Study Evaluating the Safety and 
Efficacy of AMG  757 in Combination with 
AMG  404 in Subjects with Small Cell Lung 
Cancer (SCLC)  
Short Protocol Title:  AMG 757 and AMG 404 in Subjects with Small 
Cell Lung Cancer (SCLC)  
Protocol Number:  20200439  
Investigational Product:  Tarlatamab (AMG  757), AMG  404  
Trade Name:  Not Applicable  
Sponsor  Name of Sponsor:  Amgen, Inc.  
Address:  One Amgen Center Drive  
Thousand Oaks, CA, 91329, USA  
Telephone Number:  +1 805 -447-1000  
Protocol 
Approver  Name:  , MD  
Function:  Vice President Early Development, TA Head 
Oncology  
 
Key 
Sponsor 
Contact  Name:  , MD  
Address:  One Amgen Center Drive  
Thousand Oaks, CA, 91329, USA  
Telephone Number:  
Email Address:  
 
EudraCT Number:  2020 -005957 -26 
Study ID: [REMOVED]  
Protocol Version Date:  Document Version  Date  
Original  10 February 2021  
Amendment 1  26 July 2021  
Amendment 2  28 January 2022  
Amendment 3  04 April 2023  
Amendment 4  10 November 2023  
Amendment 5  05 June 2024  
 
Data Elements Standards 
Version:  8 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 2 of 176 
CONFIDENTIAL    
This protocol was developed, reviewed, and approved in accordance with Amgen’s 
standard operating procedures.  This format and content of this protocol is aligned with 
Good Clinical Practice:  Consolidated Guidance (ICH E6).  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 3 of 176 
CONFIDENTIAL    
Confidentiality Notice  
 This document contains confidential information of Amgen In c. 
This document must not be disclosed to anyone other than the site study staff 
and members of the institutional review board/independent ethics 
committee/institutional scientific review board or equivalent.  
The information in this document cannot be used  for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent 
of Amgen Inc.  
If you have questions regarding how this document may be used or shared, call 
the Amgen Medical Information number:   US sites, 1 - 800-77-AMGEN; Canadian 
sites, 1 -866-50-AMGEN; Amgen’s general number in the US, 1 -805-447-1000.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 4 of 176 
CONFIDENTIAL    
Investigator’s Agreement:  
I have read the attached protocol entitled A Phase 1b Study Evaluating the Safety and 
Efficacy of AMG  757 in Combinatio n with AMG  404 in Subjects with Small Cell Lung 
Cancer (SCLC) , dated 05 June 2024 , and agree to abide by all provisions set forth 
therein.  
I agree to comply with the International Council for Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Pr actice (GCP), Declaration of Helsinki, and applicable 
national or regional regulations/guidelines.  
I agree to ensure that Financial Disclosure Statements will be completed by:  me 
(including, if applicable, my spouse or legal partner and dependent children ) and my 
sub-investigators (including, if applicable, their spouses or legal partners and dependent 
children) at the start of the study and for up to 1 year after the study is completed, if 
there are changes that affect my financial disclosure status.  
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of Amgen Inc.  
 
_______________________________  
Signature  
 
_______________________________  ____________________________  
Name of Investigator  Date (DD Month YYYY)  
 
_______________________________  
Title and Role of Investigator  
 
_______________________________  
Institution Name  
 
_______________________________  
Address and Telephone Number of Institution  
 
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 5 of 176 
CONFIDENTIAL    
Table of Contents   
Table of Contents  ................................ ................................ ................................ .. 5 
1. Protocol Summary  ................................ ................................ ................................  12 
1.1 Synopsis  ................................ ................................ ................................ ... 12 
1.2 Study Schema  ................................ ................................ ...........................  17 
1.3 Schedule of Activities (SoA)  ................................ ................................ ...... 19 
2. Introduction  ................................ ................................ ................................ ...........  24 
2.1 Study Rationale  ................................ ................................ .........................  24 
2.2 Background  ................................ ................................ ...............................  25 
2.2.1  Disease  ................................ ................................ .....................  25 
2.2.2  Amgen Investigational Product Background:  
Tarlatamab  ................................ ................................ ................  26 
2.2.2.1  Pharmacology  ................................ .........................  26 
2.2.2.2  Toxicology  ................................ ...............................  27 
2.2.2.3  Background Clinical Experience With 
Tarlatamab  ................................ ..............................  27 
2.2.3  Amgen Investigational Product Background:  
AMG  404 ................................ ................................ ...................  30 
2.2.3.1  Nonclinical Pharmacology  ................................ ....... 30 
2.2.3.2  Toxicology  ................................ ...............................  31 
2.2.3.3  Nonclinical Pharmacokinetics  ................................ .. 32 
2.2.3.4  Clinical Experience  ................................ ..................  32 
2.3 Benefit/Risk Assessment  ................................ ................................ ...........  34 
2.3.1  Therapeutic Context  ................................ ................................ .. 34 
2.3.2  Key Benefits  ................................ ................................ ..............  34 
2.3.3  Key Safety Information  ................................ ..............................  34 
2.3.3.1  Tarlatamab  ................................ ..............................  34 
2.3.3.2  AMG  404 ................................ ................................ . 36 
2.3.3.3  Key Risks for Tarlatamab in Combination 
with AMG  404................................ ..........................  38 
3. Objectives and Endpoints/Estimands  ................................ ................................ .... 40 
4. Study Design  ................................ ................................ ................................ ........  40 
4.1 Overall Design  ................................ ................................ ..........................  40 
4.2 Patient Input into the Study Design  ................................ ...........................  46 
4.3 Justification for Dose  ................................ ................................ .................  46 
4.4 Justification for Investigational Product Dose  ................................ ............  46 
4.4.1.1  Tarlatamab  ................................ ..............................  46 
4.4.1.2  AMG  404 ................................ ................................ . 47 
4.5 End of Study  ................................ ................................ .............................  48 
5. Study Population  ................................ ................................ ................................ .. 48 
5.1 Inclusion Criteria  ................................ ................................ .......................  48 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 6 of 176 
CONFIDENTIAL    
5.2 Exclusion Criteria  ................................ ................................ ......................  50 
5.3 Subject Enrollment  ................................ ................................ ....................  53 
5.4 Screen Failures  ................................ ................................ .........................  53 
6. Study Intervention  ................................ ................................ ................................ . 54 
6.1 Study Interventions Administered  ................................ ..............................  54 
6.1.1  Investigational Products  ................................ ............................  54 
6.1.2  Non-investigational Products  ................................ .....................  56 
6.1.3  Medical Devices  ................................ ................................ ........  56 
6.1.4  Other Protocol -required Therapies  ................................ ............  56 
6.1.5  Other Intervention Procedures  ................................ ...................  56 
6.1.6  Product Complaints  ................................ ................................ ... 57 
6.1.7  Excluded Treatments, Medical Devices, and/or 
Procedures During Study Period  ................................ ...............  57 
6.2 Dose Modification  ................................ ................................ ......................  58 
6.2.1  Dose Cohort Study Escalation/De -escalation and 
Stopping Rules  ................................ ................................ ..........  58 
6.2.1.1  Dose -Exploration  ................................ .....................  58 
6.2.1.2  Dose Level Review Team ................................ ........  58 
6.2.1.3  Step Dosing  ................................ ............................  58 
6.2.1.4  Dose -limiting Toxicities  ................................ ............  58 
6.2.2  Dosage Adjustments, Delays, Rules for Withholding or 
Restarting, Permanent Discontinuation  ................................ ..... 59 
6.2.2.1  Amgen Investigational Product:  
Tarlatamab  ................................ ..............................  59 
6.2.2.2  Amgen Investigational Product:  AMG  404 ..............  62 
6.2.3  Hepatotoxicity Stopping and Rechallenge Rules  .......................  72 
6.3 Preparation/Handling/Storage/Accountability  ................................ ............  72 
6.4 Measures to Minimize Bias:  Randomization and Blinding  .........................  72 
6.4.1  Method of Tr eatment Assignment  ................................ ..............  72 
6.4.2  Blinding  ................................ ................................ .....................  72 
6.5 Treatment Compliance  ................................ ................................ ..............  72 
6.6 Treatment of Overdose  ................................ ................................ .............  72 
6.7 Prior and Concomitant Treatment  ................................ .............................  73 
6.7.1  Prior Treatment  ................................ ................................ .........  73 
6.7.2  Concomitant Treatment  ................................ .............................  73 
6.8 Support Care and Potential Risk Management Guidelines for 
Tarlatamab  ................................ ................................ ................................  74 
6.8.1  Cytokine  Release Syndrome  ................................ .....................  74 
6.8.2  Immune -effector Cell -associated Neurologic 
Syndrome  ................................ ................................ ..................  78 
6.8.3  Neurologic Events  ................................ ................................ ..... 80 
6.8.4  Pituitary Dysfunction  ................................ ................................ .. 81 
6.8.5  Neutropenia  ................................ ................................ ...............  83 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 7 of 176 
CONFIDENTIAL    
6.8.6  Tumor Lysis Syndrome  ................................ ..............................  85 
6.8.7  Vaccines  ................................ ................................ ....................  85 
6.8.8  Management of SARS -CoV-2 Infection and COVID -19 
Disease  ................................ ................................ .....................  85 
7. Discontinuation of Study Treatment and Subject 
Discontinuation/Withdrawal  ................................ ................................ ...................  88 
7.1 Discontinuation of Study Treatment ................................ ...........................  88 
7.2 Continuation on Study Treatment After Radiologic Disease 
Progression  ................................ ................................ ...............................  89 
7.3 Subject Discontinuation/Withdrawal from the Study  ................................ .. 89 
7.3.1  Reasons for Removal from Study  ................................ ..............  90 
7.4 Lost to Follow -up ................................ ................................ .......................  90 
8. Study Assessments and Procedures  ................................ ................................ .... 90 
8.1 General Study Periods  ................................ ................................ ..............  91 
8.1.1  Screening, Enrollment and/or Randomization  ............................  91 
8.1.2  Treatment Period  ................................ ................................ ....... 91 
8.1.3  Safety Follow -up ................................ ................................ ........  92 
8.1.4  Long -term Follow -up ................................ ................................ .. 93 
8.1.5  End of Study  ................................ ................................ ..............  93 
8.2 General Assessments  ................................ ................................ ...............  93 
8.2.1  Informed Consent  ................................ ................................ ...... 93 
8.2.2  Demographics  ................................ ................................ ...........  93 
8.2.3  Medical History  ................................ ................................ ..........  93 
8.2.4  Physical Examination  ................................ ................................  94 
8.2.5  Physical Measurements  ................................ ............................  94 
8.2.6  Substance Abuse History  ................................ ..........................  94 
8.2.7  Performance Status  ................................ ................................ ... 94 
8.3 Efficacy Assessments  ................................ ................................ ...............  94 
8.3.1  Radiologic Imaging Assessment  ................................ ................  94 
8.4 Safety Assessments  ................................ ................................ ..................  96 
8.4.1  Vital Signs and Pulse Oximetry  ................................ .................  96 
8.4.2  Neurological Examination  ................................ ..........................  97 
8.4.3  Writing Test  ................................ ................................ ...............  97 
8.4.4  Mini-Mental Status Examination  ................................ ................  97 
8.4.5  Electrocardiograms (ECGs)  ................................ .......................  97 
8.4.6  Clinical Laboratory Assessments  ................................ ...............  98 
8.4.7  Vital Status  ................................ ................................ ................  98 
8.4.8  Other Safety  ................................ ................................ ..............  98 
8.4.8.1  Echocardiogram (ECHO)/Multigated 
Acquisition (MUGA) Scan  ................................ ........  98 
8.4.8.2  Hypersensitivity  ................................ .......................  99 
8.4.9  Adverse Events and Serious Adverse Events  ............................  99 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 8 of 176 
CONFIDENTIAL    
8.4.9.1  Time Period and Frequency for Collecting 
and Reporting Safety Event Information  ..................  99 
8.4.9.2  Method of Detecting Adverse Events and 
Serious Adverse Events  ................................ ........  100 
8.4.9.3  Follow -up of Adverse Events and Serious 
Adverse Events  ................................ .....................  100 
8.4.9.4  Regulatory Reporting Requirements for 
Serious Adverse Events  ................................ ........  101 
8.4.9.5  Safety Monitoring Plan  ................................ ..........  101 
8.4.9.6  Pregnancy and Lactation  ................................ ....... 102 
8.5 Pharmacokinetic Assessments  ................................ ................................  102 
9. Statistical Considerations  ................................ ................................ ....................  105 
9.1 Statistical Hypotheses  ................................ ................................ .............  105 
9.2 Sample Size Determination  ................................ ................................ ..... 105 
9.3 Populations for Analysis  ................................ ................................ ..........  106 
9.3.1  Covariates  ................................ ................................ ...............  107 
9.4 Statistical Analyses  ................................ ................................ .................  107 
9.4.1  Planned Analyses  ................................ ................................ .... 107 
9.4.1.1  Interim Analysis and Early Stopping 
Guidelines  ................................ .............................  107 
9.4.1.2  Primary Analysis  ................................ ...................  110 
9.4.1.3  Final Analysis  ................................ ........................  110 
9.4.2  Methods of Analyses  ................................ ...............................  110 
9.4.2.1  General Considerations  ................................ .........  110 
9.4.2.2  Efficacy Analyses  ................................ ..................  110 
9.4.2.3  Safety Analyses  ................................ ....................  111 
9.4.2.4  Other Analyses  ................................ ......................  112 
9.4.2.5  Adaptive Design  ................................ ....................  112 
10. References  ................................ ................................ ................................ .........  114 
11. Appendices  ................................ ................................ ................................ .........  117 
11.1  Appendix 1.  List of Abbreviations  ................................ ...........................  118 
11.2  Appendix 2.  Clinical Laboratory Tests  ................................ ....................  123 
11.3  Appendix 3.  Study Governance Considerations  ................................ ..... 126 
Dose Level Review  Meetings (DLRM)  ................................ .....................  126 
Regulatory and Ethical Considerations  ................................ ....................  127 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 9 of 176 
CONFIDENTIAL    
Informed Consent Process  ................................ ................................ ...... 128 
Data Protection/Subject Confidentiality  ................................ ...................  130 
Publication Policy  ................................ ................................ ....................  131 
Investigator Signatory Obligations  ................................ ...........................  132 
Data Quality Assurance  ................................ ................................ ...........  132 
Source Documents  ................................ ................................ ..................  133 
Study and Site Closure ................................ ................................ ............  134 
Compensation  ................................ ................................ .........................  135 
11.4  Appendix 4.  Safety Events:  Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  ................................ ..... 136 
Definition of Adverse Event  ................................ ................................ ..... 136 
Definition of Serious Adverse Event  ................................ ........................  137 
Recording Adverse Events and Serious Adverse Events  ........................  138 
Evaluating Adverse Events and Serious Adverse Events  ........................  139 
Reporting of Serious Adverse Event  ................................ ........................  140 
11.5  Appendix 5.  Contraceptive Guidance and Collection of 
Pregnancy and Lactation Information  ................................ ......................  145 
Definition of Females of Childbearing Potential  ................................ ....... 145 
Collection of Pregnancy Information  ................................ ........................  146 
Collection of Lactation Information  ................................ ..........................  148 
11.6  Appendix 6.  Sample Storage and Destruction  ................................ ........  151 
11.7  Appendix 7.  Hepatotoxicity Stopping Rules:  Suggested Actions 
and Follow -up Assessments an d Study Treatment Rechallenge 
Guidelines  ................................ ................................ ...............................  153 
Criteria for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -
required Therapies Due to Potential Hepatotoxicity  .................  153 
Criteria for Rechallenge of Amgen Investigational Product and 
Other Protocol -required Therapies After Potential 
Hepatotoxicity ................................ ................................ ..........  154 
Drug -induced Liver Injury Reporting and Additional 
Assessments  ................................ ................................ ...........  155 
11.8  Appendix 8.  Performance Status According to Eastern 
Cooperative Oncology Group (ECOG)  ................................ ....................  157 
11.9  Appendix 9.  Mo dified Response Evaluation Criteria in Solid 
Tumors Version 1.1 (Modified RECIST 1.1)  ................................ ............  158 
11.10  Appendix 10.  Sc hedule of Activities:  ................................ .......................  162 
 
List of Tables  
Table 1 -1.  Summary of Single Step Dosing Schedule of Tarlatamab  to 
Mitigate  Cytokine Release Syndrome (CRS) During Cycle  1 .................  19 
Table 1 -2.  Schedule of Activities:  Tarlatamab Monotherapy  ................................ ........  20 
Table 2 -1.  Key Sa fety Risk of Tarlatamab  ................................ ................................ .... 35 
Table 2 -2.  Key Safety Risks of AMG  404 ................................ ................................ ...... 37 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 10 of 176 
CONFIDENTIAL    
Table  2-3.  Potential Safety Concerns Based on Drug Class Effects, 
Biological Mechanism of Action, and Nonclinical Studies  ........................  38 
Table 4 -1.  Planned Target Doses per Dose Cohort Level  ................................ .............  41 
Table 4 -2.  Guideline for Escalation/De -escalation  ................................ ........................  44 
Table 6 -1.  Investigational Products  ................................ ................................ ...............  55 
Table  6-2.  AMG  404 Dose Modification and Toxicity Management Guidelines 
for Immune -Related Adverse Events  ................................ ......................  63 
Table 6 -3.  Management of Infusion -Related Reactions With AMG  404 ........................  70 
Table 6 -4.  Grading and Management of Cytokine Release Syndrome ..........................  75 
Table 6 -5  ASBMT Immune Effector Cell -associated Neurotoxicity Syndrome 
(ICANS) Consensus Grading for Adults  ................................ ..................  79 
Table 6 -6.  Management of Adverse Events Related to Neurologic Events  ...................  80 
Table 6-7  Monitoring and Management of Pituitary Gland Dysfunction 
(González -Rodríguez and Rodríguez -Abreu, 2016; Brahmer et 
al, 2018)  ................................ ................................ ................................ . 82 
Table  6-8.  Tarlatamab Dose Modification Guidelines for Neutropenia  ..........................  84 
Table  6-9.  Infusion Interruptions/Delays/Withholding/Permanent 
Discontinuation and Management of SARS -CoV-2 Infection 
and COVID -19 Disease  ................................ ................................ ..........  86 
Table 9 -1.  Probability of Observing at Least 1 DLT ................................ .....................  106 
Table  9-2.  Stopping Boundary for Dose Expansion with Posterior Probability 
of 80 and Grade  4 or Higher Treatment -related Adverse 
Event Limit of 20  ................................ ................................ ................  108 
Table 9 -3 Operating Characteristics with  Batch Size of  Subjects  ............................  108 
Table  9-4.  The Criteria for Evaluating the Use of Siltuximab  ................................ ....... 109 
Table 11 -1.  Analyte Listing  ................................ ................................ .........................  124 
Table 11 -2.  DILI Potential Analyte Listing  ................................ ................................ ... 125 
Table  11-3.  Conditions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -required 
Therapies Due to Potential Hepatotoxicity  ................................ ............  154 
Table 11 -4.  List of Schedule of Activities Tables  ................................ .........................  162 
Table 11 -5.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only 
(AMG  404 Administered )  ................................ ............................  163 
Table 11 -6.  Schedule of Activities:  One -Step Dosing – Cycle  1 Only 
(AMG  404 Administered ) ................................ ............................  166 
Table 11 -7.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only 
(AMG  404 Administered )  ................................ ..........................  169 
Table 11 -8.  Schedule of Activities:  Cycle 2 and Beyond (If AMG 404 was 
Administered on or 8 in Cycle  1) ................................ .................  171 
Table 11 -9.  Schedule of Activities:  Cycle 2 and Beyond (If AMG 404 was 
Administered on in Cycle  1) ................................ ......................  173 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 11 of 176 
CONFIDENTIAL    
List of Figures  
Figure 1 -1.  Study Schemac ................................ ................................ ...........................  17 
Figure  4-1.  Part 1 Tarlatamab and AMG  404 Planned Dose Levels  ..............................  43 
Figure  11-1.  Sample Electronic Serious Adverse Event Contingency Report 
Form (paper -based form)  ................................ ................................ ...... 142 
Figure  11-2.  Pregnancy and Lactation Notification Forms  ................................ ...........  149 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 12 of 176 
CONFIDENTIAL    
1. Protocol Summary   
1.1 Synopsis   
Protocol Title:   A Phase 1b Study Evaluating the Safety and Efficacy of AMG  757 in 
Combination with AMG  404 in Subjects with Small Cell Lung Cancer (SCLC)  
Short Protocol Title:   AMG 757 and AMG 404 in Subjects with Small Cell Lung Cancer 
(SCLC)  
Study Phase:   1b 
Indication:   Small cell lung cancer (SCLC)  
Rationale  
Delta -like protein 3 (DLL3), a non -canonical Notch ligand, is a promising target for the 
development of T -cell directed therapies due to its high expression on the cell surface  of 
neuroendocrine tumor cells, and minimal, mainly cytoplasmic localization in normal 
tissues (Owen et al, 2019).  Tarlatamab (International Nonproprietary Name 
[INN];  AMG  757) is a half -life extended (HLE) bi -specific T -cell engager (BiTE®) molecule 
comb ining the binding specificities for DLL3 and cluster of differentiation 3 ( CD3) 
genetically fused to the N -terminus of a single chain immunoglobulin G (IgG) Fc 
(fragment crystallizable; single chain fragment crystallizable [scFc]) region.  Currently, 
tarlatamab is being evaluated in a phase  1 study (Study  20160323 ) of subjects with 
small cell lung cancer (SCLC).  
AMG  404 is a fully human antibody that binds human programmed cell death -1 (PD -1) 
with high affinity and blocks the ability of this receptor to int eract with its ligands, 
programmed death -ligand  1 (PD -L1) and programmed death -ligand  2 (PD -L2).  
AMG  404 has been  evaluated as a monotherapy agent  in a phase  1 study 
(Study  20180143) of subjects with advanced or metastatic solid tumors.  
Pembrolizumab (Key truda) and nivolumab (Opdivo), both antibodies blocking human 
PD-1, were approved by the United States food and drug administration ( US FDA ) 
under the accelerated approval program for treatment of patients with metastatic SCLC 
who have progression after platinum -based chemotherapy and at least 1  other line of 
therapy (Keytruda United states prescribing information [ USPI ], 2020; Opdivo 
USPI, 2019), based on relatively low response rates (19  with pembrolizumab and 12  
with nivolumab; Keytruda  USPI, 2020; Opdivo USPI, 2019).  However, both approvals 
were subsequently withdrawn after confirmatory  studies  did not  meet their primary  
endpoint  of overall survival (OS)  (Merck, 2021; Bristol Myers Squibb, 2020).  These data 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 13 of 176 
CONFIDENTIAL    
suggest that immune checkpoint inhibition may need to be combined with other 
therapies in second line or later.  
The combination of tarlatamab and anti -PD-1 antibodies increases T -cell mediated 
redirected lysis of tumor cells that express DLL3 in vitro as compared to tarlatamab 
alone.  In addition, upregulation of PD -1/PD -L1 in the tumor microenvironment is a 
mechanism of resistance to BiTE therapy that treatment with anti -PD-1 therapy may 
mitigate (Friberg and Reese, 2017; Köhnke et al, 2015).  These data support testing the 
combination of tarlatamab and AMG  404 in patients with SCLC.  
Objective(s) and Endpoint(s)  
 
Objectives  Endpoints  
Primary  
 To evaluate the safety, tolerability, 
and recommended phase  2 dose 
of tarlatamab in combination with 
AMG  404  Dose -limiting toxicities (DLTs), 
treatment -emergent and 
treatment -related adverse events, 
changes in vital signs, 
electrocardiograms (ECGs), and 
clinical laboratory tests  
Secondary  
 To evaluate anti -tumor activity of 
tarlatamab in combination with 
AMG  404  Objective response (OR) per 
modified response evaluation 
criteria in solid tumors (RECIST) 
v1.1, duration of response (DOR), 
disease control rate (DCR), 
progression -free survival (PFS), 
and overall survival (OS).   
 To characterize the 
pharmacokinetics (PK) of 
tarlatamab in combination with 
AMG  404  PK parameters including, but not 
limited to, maximum serum 
concentration (C max), minimum 
serum concentration (Cmin), and 
area under the concentration -time 
curve (AUC) over the dosing 
interval  
 
Overall Design  
This is a phase 1b, multicenter, open -label study evaluating the safety, tolerability, 
pharmacokinetics (PK) , pharmacodynamics (PD), and efficacy of tarlatamab  in 
combination with AMG  404 in subjects with SCLC.  The study will consist of dose 
exploration (Part 1) and dose expansion (Part 2).  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 14 of 176 
CONFIDENTIAL    
 
Part 1 (Dose Exploration)  
The dose exploration part of the study will estimate the recommended phase  2 dose 
(RP2D)  of tarlatamab in combination with AMG  404 using a modified toxicity probability 
interval (mTPI -2) design.  A combination RP2D may be identif ied based on emerging 
safety, efficacy, and pharmacodynamic data prior to reaching a maximum tolerated 
dose ( MTD ). 
Part 2 (Dose Expansion)  
Upon completion of Part 1 of the study, enrollment will commence in Part 2 to confirm 
the safety and tolerability of the selected dose and to further evaluate the efficacy of 
tarlatamab in combination with AMG  404. 
Number of Subjects  
Study enrollment ended in   A total of  subjects were enrolled in this 
study including  subjects in Part  1, and  subjects in Part  2. 
Summary of Subject Eligibility Criteria  
Adult subjects (≥ 18 years of age) with SCLC are eligible to enroll.  Subjects must have 
histologically or cytologically confirmed SCLC and have progressed or recurred following 
at least 1 platinu m-based regimen.  Subjects must have measurable disease per 
modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, have an 
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1, and adequate 
organ function (refer to incl usion criteria 107). 
For a full list of eligibility criteria, please refer to Section  5.1 to Section  5.2. 
Treatments  
Tarlatamab is an Amgen investigational product used in this study.  Tarlatamab  will be 
manufactured and packaged by Amgen Inc. and distributed using Amgen clinical study 
drug distribution procedures.  Tarlatamab  will be administered as a short -term 
intrave nous (IV) infusion (approximately 60 minutes [  10 minutes]  followed by a flush) 
on  in a  cycle beginning in cycle  2.  The starting dose of 
tarlatamab will be a target dose of  mg with 1 -step dosing.  The highest planned target 
dose of tarlatamab  will not exceed  mg using  regimen  
(see Section  4.1 for details on the starting dose).  To reduce the risk of cy tokine release 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 15 of 176 
CONFIDENTIAL    
syndrome (CRS), premedication with dexamethasone  mg IV (or equivalent dose of 
other corticosteroids) will be administered within 1 hour prior to all cycle  1 doses.  
Intravenous hydration (1L normal saline over 4 to 5 hours) will also be administered  
following administration of tarlatamab in cycle  1.  In addition, 1-step-dosing will be 
implemented in cycle  1 with  mg administered on cycle  1   Sites are required to 
have tocilizumab or siltuximab (if tocilizumab not available) on site f or potential treatment 
of CRS.  
AMG  404 is an Amgen investigational product used in this study.  AMG  404 will be 
manufactured and packaged by Amgen Inc. and distributed using Amgen clinical study 
drug distribution procedures.  AMG  404 will be administered a s a short -term IV infusion 
(30 minutes [  5 minutes])  (± 3 days) at a dose of  mg  (note if 
AMG  404 is initially administered on cycle  1  there will be a  interval 
between the  mg cycle  1  and  mg cycle  2-  dose).  Since treatment 
initiation with tarlatamab may result in CRS, the first dose of AMG  404 will be 
administered on either  in cycle  1, and subsequently  
(  beginning on cycle  2  or cycle  2  
 
Statistical Considerations  
A total of approximately  subjects were anticipated to be enrolled in the study (up to 
 subjects in a dose exploration phase and the remaining subjects enrolled in a dose 
expansion phase).  Up to  planned dose cohorts may be examined during dose 
exploration.  Each cohort will en roll  subjects.  Additional subjects can be enrolled if 
more data are needed.  Up to  subjects can be enrolled in dose exploration part.  At 
least  DLT - evaluable subjects need to be treated at a selected dose level.  For the 
Dose Exploration phas e, the sample sizes are empirically decided and consistent with 
conventional early oncology studies  with the objective to estimate the RP2D  and to 
evaluate safety and tolerability.  Formal safety interim analyses will be performed for 
every  subjects who  have had opportunity to have at least  of follow up since 
first dose of tarlatamab.  If the sample size in the dose expansion phase of 10 (or  20), 
there is 65  (88) probability of observing at least 1 adverse event with 10  incidence 
rate and the exact 95 confidence interval for 20  objective response (OR) is 3  to 
56 (6 to 44).  Study enrollment ended in .  A total of  subjects were 
enrolled including  subjects in Part  1, and  subjects in Part  2.   
For a full description of statistical analysis methods, please refer to Section  9. 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 16 of 176 
CONFIDENTIAL    
Statistical Hypotheses  
No formal statistical hypotheses will be tested.  
 
 
Sponsor Name:    Amgen, Inc.  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 17 of 176 
CONFIDENTIAL    
1.2 Study Schema   
Figure 1-1.  Study Schemac  
 
C  cycle; DLT  dose level toxicity; FIH  first-in-human; IV  intravenous;  PD  pharmacodynamics; Ph1  phase  1; PK  pharmacokinetics; 
a The starting dose and associated dosing schedule of tarlatamab will be a target dose of  mg with 1 -step dosing  
b If the combination is not tolerated (based on target DLT rate > 30 ), AMG  404 may be administered on cycle  1   Based upon emerging PK, PD, and safety 
data in the current study as well as the ongoing FIH study (20160323), alternative (intermediate) dose cohort levels,
as part of the de -escalation recommendations may be explored (see Section  4.1 and Figure  4-1 for study 
design details pertaining to footnote b)  
Study Periods : 
 Screening:  up to  before enrollment  
 Treatment:  treatment continues until confirmed radiographic progressi on or disease progression* 
 End of treatment:  should occur as soon as possible (within ) after the last dose of investigational product  
 Safety follow -up:  approximately after the end of the last dose of tarlatamab and approximately days after the last dose of AMG  404 
 Long -term follow -up:  every 3 months ( 2 weeks)  up to 1 year from the first dose of tarlatamab for all subjects who have not withdrawn consent by clinic visit, 
telephone, or chart review to assess for survival and/ or the commencement of subsequent cancer therapy only 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 18 of 176 
CONFIDENTIAL    
*Note: Subjects with confirmed disease progression per modified RECIST 1.1 criteria who have clinical benefit in the investig ator’s judgment may be allowed to 
continue treatment after approval by the Me dical Monitor as per Section 7.2.   
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024  Page 19 of 176 
CONFIDENTIAL    
1.3 Schedule of Activities (SoA)   
Table 1-1.  Summary of Single Step Dosing Schedule of Tarlatamab  to Mitigate  
Cytokine Release Syndrome (CRS) During Cycle  1  
Tarlatamab 
Step Dosing 
One-step First step dose  N/A Step dose  
(equal to Target 
dose)  Target dose  
N/A  not applicable  
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 20 of 176 
CONFIDENTIAL    
Table 1-2.  Schedule of Activities:  Tarlatamab Monotherapy   
STUDY PERIOD/ TREATMENT CYCLE  Every Cyclebb Every Other Cycle  EOTii SFU-1ee,hh SFU-2ff,hh LTFUaa 
WEEKb 1 3 1     
DAYb 
HOUR (relative to infusion)d Pre 757 EOI 757  Pre 757 EOI 757  Pre 757 EOI 757      
General/Safety Assessments  
Clinical Evaluatione X  X    X X X  
Vital signs, pulse oxf X  X    X X X  
12-lead ECGg Xcc  Xcc        
ECHO or MUGA            
Adverse event review  ========================================================= ➔  
Serious adverse event review  ========================================================= ➔ 
Prior/concomitant medication  ========================================================= ➔ 
Local Laboratory Assessments  
CBC with differential  X  X    X X X  
Coagulation  X      X X X  
Chemistry panelh X  X    X X X  
Lipase and Amylase  X       X   
Urinalysis      X      
Serum/urine pregnancy Testi X       X X  
Safety endocrine panelj X      X X   
CRP  X      X X   
Ferritin  X      X X   
Central and Biomarker Laboratory Tests  
Study Drug Administration  
Tarlatamab IV infusiont 
Hospital stayw 
 
MRI Brainx           
Radiological imaging and tumor burden 
assessmenty     X  Xz Xz  Xdd 
Survival Status and subsequent cancer 
therapyaa          X 
Page 1 of 1  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 21 of 176 
CONFIDENTIAL    
Abbreviations used:  0  Hour zero; when Tarlatamab is infused; ACTH  adrenocorticotropic hormone; BP  blood pressure; C   cycle; C1   cycle  1
CBC   complete blood count; CNS  central nervous system; CRP   C-reactive  protein; CT   computed tomography;
ECG  electrocardiogram; ECHO   echocardiogram; ECOG   Eastern Cooperative Oncology Group; eCRF  electronic case report form; 
EOI  end of infusion; EOT  end of tr eatment; FFPE   formalin -fixed  paraffin -embedded; FSH   follicle  stimulating  hormone; FT4  free thyroxine; 
HBcAb   anti-hepatitis B antibody; HBsAg  hepatitis B antigen; HCV  hepatitis C; HIV   human immunodeficiency virus; HR  heart rate; IGF -1  insulin-like growth 
factor 1; IV   intravenous; LH  luteinizing hormone; MUGA   multigated acquisition; LDH  lactate dehydrogenase; LTFU  long-term follow -up; MRI  magnetic 
resonance imaging; PD  progressive disea se; PK  pharmacokinetic; Pre  pre-infusion; Q cyc  every cycle; Q2 
Cyc  every 2 cycles; RECIST  response evaluation criteria in solid tumors; RR   respiratory rate; SCR  screening; SFU  safety follow -up; SOI  start of infusion; 
TLS  tumor lysis sy ndrome; TSH  thyroid stimulating hormone  
a All screening procedures should be performed within  prior to cycle  1  dosing.   
b Each visit week and day is relative to  of each cycle.  Cycle 1 and 2 visits have a  1-day window from designated time point unless otherwise specified.  
All subsequent visits beginning in cycle  3 will have a  3-day window.  
c See Section  6.2.1.3  for more details regarding Step Dosing.  
d  End of infusion (EOI) assessments or procedures are to be completed immediately after infusion of tarlatamab .  EOI indicates the time when the 
investigational product infusion and saline flush is completed.  Assessments after EOI indicate the time relative  to EOI.  Investigational product infusions are 
marked in the EOI column.  
 Assessments are done pre -infusion unless specified.  
 Laboratory assessments that were done within 24 hours prior to infusion do not need to be repeated (except for cycle  1  dosi ng where laboratory 
assessments that were done within 48 hours prior to infusion do not need to be repeated).  
 All assessments and procedures should be collected at the exact nominal time point as noted in the Schedule of Assessments.  If unable to perform a 
procedure at the specified nominal time point, collect it as close as possible to the nominal time point and record the actua l collection time.  
e Clinical evaluation including physical exam, ECOG, weight and neurological exams, writing test, and mini-mental status exams (neurology specialty consultation 
service as clinically indicated).  Mini mental status exams and writing test are required on days   clinical evaluation required per dosing 
regimen),  (may be performed if clinically indicated on days ) in cycle  1.  Mini mental status exam and writing test may be 
performed in cycle  2 and beyond at the investigator’s discretion.  Performed at screening only:  demographics, medical history, and heigh t.  Clinical evaluation 
should be completed within 6  hours prior to the first dose of tarlatamab.  
f Vital signs (BP, HR, RR, temp) and pulse oximetry will be assessed.  Vitals will be taken pre -AMG  404 infusion and at AMG  404 EOI.   
.  For each 
tarlatamab -infusion for the first 2 cycles (during the hospitalization period) vital signs shoul d be assessed as detailed in Section  8.4.1 . 
g ECGs will be collected once and considered safety ECGs.  ECGs should be collected prior to blood draws w hen assessments are conducted at the same 
nominal time point (pre -infusion timepoints for tarlatamab and AMG  404 may be collected 15 minutes prior to infusion, post -infusion time points for tarlatamab 
may be collected ± 15 minutes of indicated time point).   See Section  8.4.5 . 
h For cycles  1 and 2 only, please collect LDH, phosphorus, and uric acid along with the chemistry panel for TLS monitoring.  
i Serum pregnancy test at screening; serum or urine pregnancy test monthly until  from the last investigational product (tarlatamab or AMG  404) dose.  
Additionally, a pregnancy test at  after last dose of AMG  404. 
j Safety endocrine panels:  ACTH, cortisol, TSH, and FT4 will be evaluated at screening,  of every cycle starting with cycle  2, EOT, and SFU -1.  Prolactin, 
FSH, LH, testosterone (in males) and estradiol (in females) will be evaluated only at screening, EOT, and as clini cally indicated.  
m A tumor biopsy is required at screening if patient has received any treatment prior to participating into this study and biop sy can be performed safely as 
determined by the investigators.  Tumor tissue (archival or fresh biopsy) must be available.  Subject s must consent to allow the acquisition of FFPE material 
(block or unstained slides) by study personnel.   

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 22 of 176 
CONFIDENTIAL    
r AMG  404 PK samples to be collected at pre-infusion and end of infusion in cycles  3, 5, 7, 9, and 11 and at pre -infusion in cycles  4, 6, 8, 10, and 12.  
u Dexamethasone  mg IV (or equivalent dose of other corticosteroids) will be administered within 1 hour prior to all tarlatama b doses, in week 1 and step doses 
of tarlatamab in cycle  1 only.  
v Refer to Section  6.1.4  for administration details.  
x All subjects must have MRI/CT of the brain performed within  prior to the first dose of tarlatamab.  All brain scans on protocol are required to be MRI 
unless MRI is contraindicated, then CT with contrast is acceptable.  Subsequently, MRI brain can be performed at any time if clinically indicated per standar d 
of care.  
y  
 Tumor burden assessments will be performed based on modified RECIST 1.1  guidelines (see Section  11.9).  
 
 
z 
aa LTFU will be conducted every 3 months (  2 weeks) for 1 year from the first dose of tarlatamab on all subjects who have not withdrawn consent by clinic visit, 
telephone, or chart review to assess for survival and/or the commencement of subsequent cancer therapy only.  If the investigator becomes  aware of serious 
adverse events suspected to be related to investigational product or any fatal adverse event (regardless of causality) after the protocol -required reporting 
period (as defined in Section  8.4.9.1.3 ) is complete, then these serious adverse events wi ll be reported to Amgen immediately and no later than 24 hours 
following the investigator’s awareness of the event on the Event eCRF . 
bb Assessments to be completed at specified timepoint beginning with cycle  3 and at each subsequent cycle unless otherwise specified.  
cc For cycles  3 and 4 only:  please collect ECG post -tarlatamab infusion.  No further ECG’s are collected after cycle  4.   

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 23 of 176 
CONFIDENTIAL    
dd For subjects who discontinued treatment for any reason other than confirmed PD, every effort should be made to perform radiog raphic imaging (CT/MRI) of the 
chest, abdomen, pelvis, and all other known sites of disease every 3 months until documentation of c onfirmed PD per modified RECIST 1.1, clinical 
progression, start of new anticancer therapy, or up to 12 months after the first dose of tarlatamab, whichever occurs first.   
ee The first safety follow -up visit should be completed from the las t dose (tarlatamab or AMG  404).  
ff The second safety follow -up visit should be completed after the last dose of AMG  404 or prior to initiation of other therapy, whichever occurs first.  
hh Subjects who discontinue AMG  404 but remain on treatment with AMG  757 will continue to have safety event collection at regularly scheduled study visits.  The 
second safety follow -up visit need only occur if  has not elapsed from the end of AMG  404 treatment at the time of end of study  treatment.  
ii After end of study, serious adverse events suspected to be related to investigational product will be reported to Amgen.  Ple ase refer to Section  8.4.9.1.3  for 
additional details.  
 
 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 24 of 176 
CONFIDENTIAL    
2. Introduction   
2.1 Study Rationale   
Delta -like protein 3 (DLL3), a non -canonical Notc h ligand, is a promising target for the 
development of T -cell directed therapies due to its high expression on the cell surface of 
neuroendocrine tumor cells, and minimal, mainly cytoplasmic localization in normal 
tissues (Owen et al, 2019).  Tarlatamab  is a half -life extended (HLE) bi -specific T -cell 
engager (BiTE®) molecule combining the binding specificities for DLL3 and cluster of 
differentiation 3 ( CD3) genetically fused to the N -terminus of a single chain 
immunoglobulin G (IgG) Fc (fragment crystal lizable; single chain fragment crystallizable 
[scFc]) region.  Currently, tarlatamab  is being evaluated in a phase  1 study 
(Study  20160323) of subjects with small cell lung cancer (SCLC).  
AMG  404 is a fully human antibody that binds human programmed cell d eath-1 (PD -1) 
with high affinity and blocks the ability of this receptor to interact with its ligands, 
programmed death -ligand 1 (PD -L1) and programmed death -ligand 2 (PD -L2).  
AMG  404 has been  evaluated as a monotherapy agent  in a phase  1 study 
(Study  20180143) of subjects with advanced or metastatic solid tumors.  
Pembrolizumab (Keytruda) and nivolumab (Opdivo), both antibodies blocking human 
PD-1, were  approved by the United States food and drug administration ( US FDA ) 
under the accelerated approval pro gram for treatment of patients with metastatic SCLC 
who have progression after platinum -based chemotherapy and at least 1  other line of 
therapy (Keytruda United states prescribing information [ USPI ], 2020; Opdivo 
USPI, 2019), based on relatively low resp onse rates (19  with pembrolizumab and 12  
with nivolumab; Keytruda USPI, 2020; Opdivo USPI, 2019).  However, both approvals 
were subsequently withdrawn after confirmatory studies  did not  meet their primary  
endpoint  of overall survival (OS)  (Merck, 2021; Bristol Myers Squibb, 2020).  These data 
suggest that immune checkpoint inhibition may need to be combined with other 
therapies in second line or later.  
The combination of tarlatamab  and anti -PD-1 antibodies increases T -cell mediated 
redirect ed lysis of tumor cells that express DLL3 in vitro as compared to tarlatamab  
alone.  In addition, upregulation of PD -1/PD -L1 in the tumor microenvironment is a 
mechanism of resistance to BiTE therapy that treatment with anti -PD-1 therapy may 
mitigate (Fri berg and Reese, 2017; Köhnke  et al, 2015).  These data support testing the 
combination of tarlatamab  and AMG  404 in patients with SCLC.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 25 of 176 
CONFIDENTIAL    
2.2 Background   
2.2.1  Disease   
Small cell lung cancer  (SCLC), accounting for 10  to 15 of lung cancer 
(Rudin  et al, 2015), is an aggressive lung cancer subtype with neuroendocrine 
differentiation and strongly associated with smoking (Koinis et al, 2016).  It displays a 
distinct natural history characterized by a high growth fraction, rapid doubling time and 
early establishment of widespread metastatic lesions (Gustafsson et al, 2008).  While 
30 of patients present with disease confined to 1 hemithorax (limited disease [LD]), the 
majority of cases have disease not encompassed by one radiothe rapy field (extensive  
disease [ED]).  Small cell lung cancer is exquisitely sensitive to first -line chemotherapy 
(approximately 60  to 70 response rates) and to radiation which is stark contrast to 
subsequent resistance to second line and subsequent thera pies after disease 
recurrence (Byers and Rudin, 2015).  Patients with ED develop drug resistance and die 
as a result of disease at a median time of 10 to 12 months from diagnosis (Rudin  et al, 
2015).  For patients with ED SCLC, first -line treatment is plat inum -based chemotherapy.  
Most patients in the United States receive platinum -etoposide (EP) chemotherapy (with 
either carboplatin or cisplatin), and some patients receive platinum -irinotecan as an 
alternative, especially outside the United States.  In Mar ch 2019, atezolizumab was 
approved by the US FDA in combination with carboplatin and etoposide for the first -line 
treatment of adult patients with ED -SCLC ( TECENTRIQ United States Prescribing 
Information [USPI], 2019).  In March 2020, durvalumab, in combi nation with 
standard -of-care chemotherapy, etoposide, and carboplatin or cisplatin, was approved 
by the FDA as a frontline treatment for adult patients with extensive stage SCLC 
(IMFINZI® USPI).  Similar approvals for these molecules have also now been rec eived in 
European union ( EU) and other geographic regions, although levels of adoption remain 
variable globally.  
After relapse, topotecan is approved by the US FDA for relapses that occur after 45 days 
from the completion of chemotherapy.  However, despite  its indication in this setting, 
topotecan has produced disappointing response rates (Byers  and Rudin, 2015).  Based 
on the results of an open -label study of 105 patients with SCLC after failure of first -line 
therapy, lurbinectedin recently received accele rated approval by the US FDA following 
progression on or after platinum -based chemotherapy (Trigo et al, 2020).  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 26 of 176 
CONFIDENTIAL    
2.2.2  Amgen Investigational Product Background:  Tarlatamab   
Tarlatam ab (International Nonproprietary Name [INN]; AMG  757) is an HLE BiTE® 
antibody construct combining the binding specificities for DLL3 and CD3 genetically 
fused to the N -terminus of a single chain IgG  Fc (fragment crystallizable; scFc) region 
and is being developed with the intent to treat patients with SCLC . 
Refer to the specific section of the Investigator Brochure  for additional information 
related to the physical, chemical, and pharmaceutical properties and formulation(s).  A 
detailed description of the chemistry, pharmacology, efficacy, and safety of tarlatamab  is 
provided in the Investigator’s Brochure.  
2.2.2.1  Pharmacology   
The activity of tarlatamab  requires the simultaneous binding to both target cells and 
T cells.  The pharmacological effect of tarlatamab  is mediated by specific redirection of 
previously primed cytotoxic CD8+ or CD4+ T lymphocytes to kill DLL3+ cells.  
Tarlatamab  is a potent molecule showing mean half -maximal lysis of human tumor cell 
lines by human effector cells in vitro over a r ange of  
As part of the T cell activation process, BiTE® antibody constructs, such as tarlatamab , 
cause the formation of a cytolytic synapse between T cells and target cells.  This has 
been exemplified using an epithelial cell adhesion molecul e (EpCAM) -specific BiTE® 
antibody construct (Offner et al, 2006).  
The subsequent release of the pore -forming protein perforin and the apoptosis -inducing 
proteolytic enzyme granzyme B by T cells results in the induction of apoptosis in the 
target cells.  
Tarlatamab -mediated T cell activation not only induces the directed release of cytotoxic 
proteins to target cells, but also results in a transient production of inflammatory 
cytokines such as tumor necrosis factor (TNF), interferon gamma (IFN -) and 
interleuk in 2 (IL-2) by T cells.  In vitro studies demonstrated that cytokine release by 
tarlatamab -activated T cells is attenuated by corticosteroids, but this can be 
accompanied by a slight reduction in cytotoxic potency  
Tarlatamab  monotherapy induced regression of established SCLC primary tumors and 
liver metastases in orthotopic mouse models, with evidence for BiTE® target 
engagement and increased T cell infiltration and proliferation in tumors  
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 27 of 176 
CONFIDENTIAL    
2.2.2.2  Toxicology   
The cynomolgus monkey was chosen to evaluate the nonclinical safety of tarlatamab  
because both the CD3 and DLL3 binding moieties of tarlatamab  cross -reacted with 
similar high affinities to the analogous human and cynomolgus monkey antigens.  The 
potential toxicity of tarlatamab  was evaluated in a Good Laboratory Practice (GLP) 
compliant   cynomolgus monkey toxicology studies.  In the  
study, tarlatamab was administered once weekly by intravenous (IV) infusion at  
 and  g/kg.  Tarlatamab -related changes were limited to a minor decrease in 
lymphocyte p opulations (detected after the second dose only) at  µg/kg, a slightly 
increased heart rate (HR) (on  but not at ) at ≥  g/kg, and a minimal to 
mild mixed inflammatory cell infiltrate in the pituitary at  and  g/kg.  There was no 
evidence of tissue injury associated with the infiltrate.  A dose -related increase in 
incidence of anti -drug antibodies (ADAs) was detected.  One animal had vascular 
injury -associated changes in the heart and lung that were consistent with secondary 
effects  likely mediated by ADA -related immune complexes (ADA -IC).  It is important to 
note that the production of ADAs in animals is not predictive of a potential for antibody 
formation in humans.  All tarlatamab -related effects  exhibited full or partial reversib ility 
and all changes were considered not adverse.  In the  study, tarlatamab -related 
clinical pathology changes were limited to a minimal decrease in lymphocytes at 
 µg/kg.  In addition, tarlatamab -related changes were observed in the pituitary  gland 
at ≥  µg/kg, characterized as a minimal to mild mononuclear cell infiltrate composed 
primarily of lymphocytes, with no evidence of tissue injury.  The Highest Non -Severely 
Toxic Dose (HNSTD) was determined to be  g/kg in both the  
studies based on the absence of any tarlatamab -related adverse findings.  
2.2.2.3  Background Clinical Experience With Tarlatamab   
As of 29 September  2021  data cut,  subjects were  enrolled in the tarlatamab first in 
human (FIH) Study  20160323, 120 (96.8 ) of whom  received at least 1 dose of 
tarlatamab.   subjects received monotherapy in Part A1  (cohorts 1  to 10, 
cohort 23, and cohort 26 in the dose exploration phase):  1 subject each was assigned  
 mg of tarlatamab;  subjects were assigned mg; 
 subjects were assigned  mg;  subjects were assigned  mg (ie,  mg starting 
cycle  1  after an initial step dose of  mg at cycle  1  subjects were 
assigned  mg;  subjects were assigned  mg;  subjects were assigned  
 mg;  subjects were assigned  mg (ie,  mg starting cycle  1  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 28 of 176 
CONFIDENTIAL    
following 2-step dose of  mg at cycle  1  and  mg at cycle  1  of tarlatamab 
monotherapy  administered IV  ; and  subjects were assigned 
 mg of extended IV dosing.  Overall, all  subjects (100 ) in Part A1  had 
treatment -emergent adverse events; the most commonly reported adverse events we re 
cytokine release syndrome (CRS) ( subjects [44.4 ]); pyrexia (  subjects 
[33.3]); fatigue  ( subjects [28.4 ]); constipation (  subjects [24.7 ]); nausea 
( subjects [25.9 ]); decrease appetite (  subjects [23.5 ]); anaemia and headache 
( subjects [17.3 ]); and dysgeusia  ( subjects [19.8 ]).  Serious adverse events 
were reported for  subjects (49.4 ), treatment -related adverse events leading to 
withdrawal from tarlatamab were reported for  subjects (3.7 ), and grade ≥ 3 
treatment -emergent adverse events were reported for  subjects (53.1 ).   subject 
(1.2), who received 2  doses of tarlatamab at  mg IV  had a 
treatment -emergent fatal adverse event of pneumonitis, which was considered to be a 
dose -limiting toxicity (DLT) event.  
Among subjects who received tarlatamab in Part A1 (ie, cohorts 1 to 10, cohort 23, and 
cohort 26), CRS is the most frequently reported adverse event occurring in  subjects 
(44.4) with grade  2 CRS occurring in  subjects (9.9 ) and grade  3 CRS occurrin g 
in  subject (1.2 ).  No grade  4 or higher CRS has been reported at the time of the data 
cutoff date.   Cytokine release syndrome presented mainly as fever, tachycardia, nausea, 
and fatigue  hypotension and was reversible.  In  subjects (13.6 ), CRS was 
reported as a serious adverse event, 1 event of which led  to treatment discontinuation.  
Cytokine release syndrome  occurred predominantly following the first 2  doses of 
tarlatamab  in cycle  1 (CRS typically did not recur in subsequent cycles following cycle  1) 
and was managed with supportive care and corticosteroids.  
As of 29 September  2021, preliminary efficacy data was available for  subjects  who 
received monotherapy  in Part A1.   Overall,  a confirmed  partial response (PR)  was 
observed starting at a  dose  level of  through   mg in a total of   subjects for an 
overall objective response rate  (95 CI) of 19.5  (11.3, 30.1).   The disease control 
rate (95 CI) was 49.4  (37.8, 61.0).  
As of 29 September 2021, data cut,  subjects (100.0 ) receiving monotherapy in 
Part A2 (ie, cohort 30) had treatment -emergent events.  Grade  3 adverse events were 
reported in  subjects (35.3 ).  Serious adverse events were reported in  subjects 
(52.9).  No adverse events were fatal or led to discontinuation of tarlatamab.  Adverse 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 29 of 176 
CONFIDENTIAL    
events by preferred term reported for  20.0 of subjects were CRS (  subjects 
[76.5]); dysgeusia and pyrexia (each  subjects [47.1 ]); decreased appetite, 
headache, and vomit ing (each  subjects [29.4 ]); and arthralgia, fatigue, and nausea 
(each  subjects [23.5 ]). 
Among subjects who received tarlatamab in Part A2, CRS was grade  2 in  subjects 
(11.8); no grade  3 events were reported.  In  subjects (41.2 ), CRS was reported 
as a serious adverse event.  No CRS (AMQN) adverse events were fatal or led to 
discontinuation of tarlatamab.  
Neutropenia was grade  2 in  subjects (23.5 ) and grade  3 in  subjects (11.8 ).  
Neutropenia was reported as a serious adverse event  in  subject (5.9 ).  No 
neutropenia adverse events were fatal or led to discontinuation of tarlatamab.  
As of the data cut -off,  subjects received  in 
Part C of the ongoing FIH  Study  20160323  with  subjects assigned   mg and 
 subjects assigned  mg of tarlatamab.  Cohort 16 with  mg of tarlatamab 
administered over 1 -hour  in  administered at 
 mg  has been deemed safe and tolerable by the  dose level review 
team (DLRT).   As of  29 September  2021,  (100) subjects had  treatment -emergent 
adverse events,  (37.5) subjects had  serious treatment -emergent adverse events, 
 (37.5) subjects  had grade  3 treatment -emergent adverse events,  (0) subjects 
had treatment -emergent adverse events  that led to treatment discontinuation.   The most 
common adverse events include:  fatigue (  subjects [62.5 ]), nausea (  subjects 
[37.5]), decreased  appetite (  subjects [37.5 ]), vomiting (  subjects [37.5 ]), 
constipation (  subjects [25 ]), contusion (  subjects [25 ]), dyspnea (  subjects 
[25.0]), headache (  subjects [25 ]), myalgia (  subjects [25.0 ]), and pyrexia 
( subjects [25 ]).  Cytokine release syndrome was reported in  subject (12.5 ); the 
event  was grade  2, nonserious, and did not lead to discontinuation of treatment.  
 subjects received a CRS mitigation strategy in Part D of the ongoing FIH 
Study  20160323 consisting of  mg tarlatamab plus dexamethasone.  All 
 subjects (100.0 ) repo rted a treatment -emergent adverse event.  Grade   3 adverse 
events were reported for  subjects (57.1 ).  A fatal adverse event was reported in 
 subject (7.1 ); the preferred term was small cell lung cancer.  Adverse events by 
preferred term reported for  20.0 of subjects were CRS (  subjects [64.3 ]), pyrexia 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 30 of 176 
CONFIDENTIAL    
( subjects [50.0 ]), dysgeusia (  subjects [42.9 ]), constipation (  subjects [35.7 ]), 
and fatigue, headache, hypomagnesemia, hypotension, and nausea (each  subjects 
[21.4]).  Reported CRS of g rade ≥ 2 was reported in  subjects (28.6 ).  No grade  3 
CRS adverse events were reported.  Serious CRS was reported in  subjects (28.6 ).  
Cytokine release syndrome led to discontinuation of tarlatamab in  subject (7.1 ). 
As of 29 September 2021, with  a total of  subjects (  subjects in Study  20160323, 
 subject in Study  2020040, and  subject in Study  20200439) exposed to tarlatamab, 
grade  2 neutropenia was observed in  subjects (11.7 ), and  subjects (4.1 ) 
experienced grade  4 or higher neutropenia events.  There were no fatal neutropenia 
events.  Serious adverse events of neutropenia were reported for  subjects (1.7 ).  
tarlatamab was interrupted in  subjects (3.3 ) due to neutropenia and discontinued in 
 subjects (1.7 ) (inter rupted in  subject prior to discontinuation).  There were no cases 
of febrile neutropenia.  
As of 26 February 2021, preliminary  PK data for tarlatamab  were available for  
 subjects (  subjects  from monotherapy  cohorts and  subjects from the 
 cohorts).  
Within the evaluated target dose range  of  mg  (with or without one 
step dosing paradigm), the serum tarlatamab exposures increased in an  approximate  
dose -proportional manner with mean estimated  t1/2 at steady state r anging from  
.  Approximate steady state in serum tarlatamab exposures was achieved within 
4 weeks of every other week target regimen initiation.  
Refer to the AMG  757 Investigator’s Brochure for additional information.  
2.2.3  Amgen Investigational  Product Background:  AMG  404  
2.2.3.1  Nonclinical Pharmacology   
AMG  404 is a fully human antibody that bind s human and cynomolgus monkey PD -1 
with high affinity and blocks the ability of these receptors to interact with human ligands, 
PD-L1 and PD -L2.  The ligand blocking activity of AMG  404 was evaluated in 3 different 
assays using 3 different readouts and bot h cell -expressed, as well as recombinant, 
soluble ligands.  In each assay, AMG  404 demonstrated the expected dose -dependent 
activity, indicating it is a potent inhibitor of human and cynomolgus monkey PD -1 
binding.  
AMG  404 blocks the interaction between cy nomolgus monkey PD -1 and human PD -L1 
with a similar half maximal inhibitory concentration (IC 50) as human PD -1 and human 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 31 of 176 
CONFIDENTIAL    
PD-L1, suggesting that cynomolgus monkey is an appropriate species for nonclinical 
safety evaluation.  
AMG  404 is an IgG1 antibody; however, the Fc region has been modified to eliminate 
undesired interactions with Fc gamma receptors.  The absence of Fc -binding to Fc  
gamma receptors was demonstrated in a functional assay where AMG  404 induced little 
to no antibody -dependent ce llular cytotoxicity (ADCC) as compared to a positive control 
anti-CD38 antibody.  These results demonstrate that the Fc region of AMG  404 does not 
interact with Fc gamma receptors.  
2.2.3.2  Toxicology   
The potential for AMG  404 to cause acute release of cytokines from human peripheral 
blood leukocytes (PBL) in the presence of human endothelial cells (HUVECs) was 
evaluated in vitro.  Human PBL were cultured in autologous Platelet Poor Plasma  (PPP) 
in the presence of HUVECs with AMG  404 (  µg/mL) for 24  hours, and 
supernatants from the cultures were subsequently assessed for the presence of 
cytokines ( IFNγ, IL -1β, IL -2, IL-4, IL-6, IL-8, IL-10, IL -12 p70, and TNFα).  Under the 
condi tions tested in this assay, AMG  404 did not induce cytokine release above 
background levels.  
AMG  404 was evaluated in a  GLP toxicology study in cynomolgus monkeys.  
Doses of  mg/kg were administered by slow IV bolus, and doses of  or 
 mg/kg were administered subcutaneously (SC) (3 animals/sex/group).  Animals 
were dosed onc e weekly (4 total doses).  There were no AMG  404-related clinical signs 
or effects on body weight, food consumption, respiratory rate (RR), body temperature, 
organ weights, or urinalysis parameters and no AMG  404-related ocular, 
electrocardiographic, neuro logic, or macroscopic findings.  AMG  404-related clinical 
pathology changes were limited to mild decreases in lymphocytes for females at all dose 
levels on day   that were generally similar to control and/or baseline values on 9 and 
throughout the remainde r of the study, and mildly increased C -reactive protein in some 
animals.  AMG  404-related microscopic findings included an increased incidence and/or 
severity of mononuclear cell infiltration in the brain (minimal to mild) and/or spinal cord 
(minimal) of a nimals given ≥  mg/kg IV or  mg/kg SC and at the administration site 
(minimal to mild) of males given  mg/kg SC.  The increased incidence and/or severity 
of mononuclear cell infiltration in the brain and/or spinal cord observed in this study may 
represent an exacerbation of this background finding in cynomolgus monkeys, while the 
mononuclear cell infiltration at the administration site was considered an expected 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 32 of 176 
CONFIDENTIAL    
reaction to the administration of an exogenous protein.  In conclusion, administration o f 
AMG  404 by once weekly IV bolus or SC injection was well tolerated in cynomolgus 
monkeys at levels of  mg/kg IV and  mg/kg IV and SC.  
2.2.3.3  Nonclinical Pharmacokinetics   
The PK o f AMG  404 was characterized after single IV bolus injection at  and  mg/kg 
and single SC injection at  mg/kg to male cynomolgus monkeys.  Serum concentrations 
of AMG  404 declined in a biphasic manner for the first 168 hours post dose followed by 
a mor e rapid decrease, most likely because of the formation of anti -AMG  404 antibodies 
which were observed in all animals at 336 hours post dose.  
The toxicokinetics of AMG  404 were characterized in a GLP study after weekly IV 
administration of  or  mg/kg o r SC administration of  mg/kg for 4 consecutive 
weeks.  Following repeat dose administration, AMG  404 exposure increased 
approximately dose -proportionally from  to  mg/kg as measured by maximum 
serum concentration (C max) and area under the concentr ation -time curve (AUC) over 
 days.  AMG  404 exposures were similar between male and female animals.  
2.2.3.4  Clinical Experience   
As of the 30 April 2021 data cutoff date, preliminary saf ety data were available for 
 subjects with advanced or metastatic solid tumors who had received at least 1  dose 
of AMG  404 IV  (  in monotherapy Study  20180143 .  These subjects 
were dosed at 1 of 3 dose levels:   subjects were dosed at the  mg dose level, 
 subjects at the  mg dose level, and  subjects at the  mg  dose level 
(the highest dose level studied to date).  
Among the  subjects treated with at least 1 dose of AMG  404 in Study  20180143, the 
treatment emergent a dverse events, any grade, with a subject incidence of at least 10  
by preferred term were:  fatigue (n   33.8), nausea (n   26.9), decreased 
appetite (n   23.1), vomiting (n   16.9), pyrexia (n   16.2), diarrhea 
(n   15.4), constipation (n   14.6), anemia (n  13.8), arthralgia, 
abdominal pain, and rash (n  11.5 each), and aspartate aminotransferase 
increased, hypothyroidism, and dyspnea (n   10.0 each).  Treatment -emergent 
adverse events with a worst gr ade ≥ 3, with a subject incidence of at least 2  were:  
anemia (n   5.4), sepsis (n   3.8), fatigue (n   3.1), seizure (n   2.3), 
and abdominal pain, aspartate aminotransferase increased, back pain, decreased 
appetite, disease progression, d yspnea, hyponatremia, postoperative wound infection, 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 33 of 176 
CONFIDENTIAL    
urinary tract infection, colorectal cancer metastatic, metastases to spine, malignant 
neoplasm of thymus, and pancreatic cancer (n   1.5 each).  In  subjects (6.2 ), 
reported treatment emergent adve rse events led to AMG  404 discontinuation and the 
adverse events were:  brain edema, diarrhea, dysarthria, hemorrhage, 
immune -mediated enterocolitis, malignant neoplasm  of thymus, porocarcinoma, and 
tumor hemorrhage (n   0.8 each).   subjects r eported treatment emergent 
fatal adverse events, of which  (11.5 ) came under the System Organ Class, 
neoplasms benign, malignant, and unspecified (incl cysts and polyps) and the remaining 
4 treatment emergent fatal adverse events were:  disease progress ion, coronavirus 
disease 2019 (COVID -19), hemorrhage, and (uncoded) recurrent undifferentiated 
hepatic sarcoma (n    0.8 each).  
Hypothyroidism, colitis, and myasthenia gravis are  identified adverse drug reactions 
(ADRs) to  AMG  404.  In Study  20180143, administration of AMG  404 has been 
associated with  the reported events of hypothyroidism (  subjects [10.0 ], all subjects 
experienced an event grade ≤ 2) or blood thyroid stimulating hormone (TSH) increased 
(  subjects [3.1 ],  subject e xperienced a grade  3 event,  subjects experienced a 
grade ≤ 2  event).   In total,  subjects (13.1 ) experienced an event associated with an 
underactive thyroid.    hypothyroidism event was serious.   No event of 
hypothyroidism or blood TSH increased led  to AMG  404 discontinuation.   Administration 
of AMG  404 has been associated with noninfectious colitis in  subjects (1.5 ).   
subject experienced the adverse events colitis (grade  2, nonserious), immune -mediated 
enterocolitis (grade  3, serious), and di arrhea (grade  2, nonserious).   The  subject 
experienced the adverse event immune -mediated enterocolitis (grade  2, 
nonserious).   Both subjects with noninfectious colitis discontinued AMG  404 due to 
colitis/diarrhea.   Administration of AMG  404 has been  associated with the serious 
adverse event myasthenia gravis in  subject.  This was a study subject in a phase 1b/2 
combination study of AMG  404 and  (Study  20190505  Subprotocol  C).  Both 
study drugs were permanently  discontinued because of the eve nt.  As of 30 April 2021, 
 study subjects had been exposed to this investigational product combination.  The 
myasthenia gravis event was reported in  subject, between the ages of 60 and 
70 years, with stage  4 prostate cancer.  
As of 30 April 2021, prelimi nary efficacy data were available for  subjects dosed with 
AMG  404 who had an objective response value recorded.  Among all cohorts, 
 subjects (9.5 ) had a confirmed partial response, and  subjects (43.1 ) had stable 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 34 of 176 
CONFIDENTIAL    
disease.  Among cohorts 6, 7, 8,  and 9, there were  subjects with a response value 
who were dosed with AMG  404  mg IV   Of these  subjects,  subjects 
(13.4) had a confirmed partial response, and  subjects (44.8 ) had stable disease.  
Refer to the AMG  404 Investigator’s Broc hure for additional information.  
2.3 Benefit/Risk Assessment   
2.3.1  Therapeutic Context   
The combination of tarlatamab  and AMG  404 will be investigated in subjects with SCLC.  
2.3.2  Key Benefits   
Key benefits of the combination  of tarlatamab  and AMG  404 will be investigated and will 
be described when the data become available.  Potential benefits include reduction or 
regression of SCLC disease burden.  
2.3.3  Key Safety Information   
2.3.3.1  Tarlatamab   
Based on experience with tarlatamab in the phase  1 FIH Study  20160323 for the 
indication of SCLC, the key safety information for  tarlatamab includes CRS and 
neutropenia as identified risks.  The additional potential safety concerns of neurological 
events, pituitary dysfunction , and tumor lysis syndrome (TLS) are  summarized in  the 
sections below and are  based on the biological mechanism of action, experience wit h 
other BiTE molecules, and on the potential for on target, off -tumor effect.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 35 of 176 
CONFIDENTIAL    
  Table 2-1.  Key Safety Risk of Tarlatamab   
Safety Risk  Description  
CRS  CRS is an adverse drug reaction of tarlatamab  administration based  on 
safety  data from tarlatamab  phase  1 FIH  Study  20160323 for the 
indication SCLC.  
CRS is a systemic inflammatory response characterized by a release of 
cellular cytokines.  CRS is risk of T-cell directed therapies.  CRS is a risk 
associated with therapy with the approved BiTE molecule, blinatumomab 
(anti-CD19 BiTE antibody construct) in patients with ALL and is 
associated also with other BiTE molecules currently in development for 
treatment of solid and hematologic cancers.  
Clinical signs and symptoms of CRS may include the following:  
• Constitutional:  fever  rigors, malaise,  fatigue , anorexia, myalgias, 
arthralgias, nausea, vomiting, headache  
• Neurologic:  headache, mental status changes, confusion, delirium, 
world finding difficulty or frank aphasia, hallucinations, tremor, 
dysmetria, altered gait, seizures  
• Respiratory:  dyspnea, tachypnea, hypoxemia  
• Skin:  rash  
• Gastrointestinal:  nausea, vomi ting, diarrhea  
• Cardiovascular:  tachycardia, widened pulse pressure,  hypotension, 
increased cardiac output (early), potentially diminished cardiac output 
(late)  
• Coagulation:  elevated D -dimer, hypofibrinogenemia  bleeding,  
• Renal:  azotemia  
• Hepatic:  tr ansaminitis, hyperbilirubinemia  
Infusion reactions may be clinically indistinguishable from manifestations 
of CRS.   Specific recommendations for the management of CRS, and 
infusion interruption and stopping rules are found in  Table 6 -4 
Neutropenia  Neutropenia has been observed in patients receiving tarlatamab.  The risk 
mitigation plan includes monitoring of laboratory parameters (including, 
but not limited, to white blood cell count , and absolute neutrophil count) 
which will be evaluated at baseline and monitored throughout the study.  
Specific recommendations for the management of neutropenia, and 
infusion interruption and stopping rules are found in Table  6-8. 
ALL  acute lymphoblastic leukemia; BiTE  bi-specific T -cell engager; CD -19  cluster of differentiation  19; 
CRS  cytokine release syndrome; FIH  first-in-human; GLP  Good Laboratory Practices; SCLC  small 
cell lung cancer  
2.3.3.1.1  Additional Potential Safety Concerns for Tarlatamab   
2.3.3.1.1.1  Neurological Events   
There exists the risk of neurotoxicity with administration of tarlatamab.  Very low levels of 
DLL3 expression have been detected in the brain.  In addition, a wide range o f 
commonly observed neurological symptoms have been associated with the use of the 
approved BiTE molecule, blinatumomab (anti CD19 BiTE antibody construct) in 
patients with acute lymphoblastic leukemia (ALL).  The spectrum of neurologic events 
associated  with blinatumomab has not been observed in clinical trials for other BiTE 
molecules, and the neurotoxicity may in part be  associated with targeting CD19. 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 36 of 176 
CONFIDENTIAL    
Neurological events have been observed with tarlatamab administration in the 
tarlatamab phase  1 FIH Study  20160323 for the indication SCLC.  No neurologic events 
were observed in the tarlatamab  GLP toxicology studies in 
cynomolgus monkeys.  
2.3.3.1.1.2  Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)  
For this trial, Immune Effector C ell-Associated Neurotoxicity Syndrome (ICANS ) 
will be defined according to the criteria referenced in the publication by Lee et al 
(2019).  While the grading system has been developed in large part from chimeric 
antigen receptor T cells (CAR -T) therapies, symptoms of ICANS may be shared 
among immune effector cell -associated therapies such as BiTE® molecules.  
Refer to Section  6.8.2  for details on specific guidance for ICANS.  
2.3.3.1.1.3  Pituitary Dysfunction   
There  exists the risk of pituitary dysfunction with administration of tarlatamab.  The target 
DLL3 protein is expressed in the pituitary and there were observations of a tarlatamab 
related mixed inflammatory cell infiltrate in the pituitary in the  GLP 
cynomolgus monkey toxicology stu dies.  
2.3.3.1.1.4  Tumor Lysis Syndrome   
Tumor lysis syndrome, a severe, life -threatening disorder that can occur in highly 
proliferative malignancies or with debulking of extensive tumor burd en, is characterized 
by a group of metabolic disorders caused by the massive and abrupt release of cellular 
metabolites into the blood after lysis of the malignant cells (Coiffier et al, 2008).  The 
metabolic complications predispose patients with cancer t o various clinical 
complications, including renal failure, seizures, cardiac arrhythmias, and even sudden 
death.  Tumor lysis syndrome occurs primarily during treatment of neoplasms which are 
rapidly proliferating such as aggressive lymphomas and acute leu kemias.  It has been 
reported to occur rarely in solid tumors.  With the introduction of more effective 
therapeutic agents, the possible occurrence of TLS in patients with bulky, 
treatment -sensitive solid tumors must be recognized.  Therefore, there is a r isk of TLS in 
humans with administration of tarlatamab . 
2.3.3.2  AMG  404  
AMG  404 has been  evaluated as a monotherapy agent  in a FIH, phase  1 study 
(Study  20180143) of subjects with advanced or metastatic solid tumors. Based on the 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 37 of 176 
CONFIDENTIAL    
available  clinical data with AMG  404, hypothyroidism,  colitis, and myasthenia gravis are 
identified risks of AMG  404. ( Table 2 -2). 
Table 2-2.  Key Safety Risks of AMG  404  
Safety Risk  Description  
Hypothyroidism  Administration of AMG  404 has been associated with hypothyroidism or 
blood thyroid stimulating hormone increased.  Signs and symptoms that 
may be associated with hypothyroidism include fatigue, increased 
sensitivity to cold, constipation, dry skin, weight gain, hoarseness, muscle 
weakness, myalgia, arthralgia, menstrual disturbance, alopecia, 
bradycardia, hypercholesterolemia, depression, impaired memory, and 
enlarged thyroid gland (goiter).  
Hypothyroidism or blood thyroid stimulating hormone increased rep orted 
events did not lead to AMG  404 discontinuation or AMG  404 treatment 
interruption.  Subjects should be monitored for laboratory values of thyroid 
stimulating hormone and Free T4, and signs and symptoms of 
hypothyroidism during AMG  404 treatment.  Subj ects should continue to 
be monitored after discontinuation of AMG  404 due to the risk of late 
onset hypothyroidism.  Requirements for monitoring and management of 
hypothyroidism are provided in the clinical study protocol.  
Colitis  Administration of AMG  404 has been associated with colitis. Signs and 
symptoms that may be associated with colitis include diarrhea, abdominal 
pain, abdominal cramping, and blood or mucus in the stool.  
Colitis events have led to AMG  404 discontinuation.  Subjects should be 
monitored for signs and symptoms of colitis during AMG  404 treatment.  
Subjects should continue to be monitored after discontinuation of 
AMG  404 due to the risk of late onset colitis.  Requirements for monitoring 
and management of coliti s are provided in the clinical study protocol(s).  
Myasthenia Gravis  Administration of AMG  404 has been associated with the serious 
myasthenia gravis in  subject in a combination study of AMG  404 and 
 for prostate cancer.  
Signs and symptoms that may be associated with myasthenia gravis 
include diplopia, ptosis, muscle weakness and fatigability, difficulty with 
speech, swallowing, and/or breathing.  Myasthenia gravis event led to 
permanent discontinuation of the study drugs.  Subjects should be 
monitored for signs and symptoms of myasthenia gravis during AMG  404 
treatment.  
 
2.3.3.2.1  AMG  404 Potential Safety Concerns   
Additional key safety information ( Table  2-3), which are based on the mechanism of 
action, the nonclinical safety pharmacology and toxicology studies for AMG  404, 
available data from the ongoing clinical study, and cl ass effects of approved 
anti-PD-1/PD -L1 checkpoint inhibitors, but for which a causal association with AMG  404 
has not been established, are summarized below.   
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 38 of 176 
CONFIDENTIAL    
Table  2-3.  Potential Safety Concerns Based on Drug Class Effects, Biological 
Mechanism of Action, and Nonclinical Studies   
Safety Risk  Description  
Immune -related toxicities  Immune -related adverse effects associated with PD -1 blocking agents 
include pneumonitis, hepatitis, endocrinopathies, nephritis and renal 
dysfunction, skin reactions, encephalitis, and other immune -related 
adverse reactions  (including the identified risks of hypothyroidism, colitis 
and myasthenia gravis).   
Infusion -related reactions  Severe and life -threatening infusion -related reactions have been 
observed with other anti -PD-1 therapies and may occur with the 
administration of AMG  404.  Signs and symptoms may include pyrexia, 
chills, rigors, flushing, urticaria, hypotension, dyspnea, wheezing, 
headache, back pain, and abdominal  pain.  
Embryofetal toxicity  Based on its mechanism of action, AMG  404 may cause fe tal harm if 
administered during pregnancy. Animal studies published in the 
literatures have demonstrated that inhibition of the PD -1/PD -L1 pathway 
can lead to increased risk of immune -mediated rejection of the 
developing fetus resulting in fetal death. How ever, the risk to a fetus 
following conception by an AMG  404 exposed male, or the risk to a fetus 
from an AMG  404 exposed male sexual partner of a pregnant woman, is 
uncharacterized.  
PD-1  programmed cell death 1; PD -L1  programmed death ligand 1  
Clinical signs and symptoms of immune -related toxicities and infusion -related reactions, 
along with safety laboratory parameters, will be monitored during the study to ensure 
subjects’ safety.  To mitigate embryofetal toxicity ri sk, study subject contraception will be 
required, and pregnancy status will be monitored.  Refer to Section  6.2.2.2.1  for specific 
recommendations regarding the mitigation and management of immune -related toxicities 
and infusion -related reactions.  
Refer to the AMG  404 Investigator’s Brochure for further description of key safety 
information.  
2.3.3.3  Key Risks for Tarlatamab in C ombination with AMG  404  
To date, there is limited safety data with BiTE molecules in combination with PD -1 
inhibitors.  However, in a phase  1 study, the combination of the BiTE molecule 
blinatumomab with the PD -1 inhibitor nivolumab was reported to be safe and tolerable in 
a small number of subjects with ALL (Webster  et al, 2018).  No clinical or preclinical 
safety information is available for the combination of tarlatamab  with AMG  404.  In the 
ongoing tarlatamab  FIH study (20160323), a  
 being conducted ( tarlatamab  dose level of  mg in  
 deemed safe and tolerable).  Based on biological mechanism of  action 
and initial clinical safety information from the monotherapy study with tarlatamab  
(20160323), the key safety information and additional risks described for monotherapy 
would also be expected along with the key risks described for AMG  404.  Moreove r, with 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 39 of 176 
CONFIDENTIAL    
combination treatment, adverse events may be more severe and occur at different time 
points and/or dose levels in comparison to monotherapy.  In particular, synergistic 
activation of T cells is expected and may contribute to more severe immune -related 
toxicities.  Pneumonitis is an immune mediated toxicity for the PD -1 inhibitor class of 
drugs and has been observed in tarlatamab .  Refer to Section 6.8 for specific 
recommendations regarding the mitigation and management of CRS and 
infusion -related reactions.  Key safety risks for the combination of tarlatamab  and 
AMG  404 include:   
 exacerbated CRS and/or infusion reactions  
 exacerbated pituitary dys function  
 exacerbated neurologic events  
The available data thus far with BiTE® molecules in combination with anti -PD-1 suggests 
that the combination is tolerable.  Additionally, given the overall low incidence of grade  2 
or higher CRS (preferred term, 11 , with only 1 G3 CRS reported) with a reported 
incidence of grade  2 or higher CRS following cycle  1  administration of 6  
(preferred term) with tarlatamab monotherapy along with the low risk of reported 
infusion -related reactions (preferred term) repo rted thus far with AMG  404 monotherapy, 
the likelihood of the combination developing intolerable CRS or infusion -related 
reactions appears to be sufficiently low to merit the administration of both investigational 
products initially on cycle  1   To f urther mitigate this risk, a 1 -week stagger in 
enrollment of Subject 1 and Subject 2 in each dose cohort will take place to monitor for 
potential first dose effects associated with the combination therapy given on cycle  1 
  If de -escalation is necess ary, the study design incorporates the possibility that 
first dose effects, such as CRS, may be exacerbated with the combination on cycle  1 
 by adjusting the dosing schedule to allow for AMG  404 to be administered initially 
on cycle  1  or cycle  1  based on emerging safety data and the 
recommendations of the dose level review meeting (DLRM).  
Initially, subjects will be hospitalized after administration of tarlatamab  and AMG  404 to 
monitor for these safety risks (refer to Section  8.1.2 ).  Clinical signs and symptoms, 
along with safety laboratory parameters, will be monitored during study treatment cycles 
to ensure subjects’ safety.  Refer to the National Comprehensive Cancer Network 
(NCCN) Clinical Practice Guideline 2019 for specific recommendations regarding the 
mitigation and management of immune -related toxicities.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 40 of 176 
CONFIDENTIAL    
3. Objectives and Endpoints/Estimands   
 
Objectives  Endpoints  
Primary  
 To evaluate the safety, tolerability, 
and recommended phase  2 dose 
of tarlatamab in combination with 
AMG  404  Dose -limiting toxicities (DLTs), 
treatment -emergent and 
treatment -related adverse events, 
changes in vital signs, 
electrocardiograms (ECGs), and 
clinical laboratory tests  
Secondary  
 To evaluate anti -tumor activity of 
tarlatamab in combination with 
AMG  404  Objective response (OR) per 
modified response evaluation 
criteria in solid tumors (RECIST) 
v1.1, duration of response (DOR), 
disease control rate (DCR), 
progression -free survival (PFS), 
and overall survival (OS).   
 To characterize the 
pharmacokinetics (PK) of 
tarlatamab in combination with 
AMG  404  PK parameters including, but not 
limited to, maximum serum 
concentration (C max), minimum 
serum concentration (C min), and 
area under the concentration -time 
curve (AUC) over the dosing 
interval  
 
 
   
Exploratory  
4. Study Design   
4.1 Overall Design   
This is a phase 1b, multicen ter, open -label study evaluating the safety, tolerability, PK, 
pharmacodynamics ( PD), and efficacy of tarlatamab  in combination with AMG  404 in 
subjects with SCLC.  The study will consist of dose exploration (Part 1) and dose 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 41 of 176 
CONFIDENTIAL    
expansion (Part  2).  Study enr ollment ended in January  2023.  A total of  subjects 
were enrolled including  subjects in Part  1, and  subjects in Part  2. 
Part 1 (Dose Exploration):  
The dose exploration part of the study will estimate the recommended phase  2 dose 
(RP2D) of tarlatamab  in combi nation with AMG  404 using a modified toxicity probability 
interval (mTPI -2) design.  A combination RP2D may be identified based on emerging 
safety, efficacy, and pharmacodynamic data prior to reaching an MTD.  
AMG  404 will be administered ( Table 6 -1) as a short -term IV infusion (30 minutes) every 
 ( 3 days) (note if AMG  404 is initially administered on cycle  1  there will 
be a  interval between the cycle  1  and cycle  2  dose).  AMG  404 will 
be administered at the recommended phase  2 dose of  mg throughout the study.  
The starting dose of tarlatamab  will be  mg with 1 -step dosing (  mg on cycle  1  
followed by  mg on c ycle 1   mg on cycle  1  and  mg  
thereafter) .  Thus far in the ongoing FIH study (Study  20160323), the highest target dose 
deemed safe and tolerable is  mg.  Planned dose levels in Study  20160323 are 
shown in Table 4 -1.  The highest planned target dose of tarlatamab  will not exceed 
 mg in this study using the  regimen.  
Table 4-1.  Planned  Target Doses per Dose Cohort Level   
Dose Cohort Levels  Dose (mg) IV  
-1 
1 
2 
3 
IV  intravenous  
Footnotes are referenced from first-in-human study (Study  20160323)  
To mitigate the risk of CRS and to potentially optimize the PD activ ity of tarlatamab , a 
step dosing approach with 1 -step dosing will be implemented as part of the dosing 
schedule.  Based on emerging safety data and the recommendations of the DLRM, the 
dosing schedule may be adjusted to allow for AMG  404 to be administered  initially on 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 42 of 176 
CONFIDENTIAL    
cycle  1  or cycle  1 .  Depending on which day AMG  404 is administered on 
in cycle  1, beginning in cycle  2, AMG  404 will be administered  beginning on 
cycle  2  or cycle  2  (see Table 11-8 and Table 11 -9 for more details).  
Part 1 may include one or more of the follow ing planned dose levels of tarlatamab  in 
combination with a fixed dose of AMG  404 (design in Figure  4-1): 
 Dose Cohort Level 1:  tarlatamab  at a target dose of  mg administered IV  
(with 1 -step dosing) in combination with AMG  404 at  mg IV  
(  beginning on cycle  1  
 Dose Cohort Level 2:  tarlatamab  at a target dose of  mg administered IV  
(with 1 -step dosing) in combination with AMG  404 at  mg IV  beginning 
on cycle  1  
 Dose Cohort Level 3:  tarlatamab  at a target dose  of  mg administered IV 
 (with 1 -step dosing) in combination with AMG  404 at  mg IV  
beginning on cycle  1  
 Dose Cohort Level -1:  tarlatamab  at a target dose of  mg administered IV 
 (with 1 -step dosing) in combination with AMG  404 at  mg IV  (in 
case Dose Cohort Level 1 is not well tolerated) beginning on cycle  1  
 Dose Cohort Level -2:  tarlatamab  at a target dose  of  mg administered IV 
 (with 1 -step dosing) in combination with AMG  404 at  mg IV  (in 
case Dose Coh ort Level -1 is not well tolerated) beginning on cycle  1  
 Dose Cohort Level -3:  tarlatamab  at a target dose of  mg administered IV  
(with 1 -step dosing) in combination with AMG  404 at  mg IV  (in case 
Dose Cohort Level -2 is not well toler ated) beginning on cycle  1  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 43 of 176 
CONFIDENTIAL    
Figure  4-1.  Part 1 Tarlatamab and AMG  404 Planned Dose Levels   
 
D  de-escala tion; E  escalation  
Based upon emerging PK, PD, and safety data in the current study as well as the 
ongoing FIH study (20160323), alternative (intermediate) dose cohort levels,  
 
as part of the de -escalation recommendations per the DLRM may be explored.  
Step Dosing  
Due to its known mechanism of action, subjects are at an increased risk for CRS during 
initiation of tarlatamab  treatment.  To mitigate this risk, tarlatamab  will be administered 
with 1 -step dosing.  One-step dosing involves a first step dose on  mg), followed 
by a step dose on  (equal to the target dose) and the target dose on  then 
 
Dose exploration will begin with  subjects treated at Dose Cohort Level 1.  The 
study DLT period is   Once all subjects enrolled at a cert ain Dose Cohort Level 
are DLT evaluable, a DLRT meeting will be convened.  Depending on observed safety 
data, the following may occur:  1) dose de -escalation to the next lowest Dose Cohort 
Level, 2)  additional enrollment to the current Dose Cohort Level, o r 3) dose escalation to 
the next highest Dose Cohort Level or initiation of enrollment in Part 2.  Re -escalation to 
the next higher Dose Level may be allowed, as appropriate.  If re -escalation occurs, 
alternative (intermediate) dose levels may be explored per the recommendations of the 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 44 of 176 
CONFIDENTIAL    
DLRM,  
. 
Dose escalation/de -escalation recommendations will be guided by a mTPI -2 model 
(Guo  et al, 2017) with a target toxici ty probability of 30 , equivalence toxicity interval of 
(25, 33) and probability of overdosing of 95 .  Beta (1, 1) is used as a prior 
distribution.  
The detailed information of escalation/de -escalation rules are defined in Table 4 -2.  The 
DLT decision starts from the  subject.  
Table 4-2.  Guideline for Escalation/De -escalation   
Number of 
Evaluable Subjects  Number of DLTs  Decision  
0 E 
1-2 D 
3 DU 
0 E 
1 S 
2 D 
≥ 3 DU 
0-1 E 
2-3 D 
≥ 4 DU 
0-1 E 
2-3 D 
≥ 4 DU 
0-1 E 
2 S 
3-4 D 
≥ 5 DU 
≤ 2 E 
3-4 D 
≥ 5 DU 
≤ 2 E 
3 S 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 45 of 176 
CONFIDENTIAL    
Number of 
Evaluable Subjects  Number of DLTs  Decision  
4-5 D 
≥ 6 DU 
D  de-escalate to the next lower dose level; DLT  dose -limiting toxicity; DU  the current dose is 
unacceptably toxic; E  escalate to the next higher dose; S  stay at the current dose  
If late onset adverse events occur during a cohort, the DLRT may adaptively re -consider 
the doses evaluated within a cohort for subsequent dosing and/or possibly trigger a 
de-escalation or wit hholding of additional doses in subsequent cohorts.  Additionally, if 
dose de -escalation occurs and based on emerging PK, PD and safety data, alternative 
(intermediate) dose levels may be explored per the recommendations of the DLRM, 
 
.  The recommended phase  2 dose will be estimated using 
isotonic regression (Ji et al, 2010) and the recommended phase  2 dose will be the dose 
level with the estimated DLT rate closest to 0.30.  In order to consider a certain dose 
level as the recommended phase  2 dose at least  DLT evaluable subjects must be 
enrolled at that dose level.  
Dose exploration phase will end once any of the following events occur:  
 Highest planned dose level is determined to be safe and tolerable (minimum of 
 evaluable subjects overall).  
 One of dose levels is determined to be safe and tolerable (minimum of 
 evaluable subjects) and the next higher dose level is determined to be unsafe 
and i ntolerable.  
 All planned dose levels (including any intermediate doses or alternate dosing 
schedules) are determined to be unsafe and intolerable.  
To minimize the number of subjects treated at potentially toxic dose levels, the first 
 subjects in each coh ort will be enrolled sequentially with a minimum of  days between 
the first dose of these subjects.  
On the basis of a review of real -time safety data and available preliminary PK data, dose 
escalation may be halted or modified by the sponsor as deemed app ropriate.  
Part 2 (Dose Expansion):  
Upon completion of Part 1 of the study, enrollment will commence in Part 2 to confirm 
the safety and tolerability of the selected dose and to further evaluate the efficacy of 
tarlatamab  in combination with AMG  404.  Forma l safety interim analyses will be 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 46 of 176 
CONFIDENTIAL    
performed for every  subjects who have had opportunity to have at least  of 
follow -up since first dose of tarlatamab .  The details are provided in Section 9.4.1 . 
The overall study design is described by a study schema in Section 1.2.  The endpoints 
are defined in Section  3. 
Subjects in this clinical investigation sh all be referred to as “subjects”.  For the sample 
size justification, see Section  9.2. 
4.2 Patient Input into the Study Design   
Patient input was not obtained for this study.  
4.3 Justification for Dose   
4.4 Justification for Investiga tional Product Dose   
4.4.1.1  Tarlatamab   
The proposed starting dose and associated dosing schedule for this study is a target 
dose of  mg administered with 1 -step dosing (  mg on cycle  1  followed by 
 mg on cycle  1  mg on cycle  1  and  mg  thereafter).  The 
selection of this starting dose and dosing schedule is based on the safety, t olerability, 
and preliminary efficacy data from the ongoing FIH study  (20160323).  
As of 29 September  2021,  subjects (96.8%) out of  enrolled in Study  20160323 
had received at least 1 dose of tarlatamab given as monotherapy in subjects with 
relapsed/ refractory SCLC (Study  20160323).   Subjects were enrolled across doses 
ranging from  mg tarlatamab administered IV   In cohort 8 with a target 
dose of  mg with 1 -step dosing (  mg on cycle  1  followed by  mg on cycle  1 
 mg on cycle  1  and  mg  thereafter),  subjects were 
enrolled and received at least 1 dose of tarlatamab.  In these  subjects, all subjects 
(100) reported treatment related adverse events of any grade, of which grade  3 or 
higher trea tment related adverse events were reported in  subjects (70.6 ) and 
serious adverse events were reported in  subjects (47.1 ).  Cytokine release syndrome 
of any grade was reported in   subjects (52.9 ).  No treatment -related adverse events 
leading to di scontinuation of tarlatamab were reported in cohort 8.  In cohort 10 with a 
target dose of  mg with 1 -step dosing (  mg on cycle  1  followed by  mg on 
cycle  1  mg on cycle  1  and  mg  thereafter), 
 subjects were  enrolled and received at least 1 dose of tarlatamab.  In these 
 subjects,  subjects (100 ) reported treatment -related adverse events of any grade, 
of which grade  3 or higher treatment related adverse events were reported in  subjects 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 47 of 176 
CONFIDENTIAL    
(46.2) and serious adverse events were reported in  subjects (46.2 ).  Cytokine 
release syndrome of any grade was reported  subjects (46.2 ), with grade  2 CRS 
reported in  subject (8 ).  No grade  3 or higher CRS was  reported in  cohort 10.  
Treatment -related advers e events leading to withdrawal of tarlatamab were reported in 
 subjects (15 ) in cohort 10.  
As a conservative approach, due to the mechanism of action, the starting dose and 
dosing schedule of tarlatamab  in combination with AMG  404 will be 2  dose levels below 
the highest target dose deemed safe and tolerable for tarlatamab  as determined in the 
ongoing monotherapy FIH study (Study  20160323).  Additionally, the potential doses 
proposed in this study will not exceed a target dose of  mg, a dose which has been 
deemed safe and tolerable with a manageable toxicity profile as monotherapy in the 
ongoing FIH study (Study  20160323).  
The selected starting dose and dosing schedule as well as the potential doses that may 
be used of tarlatamab  in combination with AMG  404 is expected to show clinical activity 
in subjects with SCLC based on the preliminary evidence of efficacy of tarlatamab  when 
administered alone in subjects with SCLC (see Section  2.2.2.3  for additional details).  
4.4.1.2  AMG  404  
The AMG  404 dose to be used in this study is  mg IV  which is the RP2D for 
monotherapy in subje cts with advanced solid tumors.  This dose was selected based on 
the safety, tolerability, PK, and PD of AMG  404 at dose levels of  mg 
in subjects with advanced solid tumors in Study  20180143.  As of the 14 February 2020 
data cut -off date , AMG  404 was safe and well tolerated across the  and -mg 
dose range with no dose -related increases in frequency or severity of adverse events in 
subjects and no DLTs.  Preliminary PK results were consistent with those for other 
therapeutic anti -PD-1 monoclonal antibodies.  An approximately dose -proportional 
increase was observed over the dose range of  mg IV  preliminary PD 
results at the -mg dose levels were consistent with the expected 
saturation of receptor occupancy ( RO) for these doses given the potent inhibition of 
PD-1/PD -L1 interactions in vitro with low nanomolar IC 50 values and preliminary 
observed AMG  404 exposures in human subjects.  Taking into consideration the 
cumulative preliminary safety, PK, and PD data, the AMG  404 RP2D for monotherapy is 
 mg IV  in subjects with advanced solid tumors.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 48 of 176 
CONFIDENTIAL    
4.5 End of Study   
An individual subject is considered to have completed the study if he/she has completed 
the last visit  shown in the Schedule of Activities .  The total study duration for an 
individual subject is approximately 24  months.  The actual duration for individual 
subjects will vary depending upon tolerability of tarlatamab  and AMG  404, evidence of 
clinical and/or radiological disease progression, and willingness to participate in the 
study.  
The end of study date is defined as the date when the last subject across a ll sites is 
assessed or receives an intervention for evaluation in the study (ie, last subject last 
visit), including any additional parts in the study (eg, long -term follow -up,  
), as applicable.  
5. Study Population   
Investigators will be expected to maintain a screening log of all potential study 
candidates that includes limited information about the potential candidate (eg, date of 
screening).  
Eligibil ity criteria will be evaluated during screening.  
Before any study -specific activities/procedures, the appropriate written informed consent 
must be obtained (see Section  11.3). 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions will not be provided.  
5.1 Inclusion Criteria   
Subjects are eligible to be included in the study only if all the following criteria apply:  
101 Subject has provided informed consent prior to initiation of any study specific 
activities/procedures.  
102 Age ≥ 18 years.  
103 Subjects with histologically or cytologically confirmed SCLC who progressed or 
recurred following at least 1 platinum -based regimen  
Note:  In countries where standard of care first line systemic treatment includes 
platinu m containing chemotherapy in combination with PD -L1 inhibitor, it is 
required that patients have failed PD-L1  inhibitor therapy as part of their first 
systemic treatment or have no access to PD-L1 inhibitors.  
Note:  If patients progress or relapse within 6 months from receiving platinum 
containing -systemic treatment for limited stage disease, they are eligible for 
study regardless of receiving PD-L1 containing regimen.  
Note:  Subjects with a diagnosis of combined small cell carcinoma with 
predominant small cells (as determined by the local pathologist) may be 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 49 of 176 
CONFIDENTIAL    
considered for inclusion based on investigator discretion and after discussion 
with the medical monitor.  
104 Subjects with disease measurable by modified Response Evaluation Criteria in 
Solid Tumors (RECIST) 1.1  
105 Subjects with treated brain metastases are eligible provided they meet the 
following criteria:  
106 Eastern Cooperative Oncology Group (ECOG) 0 to 1  
107 Adequate organ function per local labora tory, defined as follows:  
 absolute neutrophil count  1 x 109/L  
 platelet count  75 x 109/L  
 hemoglobin  9 g/dL (90 g/L)  
 Estimated glomerular filtration rate based on Modification of Diet in Renal 
Disease (MDRD) calculation > 45 mL/min/1.73 m2  
 asparta te aminotransferase (AST) and alanine aminotransferase (ALT) 
 3 x upper limit of normal (ULN) (or  5 x ULN for subjects with liver 
involvement).  
 total bilirubin (TBL)  1.5 x ULN (or  2 x ULN for subjects with liver 
metastases).  
 Prothrombin time (PT)/in ternational normalized ratio (INR) and partial 
thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) 
 1.5 x institutional ULN (subjects on stable anticoagulation are permitted)  
108 Pulmonary function:  
 No clinically significant pleural effusion. Treatment of pleural effusions to 
meet eligibility is permitted.  
 Baseline oxygen saturation > 90  on room air  
109 Cardiac function:  
 Cardiac ejection fraction ≥ 50 ,  
 No evidence of clinically significant pericardial effusion as determined by an 
echocardiogram (ECHO) or multigated acquisition (MUGA).  
 No clinically significant electrocardiogram (ECG) findings  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 50 of 176 
CONFIDENTIAL    
110 Minimum  life expectancy of 12  weeks.  
5.2 Exclusion Criteria   
Subjects are excluded from the study if any of the following criteria apply:  
Other Medical Conditions  
201 History of other malignancy within the past 2  years, with the following excepti ons: 
 Malignancy treated with curative intent and with no kno wn active disease 
present for ≥ 2 years before enrollment and felt to be at low risk for 
recurrence by the treating physician.  
 Adequately treated non -melanoma skin cancer or lentigo maligna without 
evidence of disease.  
 Adequately treated cervical carcinoma in situ without evidence of disease.  
 Adequately treated breast ductal carcinoma in situ without evidence of 
disease.  
 Prostatic intraepithelial neoplasia without evidence of prostate cancer.  
 Adequately treated urothelial papillary noninvasive carc inoma or carcinoma 
in situ. 
202 Major surgery within 28  days of first dose of tarlatamab . 
203 Untreated (includes new lesions or progression in previously treated lesions) or 
symptomatic brain metastases and leptomeningeal disease . 
204 Subject who experienced recurren t grade  2 pneumonitis or severe or 
life-threatening immune -mediated adverse events or infusion -related reactions 
including those that lead to permanent discontinuation while on treatment with 
immuno -oncology agents  
205 Subject with evidence of interstitial lu ng disease or active, non -infectious 
pneumonitis   
206 History of any immune -related colitis.  Infectious colitis is allowed if evidence of 
adequate treatment and clinical recovery exists and at least 3 months interval 
observed since diagnosis of colitis.  
207 Histo ry of allergic reactions or acute hypersensitivity reactions to antibody 
therapies.  
208 Positive/non -negative test for Human Immunodeficiency Virus (HIV).  
209 Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, 
indwelling Foley catheter, biliary drain, or peritoneal/pericardial catheter).  
 Note:  a pleural catheter or dedicated central venous access catheters such 
as a Port -a-Cath or Hickman catheter are permitted  
210 Has a diagnosis of immunodeficiency or is receiving systemic steroi d therapy or 
any other form of immunosuppressive therapy within 7 days prior to the first dose 
of tarlatamab.  
211 Presence of fungal, bacterial, viral, or other infection requiring oral or IV 
antimicrobials for management within 7 days of first dose tarlatamab . 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 51 of 176 
CONFIDENTIAL    
Note:  Simple urinary tract infections  and uncomplicated bacterial pharyngitis 
are permitted if responding to active treatment and after consultation with 
sponsor.  Subjects requiring oral antibiotics who have been afebrile > 24 hours, 
have no leukocytos is or have any clinical signs of infection are eligible.  Subjects 
who meet these  criteria and who were previously on IV antimicrobials should 
have been off IV antimicrobials for > 48 hours.  
212 Unresolved toxicity from prior anti -tumor therapy, defined as not  having resolved 
to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 
grade  1, or to levels dictated in the eligibility criteria with the exception of 
alopecia or toxicities from prior anti -tumor therapy that are considered irreversible 
(defined as having been present and stable for >  21 day) which may be allowed if 
they are not otherwise described in the exclusion criteria AND there is agreement 
to allow by both the investigator and Amgen  
213 History of hypophysitis or pituitary dysfunction  
214 Exclusion of hepatitis infection based on the following results and/or criteria:  
 Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic 
hepatitis  B or recent acute hepatitis B).  
 Negative HBsAg and positive for hepatitis B core antibody:  
hepatitis  B virus  deoxyribonucleic acid  (DNA ) by polymerase chain reaction 
(PCR) is necessary.  Detectable hepatitis B virus DNA suggests occult 
hepatitis B.  
 Positive Hepatitis C virus antibody (HCVAb):   hepatitis C virus Ribose 
nucleic acid ( RNA ) by PCR is necessary.  Detectable hepatitis C virus RNA 
suggests chronic hepatitis C.  
215 History of arterial thrombosis (eg, stroke or transient ischemic attack) within 
12 months of first dose of tarlatamab.  
216 Myocardial infarction and/or symptomatic congestive  heart failure (New York 
Heart Association > class II) unstable angina, or cardiac arrhythmia requiring 
medication within 12 months of first dose of tarlatamab.  
217 Active  autoimmune disease that has required systemic treatment (except 
replacement therapy) wit hin the past 2 years or any other diseases requiring 
immunosuppressive therapy while on study.  Subjects with Type I diabetes, 
vitiligo, psoriasis, hypo - or hyper -thyroid disease not requiring 
immunosuppressive treatment are permitted.  
Prior/Concomitant Th erapy  
218 Prior anti -cancer therapy, including anti -PD-1 or anti -PD-L1 antibody therapy:  at 
least 28 days must  have elapsed between any prior anti - cancer therapy and the 
first planned dose of tarlatamab  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 52 of 176 
CONFIDENTIAL    
233 Subjects who have received prior tarlatamab  therapy or prior DLL3 x CD3 
bispecific therapy are not eligible.  
219 History of solid organ transplantation.  
220 Live vaccine therapy within 4 weeks prior to study drug administration.  
Prior/Concurrent Clinical Study Experience  
221 Currently receiving treatment in another investigational device or drug study, or 
less than 4 weeks  since ending treatment on another investigational device or 
drug study(ies).  Other investigational procedures while participating in this study 
are excluded.  
Other Exclusions  
222 Subject has known sensitivity to any of the products or components to be 
administered during dosing.  
223 Subject likely to not be available to complete all protocol -required study visits or 
procedures, and/or to comply with all requi red study procedures (eg, Clinical 
Outcome Assessments) to the best of the subject and investigator’s knowledge.  
224 History or evidence of any other clinically significant disorder, condition, or 
disease (with the exception of those outlined above) that, in t he opinion of the 
investigator or Amgen physician, if consulted, would pose a risk to subject safety 
or interfere with the study evaluation, procedures or completion.  
225 Female subjects of childbearing potential unwilling to use protocol specified 
method of c ontraception (see Section  11.5) during treatment and for an 
additional:  
  following the last dose of tarlatamab  
  following the last d ose of AMG  404 
226 Female subjects who are breastfeeding or who plan to breastfeed while on study 
through:  
  following the last dose of tarlatamab  
  following the last dose of AMG  404 
227 Female subjects planning to become pregnant while on study thr ough  
  following the last dose of tarlatamab  
  following the last dose of AMG  404 
228 Female subjects of childbearing potential with a positive pregnancy test 
assessed at Screening by a highly sensitive serum pregnancy test.  
229 Male subjects with a  female partner of childbearing potential who are unwilling to 
practice sexual abstinence (refrain from heterosexual intercourse) or use 
contraception during treatment and for an additional:  
  following the last dose of tarlatamab  
  following the last dose of AMG  404  
230 Male subjects with a pregnant partner who are unwilling to practice abstinence or 
use a condom during treatment and for an additional:  
  following the last dose of tarlatamab  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 53 of 176 
CONFIDENTIAL    
  following the last dose of A MG 404  
231 Male subjects unwilling to abstain from donating sperm during treatment and for 
an additional:  
  following the last dose of tarlatamab  
  following the last dose of AMG  404 
232 Evidence of severe acute respiratory syndrome coronavirus 2 (S ARS-CoV-2) 
infection.  If history of SARS -CoV-2: 
 Acute symptoms of COVID -19 within prior to first dose of 
investigational product (counted from day of positive test for asymptomatic 
subjects).  
5.3 Subject Enrollment   
Before subjects begin participation in any study -specific activities/procedures, Amgen 
requires a copy of the site’s written institutional review board/independent ethics 
commit tee (IRB/IEC)  approval of the protocol, informed consent form (IC F), and all other 
subject information and/or recruitment material, if applicable (see Section 11.3). 
The subject or the subject’s legally acceptable representative  must personally sign and 
date the IRB/IEC and Amgen approved informed consent before commencement of 
study -specific procedures.  
A subject is considered enrolled when the investigator decides that the subject has met 
all eligibility criteria.  The investigator is to document this decision and date, in the 
subject’s medical record and in/on the Subject Enrollment case report form (CRF).  
Each subject who enters into th e scree ning period for the study ( defined as the point 
when the subject signs the ICF ) receives a unique subject identification number before 
any study -related activities/procedures are performed.  The subject identification number 
will be assigned manually.  Thi s number will be used to identify the subject throughout 
the clinical study and must be used on all study documentation related to that subject.  
The subject identification number must remain constant throughout the entire clinical 
study; it must not be cha nged after initial assignment, including if a subject is 
rescreened.  
Sites that do not enroll subjects within 6 months  of site initiation may be closed.  
5.4 Screen Failures   
Scree n failures are defined as subjects who consent to participate in the clinical study 
but are not subsequently enrolled in the study .  A minimal set of screen failure 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439   
Date:   05 June 2024         Page 54 of 176 
CONFIDENTIAL    
information will be collected that includes demography, screen failure details, eligibility  
criteria, and any serious adverse events.  
Individuals who do not meet the criteria for participation in this study (screen failure) may 
be rescreened.  
6. Study Intervention   
Study intervention is defined as any investigational product(s), non -investigational 
product(s), placebo, combination product(s), or medical device(s) intended to be 
administered to a study subject according to the study protocol.  
Note that in several countri es, investigational product and non -investigational product 
are referred to as investigational medicinal product and non -investigational medicinal 
product, respectively.  
A summary of the dosing and administration of each treatment  is shown in Table 6 -1 
below . 
6.1 Study Interventions Administered   
6.1.1  Investigational Products   
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 55 of 176 
CONFIDENTIAL    
Table 6-1.  Investigational Products   
Study Treatment Name  Amgen Investigational Product:a 
Tarlatamab  Amgen Investigational Product:a 
AMG  404 
Dosage Formulation  Tarlatamab is supplied as a sterile, single use, preservative free 
lyophilized drug product containing mg of tarlatamab  
per vial.  Tarlatamab is intended for reconstitution with sterile water 
for injection and dilution in an intravenous (IV ) bag with normal 
saline (  sodium chloride) and an IV solution stabilizer.  The 
drug product is formulated with  mM L -glutamic acid,  (w/v) 
sucrose,  (w/v) polysorbate 80, at a final  pH of  Note: As of Protocol Amendment  3, AMG  404 will 
not be supplied.  
AMG  404 is supplied in a 3 mL Type 1 glass 
tubing vial containing 1 mL deliverable volume of 
 mg/mL.  The drug product is formulated with 
 mM acetate (sodium counterion),  (w/v) 
sucrose, 0.01  (w/v) polysorbate 80, pH  and 
will b e prepared for IV administration by dilution.  
Unit Dose Strength(s)/  
Dosage Level(s) and 
Dosage Frequency  The starting dose and dosing schedule of tarlatamab  will be  mg 
as the target dose with 1 -step dosing.  Tarlatamab will be 
administered  after the target dose is reached.  If the 
combination of tarlatamab  and AMG  404 is not tolerated (based on 
target DLT rate >  30), tarlatamab  dose level wi ll be further dose  
reduced or the day of administration of AMG  404 in combination 
with tarlatamab  will be adjusted.   mg  
Route of Administration  IV IV 
Accountability  The total volume of preparation, dose, start date/time, stop 
date/time, and lot number are to be recorded on each subject's 
CRF(s).  The total volume of preparation, dose, start 
date/time, stop date/time, and lot number are to 
be recorded on each subject's CRF(s).  
Dosing Instructions  Tarlatamab will be administered as a short -term IV infusion for 
60 minutes (  10 minutes) followed by a flush once  
(except in cycle  1 where 1 -step-dosing will be implemented).   AMG  404 will be deliv ered using infusion pumps 
approved for use by the appropriate regulatory 
authority for the country in which the subject is 
undergoing treatment.  
AMG  404 solution for infusion will be prepared in 
bags for IV infusion and delivered through 
infusion lines.    
The drug will be administered as a short -term IV 
infusion at a constant flow rate over 30 minutes 
( 5 minutes) every  (± 3 days).   
CRF  case report form; DLT  dose limiting toxicity; IV  intravenous;
a Tarlatamab  and AMG  404 will be manufactured and packaged by Amgen Inc. and distributed using Amgen clinical study drug distribution procedures.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 56 of 176 
CONFIDENTIAL    
6.1.2  Non-investigational Products   
No non -investigational products will be administered in this study.  
6.1.3  Medical Devices   
No medical devices will be used in this study.  
Other non -investigational medical devices may be used in the conduct of this study as 
part of standard care.  
Non-Amgen non -investigational medical devices (eg, syringes, sterile needles), that are 
commercially available are not usually provided or reimbursed by Amgen (except, for 
example, if required by local regulation).  The investigator will be responsible for 
obtaining supplies of these devices.  
6.1.4  Other Protocol -required Therapies   
All other protocol -required therapies including, dexamethasone and tocilizumab 
(siltuximab may be used if tocilizumab is not available) , that are commercially available 
are not provided or reimbursed by Amgen (exc ept if required by local regulation).  The 
investigator will be responsible for obtaining supplies of these protocol -required 
therapies.  
Dexamethasone  mg IV (or equivalent dose of other corticosteroids) will be 
administered within 1 hour prior to all cyc le 1 doses of tarlatamab including all step 
doses.  Dexamethasone dose and schedule may be changed based on emerging safety 
data.  
Additionally, prophylaxis with IV hydration (1L normal saline over 4 to 5 hours) will be 
administered:  
 immediately following all tarlatamab doses in cycle  1 
Additionally, based upon emerging PK, PD, and safety data in the current study as well 
as the ongoing FIH study (20160323), the premedication regimen may be modified 
(including with additional prophylactic therapies) as per the recommendations of the 
DLRT.  
To mitigate the risk of CRS, sites are required to have tocilizumab or siltuximab (if 
tocilizumab is not available)  on site.  
6.1.5  Other Intervention Procedures   
There are  no other treatment procedures in this study.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 57 of 176 
CONFIDENTIAL    
6.1.6  Product Complaints   
A product complaint i s any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a drug(s) or device(s) after it is released for distribution to market or 
clinic by either Amgen or by distributors and partners for whom Amgen manufactures the 
material.  This includes all components distributed with the drug, such as packaging drug 
containers, delivery systems, labeling, and inserts.  
This inclu des any investigational/ non-investigational product(s), device(s) or combination 
product(s) provisioned and/or repackaged/modified by Amgen  (ie, tarlatamab  and 
AMG  404) for which Amgen wants to collect complaints.  
Any product complaint(s) associated with  an investigational product  supplied by Amgen 
are to be reported.  
6.1.7  Excluded Treatments, Medical Devices, and/or Procedures During 
Study Period   
The following treatments and/or proc edures are excluded within the timeframes specified 
during the study:  
 Other investigational agents  
 Concurrent experimental or approved anti -tumor therapies other than study drugs  
 Radiation therapy  
Exception:  radiation therapy for symptom control (eg, bone  metastasis) or brain may be 
allowed after discussion with the Medical Monitor.  The radiation therapy should not 
include the thoracic field and must have been completed at least  before the 
subsequent dose of tarlatamab . 
 Immunosuppressive agents wit h the exception of those required by protocol, 
treatment for adverse events, CNS metastases, corticosteroid replacement therapy 
or unless agreed upon by the Principal Investigator and Medical Monitor.  
 Any live vaccine therapies.  Examples of live vaccines include, but are not limited to, 
the following:  measles, mumps, rubella, chicken pox, yellow fever, rabies, bacille 
Calmette -Guerin (BCG), and typhoid (oral) vaccine.  Seasonal influenza vaccines for 
injection are generally killed virus vaccines and are a llowed.  However, intranasal 
influenza vaccines (eg, Flu -Mist®) are live attenuated vaccines, and are not allowed.  
 Subjects must not schedule any major elective surgery during the treatment period 
and for at least  after the last administration of s tudy drugs.  If a subject 
undergoes any unexpected surgery during the course of the study, all study 
treatments must be withheld, and the investigator or designee should notify the 
sponsor’s medical monitor as soon as possible.  A subject may be allowed to  resume 
study drugs if both the investigator and sponsor’s medical monitor agree to restart 
study therapy.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 58 of 176 
CONFIDENTIAL    
6.2 Dose Modification   
6.2.1  Dose Cohort Study Escalation/De -escalation and Stopping Rules   
6.2.1.1  Dose -Exploration   
The dose -exploration part of the study will estimate the recommended phase  2 dose of 
tarlatamab  in combination with AMG  404 using an mTPI2 design.  The starting dose and 
dosing schedule of tarlatama b will be  mg as the target dose with 1 -step dosing.  The 
planned dose levels are shown in Table 4 -1. 
6.2.1.2  Dose Level Review Team   
For the dose exploration phase, a DLRT will convene to review the safety data before 
recommendations to dose escalate.  The required DLRT voting members include the 
Medical Monitor, Global Safety Officer (GSO), and Site investigator or designee.  The 
DLRT members are responsible for dosing recommendations, which may include 
implementing step dosing, escalation to the next dose, de -escalation to a lower dose, 
exploring intermediate dose levels; continuation , delay, or termination of dosing; or 
repetition or expansion of a cohort; or determination of recommended phase  2 dose .  
The DLRT will not make dose escalation recommendations until at least 3 subjects 
enrolled at the dose level are deemed DLT -evaluable.  Cumulative adverse events 
profile will be taken into consideration when making recommendations on dose 
escalation or de -escalation.  See Section 11.3 for more details regarding the DLRT.  
Dose Cohort Stopping Rules  
For details on dose escalation and stopping rules, refer to Section  4.1. 
6.2.1.3  Step Dosing   
Due to its known mechanism of action, subjects are at an increased risk for CRS during 
initiation of tarlatamab  treatment.  To mitigate this risk, tarlatamab  will be administered 
with the following dosing schedule:  
 One-step dosing involving a first step dose on  mg), followed by a step dose 
on  (equal to the target dose) and the target dose on  then  
6.2.1.4  Dose -limiting Toxicities   
Dose -limiting toxicities are defined as any adverse event with an onset within first 
 following first dose of tarlatamab  with any of the following criteria unless clearly 
related to causes other than tarlatamab : 
 All grade  3 adverse events except  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 59 of 176 
CONFIDENTIAL    
 Fatigue lasting less than 7 days  
 Grade  3 non -febrile neutropenia that improves to  grade  1 within 3 weeks 
including the use of growth factor support per neutropenia management 
guidelines (see Section  6.8.5 ) 
 Endocrinopathies, if manageable with replacement therapy  
 Grade  3 nausea/vomiting or diarrhea for less than 72 hours with adequate 
antiemetic and other supportive care  
 Grade  3 amylase or lipase values that are not associated with symptoms or 
clinical manifestations of pancreatitis  
 Grade  3 hematologic lab abnormal ities that are not considered clinically 
relevant  
 Grade  3 electrolyte abnormality that lasts up to 72 hours, is not clinically 
complicated, and resolves spontaneously or responds to conventional medical 
interventions  
 Grade  4 adverse event regardless of dur ation, except:  
 Grade  4 non febrile neutropenia lasting less than or equal to 7 days including 
the use of growth factor support per neutropenia management guidelines (see 
Section  6.8.5 ) 
 Grade  4 electrolyte abnormality that lasts up to 72 hours, is not clinically 
complicated, and resolves spontaneously or responds to conventional medical 
interventions  
 Grade  4 amylase or lipase values that are not associat ed with symptoms or 
clinical manifestations of pancreatitis  
 Grade  4 hematologic lab abnormalities that are considered not clinically 
relevant  
 Grade  5 adverse events  
 Recurrent grade  2 or higher pneumonitis  
 Without exception, any other toxicity requiring per manent discontinuation of 
AMG  404 per Table  6-2.   
The following  adverse events will NOT be adjudicated as DLT regardless of the grade or 
duration:  
 Lymphopenia  
 Fever  
 Tumor lysis syndrome including associated manifestations attributable to TLS (eg, 
electrolyte abnormalities, renal dysfunction, hyperuricemia)  
6.2.2  Dosage Adjustments, Delays, Rules for Withholding or Restarting, 
Permanent Discontinuation   
6.2.2.1  Amgen Investigational Product:  Tarlatamab   
The reason for dose change of tarlatamab  is to be recorde d on each subject’s CRF s. 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 60 of 176 
CONFIDENTIAL    
6.2.2.1.1  Dosage Adjustment   
Subjects should continue on the same target dose of tarlatamab  (not including the initial 
first step dose and step doses) throughout the study with the exception of subjects who 
experienced a DLT or other intolerable tarlatamab -related adverse events but show 
evidence of clinical benefit.  These subjects will have th e option to reduce the dose to 
the immediate next lower dose level shown to be safe and tolerable in the dose 
exploration part of the study (Section 4.1).  The study drug can be resumed once the 
adverse events recover to grade  1, and the reintroduction of tarlatamab  is deemed 
safe and tolerable by the investigator, Medical Monitor, and GSO.  The subject must be 
informed of the risk of continuing on the rapy.  Each subject is allowed one dose 
reduction.  For adverse events related to CRS, neurological events, and pituitary 
dysfunction, please see Sections  6.8.1 , 6.8.3 , and 6.8.4 , respectively, for guidelines for 
dose adjustments.  
If restarting tarlatamab  due to adverse events, dose reductions would occur with 
tarlatamab  (as described in Section  6.8).  The study drug can be resumed once the 
adverse events recover to grade  0 to 1 and the reintroduction of tarlatamab  is deemed 
safe by the investigator, Medical Monitor,  and GSO.  
6.2.2.1.2  Dose Delays   
During the first  DLT observation period, if the dosing of tarlatamab  is delayed for 
more than 72 hours for reasons other than DLT during the DLT evaluation period, a 
replacement subject may be enrolled and assigned to the same dose level.  The subject 
may continue on study only after discussion with the Medical Monitor.  
After the  DLT observation period, if the dosing of tarlatamab  is delayed for 
 2 weeks, the subject should resume the treatment as soon as possible if deemed safe 
by the investigator.  If the dosing of tarlatamab  is delayed between 2 to 4 weeks due to  
severe or life -threatening treatment -related adverse events, the subject can resume 
treatment if the toxicities resolve to grade  1 or return to subjects’ baseline values within 
3 weeks and restarting of therapy has been deemed safe by the investigator a nd 
medical monitor.  
If the dosing of tarlatamab  is delayed for more than 4 weeks due to severe or 
life-threatening treatment -related adverse events, the subject will be discontinued from 
investigational product.  If the dosing delay occurred under other co nditions, the case will 
be reviewed by the sponsor to determine whether and when the subject will be allowed 
to resume tarlatamab . 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 61 of 176 
CONFIDENTIAL    
For adverse events related to CRS, neurological events, and pituitary dysfunction, 
please see Sections 6.8.1 , 6.8.3 , and 6.8.4  respectively for guidelines for dose delays.  
6.2.2.1.3  Rules for Withholding or Resta rting   
Tarlatamab  should be withheld for any of the following:  
 DLT 
 Symptomatic hypophysitis (See Section  6.8.4 ) 
 Criteria for conditional withholding of tarlatamab  due to potential hepatotoxicity 
(Section  11.7) 
Tarlatamab  dosing can be resumed if the toxicities resolve to grade  1 or return to 
subjects’ baseline values within 3  weeks.  The restarting of therapy should be deemed 
safe by the investigator and medical monitor.  
Subjects should not be restarted with tarlatamab  if the following treatment -related 
adverse events occur:  
 Criteria for permanent withholding of tarlatamab  due to potential hepatotoxicity 
(Section  11.7) 
 Any grade  4 adverse events except those not considered DLT as described in 
Section  6.2.1.4  
 Grad e 3 adverse event(s) that do not recover to grade  1 within 3 weeks  
 Any grade  3 adverse events that recur (with the exception of grade  3 laboratory 
parameters not considered clinically relevant or recurrent non -febrile grade  3 
neutropenia which resolves w ith supportive care to grade   1 or returns to 
subjects’ baseline values within 3 weeks)  
For adverse events related to CRS, neurological events and pituitary dysfunction, please 
see Sections 6.8.1 , 6.8.3 , and 6.8.4  respectively for guidelines for dose adjustment.  
6.2.2.1.4  Criteria to Pause Enrollment   
At any point during the study, enrollment will be paused at the occurrence of 2 or more 
of the same  grade  4 or one or more grade  5 investigational product -related adverse 
events.  The DLRT will be reconvened to review the safety data and determine 
appropriate next step that may include but not limited to implementing s afety/toxicity 
management, informing health authorities, voluntarily putting the clinical trial on hold, or 
proceeding with enrollment.   (Note: following occurrence of an enrollment pause and 
DLRT review, a subsequent enrollment pause will occur at the occ urrence of 2 or more 
new grade  4 or 1 more grade  5 investigational product -related adverse events; 
additionally, if a pause and a DLRT has already occurred and the appropriate 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 62 of 176 
CONFIDENTIAL    
safety/toxicity management for grade  4 adverse events have already been implemen ted 
a subsequent enrollment pause may not occur.)  
6.2.2.2  Amgen Investigational Product:  AMG  404  
6.2.2.2.1  Immune -related Adverse Reactions   
Adverse events following the administration of AMG  404 may represent an immunologic 
etiology.  Based on clinical experience with other anti -PD-L1 therapies, these 
immune -related toxicities may occur shortly after the first dose to several months after 
the last dose of treatment and may affect more than 1 body system simulta neously.  
Early recognition and management are critical to reduce complications.  
Most immune -related adverse events require adequate evaluation to confirm etiology or 
exclude other causes.  Additional procedures or tests, such as bronchoscopy, 
endoscopy, o r skin biopsy, may be included as part of the evaluation.  
Based on the type and severity of the immune -related adverse event, withholding or 
permanent discontinuation of AMG  404 may be required, in addition to treatment with 
corticosteroids and/or other th erapies.  Dose modification and toxicity management 
guidelines for immune -related adverse reactions are provided in Table  6-2. 
6.2.2.2.2  Infusion -related Reactions   
Infusion -related reactions may occur with the administration of AMG  404.  Subjects 
should be monitored for signs and symptoms of infusion -related react ions, including 
pyrexia, chills, rigors, flushing, urticaria, hypotension, dyspnea, wheezing, headache, 
back pain, and abdominal pain.  If an infusion -related reaction is suspected, perform a 
physical examination, monitor vital signs, monitor pulse oximetr y, and perform ECG if 
the patient is experiencing chest pain or sustained tachycardia.  
For mild or moderate infusion -related reactions, interrupt or slow the rate of infusion.  For 
severe or life -threatening infusion -related reactions, permanently discontinue AMG  404.  
Treatment guidelines for infusion reactions associated with the administr ation of 
AMG  404 are provided in Table 6 -3.

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 63 of 176 
CONFIDENTIAL    
Table  6-2.  AMG  404 Dose Modification and To xicity Management Guidelines for Immune -Related Adverse Events   
Immune -Related 
Adverse 
Reactions  Severity or Specific Conditions  AMG  404 Dose 
Modification  Management with 
Corticos teroids and/or Other 
Therapies  Monitor & Follow -up 
Pneumonitis  Grade  2 (symptomatic; medical intervention indicated; 
limiting instrumental ADL)  Withhold  Administer corticosteroids at 
an initial dose of 1 to 
 mg/kg/d prednisone (or 
equivalent) followed by taper.  
Consider additional 
immunosuppressive agent 
(eg, infliximab, 
mycophenolate, 
cyclophosphamide) if 
refractory to corticosteroids.  Monitor subjects for signs and 
symptoms of pneumonitis.  
Evaluate subjects with 
suspected pneumonitis with 
radiographic imaging.  Add 
prophylactic antibiotics for 
opportunistic infections.  Recurrent grade  2 
Permanently 
discontinue  Grade  3 (severe symptoms, limiting self -care ADL, 
oxygen indicated)  
Grade  4 (life -threatening respiratory compromise, 
urgent intervention indicated [eg, tracheotomy or 
intubation])  
Colitis/Diarrhea  Grade  2 (increase of 4 to 6 stools per day over 
baseline; moderate increase in ostomy output 
compared to baseline)  
Withhold  Administer corticosteroids at 
an initial dose of 1 to 
 mg/kg/d prednisone (or 
equivalent) followed by taper.  
Consider infliximab if 
symptoms refractory to 
corticosteroids within 2 to 
3 days.  Monitor subjects for signs and 
symptoms of enterocolitis (eg, 
diarrhea, ab dominal pain, blood 
or mucus in stool with or without 
fever) and of bowel perforation 
(eg, peritoneal signs and ileus).  
For subjects with grade  2 
diarrhea suspecting colitis, 
consider GI consultation and 
endoscopy to rule out colitis.  Grade  3 (increase of 7 or more stools per day over 
baseline; incontinence; hospitalization indicated; 
severe increase in ostomy output compared with 
baseline; limiting self -care ADL)  
Grade  4 (life -threatening consequences; urgent 
intervention indicated)  Permanently 
discontinue  
Page 1 of 6  
Footnotes defined on last page of this table

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 64 of 176 
CONFIDENTIAL    
Table 6 -2.  AMG  404 Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Events  
Immune -Related 
Adverse 
Reactions  Severity or Specific Conditions  AMG  404 
Dose 
Modification  Management wi th Corticosteroids and/or Other 
Therapies  Monitor & Follow -up 
Hepatotoxicity  When applicable, refer to Section  11.7 for managing AST and/or ALT and/or total bilirubin elevations, when other liver parameters remain 
within normal limits (eg, INR).  
Immune -mediated 
hepatitisa 
(Adapted from 
NCCN Guidelines)  Grade  1 (AST or ALT  ULN but  3 x ULN) without 
elevated total bilirubin  Continue  Consider holding for concerning lab value trend.  
Monitor with liver 
function tests more 
frequently until 
returned to baseline 
or stable.  Additional 
management per 
institutional and 
professional society 
guidelines.  Grade  2 (AST or ALT 3 to 5 x ULN) without elevated 
total bilirubin  Withhold  Consider corticosteroids at an initial dose of 
 mg/kg/d prednisone (or equivalent) 
followed by taper.  
Grade  3 (AST or ALT 5 to 20 x ULN) without 
elevated total bilirubin  
(Without a clear alternative etiology.  If a clear 
alternative etiology, then withhold, do not 
discontinue AMG  404.)  
Permanently 
discontinue  Administer corticosteroids at an initial dose of 
 mg/kg/d prednisone (or equivalent) 
followed by taper.  Consider mycophenolate 
mofetil if refractory to corticosteroids or no 
improvement after 3 days.  
Grade  4 (AST or ALT  20 x ULN) without elevated 
total bilirubin  
(Without a clear alternative etiology.  If a clear 
alternative etiology, then withhold, do not 
discontinue AMG  404.)  Administer corticosteroids at an initial dose of 
 mg/kg/d prednisone (or equivalent) followed 
by taper.  Consider mycophenolate mofetil if 
refractory to corticosteroids or no improvement 
after 3  days.  
Grade  1 (AST or ALT  3 x ULN) with total bilirubin 
 1.5 x ULN  
[Without a clear alternative etiology.  If a clear 
alternative etiology, then withhold, do not 
discontinue.  Consider holding for concerning lab 
value trend.]  Administer corticosteroids at an initial dose of 
 mg/kg/d prednisone (or equivalent) followed 
by taper.  Consider mycophenolate mofetil if 
refractory to corticosteroids or no improvement 
after 3 days.  
Page 2 of 6  
Footnotes defined on last page of this table

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 65 of 176 
CONFIDENTIAL    
Table 6 -2.  AMG  404 Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Events  
Immune -Related 
Adverse Reactions  Severity or Specific Conditions  AMG  404 Dose 
Modification  Management with Corticosteroids and/or Other 
Therapies  Monitor & Follow -up 
Hypophysitis  
(Event reported as 
Endocrine 
disorders, Other, 
Hypophysitis)  Grade  3 or 4 (Severe or 
medically significant but not 
immediately life -threatening; 
hospitalization or prolongation of 
existing hospitalization indicated; 
limiting self -care ADL, or;   
Life-threatening consequences; 
urgent intervention indicated)  Withhold  Administer corticosteroids at an initial dose of 
 mg/kg/d prednisone (or equivalent) followed 
by taper.  In addition, initiate hormonal 
replacement therapy as clinically indicated.  Monitor for signs and symptoms of 
hypophysitis.  Consider endocrine 
consultation.  
Adrenal 
Insufficiency  Grade  3 or 4 (severe symptoms, 
hospitalization indicated or 
life-threatening consequences, 
urgent intervention indicated)  Withhold  Initiate IV stress -dose corticosteroids on 
presentation (hydrocortisone  mg or 
dexamethasone  mg [if the diagnosis is not 
clear and ACTH stimulation testing will be 
needed]).  Taper stress -dose corticosteroids 
down to maintenance doses (prednisone 5 to  
 mg daily) over 1 to 2 weeks after discharge.  Monitor for signs and symptoms of 
adrenal insufficiency.  Consider 
endocrine consultation.  
Hypothyroidism  Grade  3 or 4 (severe symptoms, 
limiting self -care ADL; 
hospitalization indicated or 
life-threatening consequences, 
urgent intervention indicated)  Withhold  Initiate thyroid hormone supplementation.  Monitor subjects for signs and 
symptoms of hypothyroidism.  
Consider endocrine consultation.  
Hyperthyroidism  Grade  3 or 4 (severe symptoms, 
limiting self -care ADL; 
hospitalization indicated or 
life-threatening consequences, 
urgent intervention indicated)  Withhold  Initiate -Blocker (eg, atenolol, propranolol) for 
symptomatic relief.  For severe symptoms or 
concern for thyroid storm,  initiate prednisone 
 mg/kg/d (or equivalent) tapered over 1  to 
2 weeks.  Consider use of SSKI or thionamide 
(methimazole or PTU).  Monitor subjects for signs and 
symptoms of hyperthyroidism.  
Consider endocrine consultation.  
Page 3 of 6  
Footnotes defined on last page of this table

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 66 of 176 
CONFIDENTIAL    
Table 6-2.  AMG  404 Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Events  
Immune -Related 
Adverse 
Reactions  Severity or Specific Conditions  AMG  404 
Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor &  Follow -up 
Diabetes Mellitus  Grade  3 hyperglycemia  
(  mg/d  
[  mmol/L]; 
hospitalization indicated)  Withhold  Initiate insulin therapy.  Monitor subjects for hyperglycemia or other 
signs and symptoms of diabetes.  Consider 
endocrine consultation.  
Grade  4 hyperglycemia  
(  mg/dL [  mmol/L]; 
life-threatening consequences)  
Nephritis and 
Renal Dysfunction  Grade  2 (serum creatinine 1.5 to 
3.0 x baseline; 1.5 to 3.0 x ULN)  Withhold  Administer corticosteroids at an initial 
dose of  to  mg/kg/d prednisone (or 
equivalent) followed by taper.  If 
worsening or no improvement occurs, 
increase dose of corticosteroids to  to 
 mg/kg/d prednisone (or equivalent).  Monitor changes in renal function.  Evaluate 
for other causes of renal dysfunction (eg, 
recent IV contrast, medications, fluid status, 
etc,) 
Grade  3 (serum creatinine 
3.0 x baseline; 3.0 to 6.0  x ULN)  Permanently 
discontinue  Administer corticosteroids at an initial 
dose of  mg/kg/d prednisone (or 
equivalent) followed by taper.  
Grade  4 (serum creatinine 
 6 x ULN)  
Page 4 of 6  
Footnotes defined on last page of this table  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 67 of 176 
CONFIDENTIAL    
Table 6 -2.  AMG  404 Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Events  
Immune -Related 
Adverse Reactions  Severity or Specific Conditions  AMG  404 
Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor & Follow -up 
Skin Grade  3 rash or suspected 
Stevens -Johnson syndrome (SJS) 
or toxic epidermal necrolysis (TEN)  Withhold  Administer corticosteroids at an initial 
dose of  mg/kg/d prednisone (or 
equivalent) followed by taper.  Treat 
with topical emollients, oral 
antihistamines, and high-potency topical 
corticosteroids as indicated.  Monitor subjects for suspected severe skin 
reactions and exclude other causes (eg, 
infection, an effect of another drug, a skin 
condition linked to another systemic 
disease, etc,).  For signs or symptoms o f 
SJS or TEN, withhold study drug and refer 
the patient for specialized care for 
assessment and treatment.  Grade  4 rash or confirmed SJS or 
TEN 
Permanently 
discontinue  
Encephalopathy  Grade  2 (moderate symptoms, 
limited instrumental ADL)  Withhold  Administer corticosteroids at an initial 
dose of  mg/kg/d prednisone (or 
equivalent) followed by taper.  Consider 
empirical antiviral (IV acyclovir) and 
antibacterial therapy until CSF results 
obtained and negative for aseptic 
meningitis.  Monitor subjects for neurologic symptoms 
and exclude other etiologies (eg, 
infectious).  Evaluation of patients with 
neurologic symptoms may include, but not 
be limited to, consultation with a 
neurologist, brain MRI, and lumbar 
puncture.  Grade  3 or 4 (Severe symptoms; 
limiting self -care ADL; or 
life-threatening consequences; 
urgent intervention indicated)  Permanently 
discontinue  
(If event not 
attributable to 
tarlatamab ) 
Page 5 of 6  
Footnotes defined on last page of this table  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 68 of 176 
CONFIDENTIAL    
Table 6 -2.  AMG  404 Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Events  
Immune -Related 
Adverse Reactions  Severity or Specific Conditions  AMG  404 
Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor & Follo w-up 
Myocarditis  Grade  1 (asymptomatic with laboratory [eg, BNP] or cardiac 
imaging abnormalities)  Withhold  Administer corticosteroids at an 
initial dose of  mg/kg/d 
prednisone (or equivalent) 
followed by taper.  Monitor patients with 
cardiovascular 
symptoms.  Ensure 
adequate evaluation to 
confirm etiology and/or 
exclude other causes.  Grade  2 (symptoms with mild to moderate activity or 
exertion)  Permanently 
discontinue  
Grade  3 (severe with symptoms at rest or with minimal 
activity or exertion; intervention indicated)  
Permanently 
discontinue  Grade  4 (life -threatening consequences; urgent intervention 
indicated [eg, continuous IV therapy or mechanical 
hemodynamic support])  
All Other 
Immune -Related 
Adverse Reactions  Grade  3 adverse reaction involving a major organ  Withhold  Based on type and severity of 
adverse reaction, administer 
corticosteroids.  Refer to ASCO 
Clinical Practice Guidelines for 
additional recommendations.  Ensure adequate 
evaluation to confirm 
etiology and/or 
exclude other causes.  Life-threatening or grade  4 adverse reaction involving a 
major organ  Permanently 
discontinue  
Recurrent or 
Persistent 
Immune -Related 
Adverse Reactions  Recurrence of same grade  3 or grade  4 adverse reaction  
Permanently 
discontinue  Based on type and severity of 
adverse reaction, administer 
corticosteroids.  Additional 
immunosuppressive treatment 
may be required.  Ensure adequate 
evaluation to confirm 
etiology and/or 
exclude other causes.  Requirement for   mg/day prednisone (or equivalent) for 
more than 12 weeks  
Persistent grade  2 or 3 adverse reactions lasting 12  weeks 
or longer after last dose (ie, does not resolve to grade  0 or 1 
within 12 weeks)  
Page 6 of 6  
NOTE:  Recommendations adapted from the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines for the Management  of Immune -Related 
Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy (Brahmer et al, 2018).  
General consi derations : 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 69 of 176 
CONFIDENTIAL    
 Corticosteroid taper should be initiated upon improvement of signs/symptoms and/or laboratory values to grade  1 or less.  Continue corticosteroid taper over 
the course of at least 4 to 6 weeks.  
 If AMG  404 has been withheld, treatment with AMG  404 may be resumed after adverse event (or associated signs/symptoms/laboratory parameters) has been 
reduced to grade  1 or less and corticosteroid has been tapered to prednisone   mg (or equivalent).  
 For severe and life -threatening immune -related advers e reactions, IV corticosteroids should be initiated first followed by oral corticosteroids.  Other 
immunosuppressive treatment should be initiated if the event cannot be controlled by corticosteroids.  
ACTH  adrenocorticotropic hormone; ADL  activities of daily living; ALT  alanine aminotransferase; ASCO  American Society of Clinical Oncology; AST   aspartate 
aminotransferase; BNP  B-natriuretic peptide; CSF  cerebral spinal fluid; ECG  electrocardiogram; GI   gastrointestinal; INR   international normalized ratio; 
IV  intravenous; MRI  magnetic resonance imaging; NCCN  National Comprehensive Cancer Network; PTU  propylthiouracil; SJS   Stevens -Johnson sy ndrome; 
SSKI   saturated solution of potassium iodide; TEN  toxic epidermal necrolysis; ULN  upper limit of normal  
a Immune -mediated hepatitis guidance adapted from the NCCN Version 1.2020, Management of Immune Checkpoint Inhibitor -Related Toxicities  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 70 of 176 
CONFIDENTIAL    
Table 6-3.  Management of Infusion -Related Reactions With AMG  404  
Severity  AMG  404 Dose 
Modification  Management  Premedication at Subsequent Dosing  
Grade  1 
(mild transient reaction; infusion 
interruption not indicated; intervention 
not indicated)  Interrupt or slow the rate of 
the infusion to 50  or less 
of the standard rate.   Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable.  
 If the infusion is interrupted, then after all 
symptoms have resolved, consider rechallenge 
with a reduced infusion rate (50  or less of 
standard rate) and additional premedication 
(such as corticosteroids and antihistamines.  
 Treat per institutional guidelines.  None  
Grade  2 
(therapy or infusion interruption 
indicated but responds promptly to 
symptomatic treatment [eg, 
antihista mines, NSAIDs, narcotics, IV 
fluids]; prophylactic medications 
indicated for  24 hours)  Interrupt or slow the rate of 
the infusion to 50  or less 
of the standard rate.  
For subjects who develop 
grade  2 infusion -related 
reaction despite adequate 
premedication, 
permanently discontinue 
AMG  404.  Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable.  
 If the infusion is interrupted, then after all 
symptoms have resolved, consider rechallenge 
with a redu ced infusion rate (50  or less of 
standard rate) and additional premedication 
(such as corticosteroids and antihistamines).  
 Treat per institutional guidelines.  Additional 
appropriate medical therapy may include but is 
not limited to IV fluids, antihistam ines, NSAIDs, 
acetaminophen, and narcotics.  Subject may be premedicated 
1.5 hours ( 30 minutes) prior to 
infusion of AMG  404 with:  
 Diphenhydramine  mg orally 
(or equivalent dose of 
antihistamine).  
 Acetaminophen  mg 
orally (or equivalent dose  of 
antipyretic).  
Page 1 of 2  
Footnotes defined on last page of this table  
 
 
 
 
 
 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 71 of 176 
CONFIDENTIAL    
Table  6-3.  Management of Infusion -Related Reactions With AMG  404 
Severity  AMG  404 Dose 
Modification  Management  Premedication at Subsequent Dosing  
Grade  3 
(prolonged [eg, not rapidly responsive 
to symptomatic medication and/or 
brief interruption of infusion]; 
recurrence of symptoms following 
initial improvement; hospitalization 
indicated for clinical sequelae)  
OR 
Grade  4 
(life-threatening consequences; 
urgen t intervention indicated)  Permanently discontinue 
study drug.   Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable.  
 Hospitalization may be indicated.  
 Treat per institutional guidelines.  Additional 
appropriate medical therapy may include but is 
not limited to IV fluids, antihistamines, NSAIDs, 
acetaminophen, narcotics, oxygen, 
vasopressors, corticosteroids, and epinephrine.  
In cases of anaphylaxis, epinephrine should be 
used immediately.  No subsequent dosing  
Page 2 of 2  
IV  intravenous; NSAIDs  non-steroidal anti -inflammatory drugs  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 72 of 176 
CONFIDENTIAL    
 
6.2.3  Hepatotoxicity Stopping and Rechallenge Rules   
Refer to Section  11.7 for details regarding drug -induced liver injury guidelines, as 
specified in the Guidance for Industry Drug -Induced Liver Injury:  Premarketing Clinical 
Evaluation, July 2009.  
6.3 Preparation/Ha ndling/Storage/Accountability   
Guidance and information on drug accountability for the investigational product will be 
provided to the site.  
6.4 Measures to Minimize Bias:  Random ization and Blinding   
6.4.1  Method of Treatment Assignment   
Subjects who meet eligibility criteria will be assigned to treatment with tarlatamab  and 
AMG  404. 
6.4.2  Blinding   
This is an open -label study; blinding  procedures are not applicable.  
6.5 Treatment Compliance   
When subjects are dosed at the site, they will receive tarlatamab  and AMG  404, or 
tarlatamab monotherapy , directly from the investigator or 
designee, u nder medical supervision.  The date and time of each dose administered in 
the clinic will be recorded in the source documents and recorded in the CRF . 
6.6 Treatment of Overdose   
The effects of overdose of these products are not known.  
The administered investigational product dose may be up to 10  lower or higher than 
specified in the protocol.  A dose of up to 10  higher than the intended dose may not 
require specific intervention.  
In any case of overdose, consultation with the Amgen medical monitor is required for 
prompt reporting of clinically apparent or laboratory adverse events possibly related to 
overdosage.  Consultation with the Amgen medical monitor is also required even if  there 
are no adverse events, in order to discuss further management of the subject.  If the 
overdose results in clinically apparent or symptomatic adverse events, the subject 
should be followed carefully until all signs of toxicity are resolved or returne d to baseline 
and the adverse event(s) should be recorded/reported per Section  11.4. 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 73 of 176 
CONFIDENTIAL    
A dose of >  10 higher than the intended investigational product dose will be 
considered clinically important and classified as a serious adverse event under the 
criterion of “other medically important serious event” Section  11.4. 
6.7 Prior and Concomitant Treatment   
6.7.1  Prior Treatment   
Prior therapies that were being taken/used from  1 month prior to signing informed 
consent  will be collected.   For all prior therapies not taken for SCLC, collect therapy 
name, indication, dose, unit, frequency, route, start and stop dates.  
All prior cancer treatment therapies will be collected.  
For all prior therapies taken for  SCLC (eg, chemotherapy, immunotherapy, biological 
therapy  or targeted therapy), collect (in the order they were administered):   
 therapy name   
 indication   
 dose and schedule of the agent(s)   
 unit  
 frequency   
 start and stop dates   
 disease state in which it was administered   
 reason for discontinuation (disease progression, clinical progression, toxicity, 
subject’s  decision)  
 
Additionally, details of the dates, portals, and total administered dose by portal should be 
recorded for all courses of radiation therapy, including those directed at the primary and 
metastatic site(s).   Details of prior radioisotope therapy should also be recorded.  
6.7.2  Concomitant Treatment   
Throughout the study, investigators may prescribe any concomitant medications or 
treatments deemed necessary, including the use of growth factors such as 
erythropoiesis -stimulating proteins as well as granulocyte colony stimula ting factor 
(G-CSF),  to provide adequate supportive care except for those listed in Section  6.1.7 . 
All prescription and nonprescription  concomitant therapies are to be collected from 
informed consent through the end of safety follow -up (SFU) period .  Collect therapy 
name, indication, dose, unit, frequency, route, start date, and stop date and record in the 
electronic case r eport form (eCRF).  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 74 of 176 
CONFIDENTIAL    
6.8 Support Care and Potential Risk Management Guidelines for 
Tarlatamab   
6.8.1  Cytokine  Release Syndrome   
Cytokine release syndrome is clinically defined and may have various manifestations.  
There are no established diagnostic criteria.  Signs and symptoms may include 
(Lee et al, 2014):  
 Constitutional :  fever   rigors, malaise,  fatigue, anorexi a, myalgias, arthralgias, 
nausea, vomiting, headache  
 Neurologic:  headache, mental status changes, confusion, delirium, word finding 
difficulty or frank aphasia, hallucinations, tremor, dysmetria, altered gait, seizures  
 Respiratory:  dyspnea, tachypnea, hy poxemia  
 Skin:   rash 
 Gastrointestinal:  nausea, vomiting, diarrhea  
 Cardiovascular:  tachycardia, widened pulse pressure, hypotension, increased 
cardiac output (early), potentially diminished cardiac output (late)  
 Coagulation:  elevated D -dimer, hypofibrinogenemia  bleeding  
 Renal:  azotemia  
 Hepatic:  transaminitis, hyperbilirubinemia  
Cytokine release syndrome is an identified risk of tarlatamab  administration.  Subjects 
may be at an increased risk for CRS during the first few days following the initial infusion 
of tarlatamab  and after a dose step increase.  Cytokine release syndrome may be 
life-threatening or fatal.  Infusion reactions may be cl inically indistinguishable from 
manifestations of CRS.  Subjects will be hospitalized for intensive monitoring in cycle  1 
and cycle  2 as described in Section  8.1.2 .  Throughout the infusion with tarlatamab  and 
after the end of infusion (EOI) (as described in Section  8.1.2 ), monitor subjects 
intensive ly for clinical signs (eg, fever, hypotension, tachycardia, dyspnea, tremors) and 
laboratory changes (eg, transaminase increase)  which may be related to CRS.  
Grading and management of CRS should be performed according to the guidelines 
provided in  Table 6 -4.  For subjects with suspected CRS, samples may be collected for 
analysis after discussion with the Medical Monitor.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 75 of 176 
CONFIDENTIAL    
Table 6-4.  Grading and Management of Cytokine Release Syndrome   
CRS 
Grade  Description of Severitya Minimum Expected 
Intervention  Instructions for Dose 
Modifications of Tarlatamab  
1 Symptoms are not life 
threatening and require 
symptomatic treatment only, 
eg, fever, nausea, fatigue, 
headache, myalgias, malaise  Administer symptomatic 
treatment (eg, 
paracetamol/acetaminophen 
for fever).  
Monitor for CRS symptoms 
including vital signs and pulse 
oximetry at least Q2 hours for 
12 hours or until resolution, 
whichever is earlier.  N/A 
2 Symptoms require and 
respond to moderate 
intervention  
 Oxygen 
requiremen t < 40, OR  
 Hypotension responsive 
to fluids or low dose of 
one vasopressor, OR  
grade  2 organ toxicity or 
grade  3 transaminitis per 
CTCAE criteria  Administer:  
 Symptomatic treatment 
(eg, paracetamol/ 
acetaminophen for fever)  
 Supplemental oxygen 
when oxygen saturation 
is < 90 on room air  
 Intravenous fluids or 
low dose vasopressor for 
hypotension when 
systolic blood pressure is 
< 85 mmHg.  Persistent 
tachycardia 
(eg, > 120 bpm) may also 
indicate the need for 
intervention for 
hypotension.  
Monitor for CR S symptoms 
including vital signs and pulse 
oximetry at least Q2 hours for 
12 hours or until resolution to 
CRS grade ≤ 1, whichever is 
earlier.  
For subjects with extensive 
co-morbidities or poor 
performance status or if CRS 
does not resolve to grade ≤ 1 
in 48 hours, manage per 
grade  3 CRS guidance below.  If CRS occurs during 
tarlatamab treatment, 
immediately interrupt the 
infusion and delay the next 
tarlatamab dose until the 
event resolves to CRS grade 
≤ 1 for no less than 72  hours.   
 
Resume tarlatamab  at same 
dose or reduce to next lower 
dose, if clinically indicated. 
(continuation with the next 
planned dose may be allowed 
after discussion with the 
medical monitor).  
 
Permanently discontinue 
tarlatamab  if there is no 
improvement to CRS 
≤ grade  1 within 7 day s. 
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 76 of 176 
CONFIDENTIAL    
Table 6 -4.  Grading and Management of Cytokine Release Syndrome  
CRS 
Grade  Description of Severity a Minimum Expected 
Intervention  Instructions for Dose 
Modifications of Tarlatamab  
3  Symptoms require and 
respond to aggressive 
intervention  
 Oxygen requirement 
≥ 40, OR 
 Hypotension requiring 
high doseb or multiple 
vasopressors, OR  
grade  3 organ toxicity or 
grade  4 transaminitis per 
CTCAE criteria  Admit to intensive care unit 
for close clinical and vital sign 
monitoring per institutional 
guidelines.  
 
Administer dexamethasone 
(or equivalent) IV at a dose 
maximum of 3 doses of  mg 
( mg/day).  The dose 
should then be reduced 
step-wise.  
 
Investigators should consider 
use of tocilizumabc  mg/kg 
over 1  hour (not to exceed 
mg).  Repeat tocilizumabc 
every 8 hours as needed if 
not responsive to IV fluids or 
increasing supplemental 
oxygen.  Maximum of 3  doses 
in a period.  
Maximum total of 4 doses.  
 
Investigators may also 
consider additional  
therapy, based on clinica l 
judgment.  If CRS occurs during 
tarlatamab  treatment, 
immediately interrupt 
tarlatamab  and delay the next 
dose until event resolves to 
CRS grade ≤ 1 for no less 
than 72 hours.  
 
Resume tarlatamab  to next 
lower dose (continuation at 
same dose with 
dexametha sone 
premedication may be 
allowed after discussion with 
the medical monitor).  
 
Permanently discontinue 
tarlatamab  if there is no 
improvement to 
CRS  ≤ grade  2 within 5  days 
or CRS ≤ grade  1 within 
7 days.  
Permanently discontinue or 
reduce to next lower dose  of 
tarlatamab  if CRS 
grade  3 occurs at the initial 
first step dose.  
4 Life-threatening symptoms  
 Requirement for 
ventilator support OR  
grade  4 organ toxicity 
(excluding transaminitis) per 
CTCAE criteria  Admit to intensive care unit 
for close clinical and vital sign 
monitoring per institutional 
guidelines.  
Administer dexamethasone 
(or equivalent) IV at a dose 
maximum of 3 doses of  mg 
( mg/day).  Further steroid 
use should be discussed with 
the Amgen medical monitor.  
Investigators should con sider 
use of tocilizumabc  mg/kg 
IV over 1 hour (not to exceed 
mg).  Repeat tocilizumabc 
every 8 hours as needed if 
not responsive to IV fluids or 
increasing supplemental 
oxygen.  Maximum of 3  doses 
in a hour period.  
Maximum total of 4  doses.  
 
Investigators may also 
consider additional  
therapy, based on clinical 
judgment.  If CRS occurs during 
tarlatamab  treatment, 
immediately stop the infusion.  
Permanently discontinue 
tarlatamab  therapy.   
CRS  cytokine release syndrome; CTCAE  Common Termin ology Criteria for Adverse Events; 
IV  intravenous; N/A  not applicable  
a Revised grading system for CRS (Lee et al, 2014)  
b High dose vasopressors (all doses are required for ≥ 3 hours):  Norepinephrine monotherapy ≥ 20 µg/min; 
Dopamine monotherapy ≥ 10 µg/kg/min, Phenylephrine monotherapy ≥ 200 µg/min, Epinephrine 
monotherapy ≥ 10 µg/min; If on vasopressin, vasopressin + norepinephrine equivalent of ≥ 10 µg/min; If on 
combinatio n vasopressors (not vasopressin), norepinephrine equivalent of ≥ 20 µg/min  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 77 of 176 
CONFIDENTIAL    
c If tocilizumab is not available, siltuximab (an anti -interleukin -6 [IL-6] monoclonal antibody) may be used in 
the management of cytokine release syndrome, following the criteria outlined in Table 6 -4.  The 
recommended dose of siltuximab is  mg/kg administered over 1 hour as an intravenous infusion, 
consistent with the prescrib ing information for the treatment of multicentric Castleman’s disease (Sylvant 
Prescribing Information), and the CARTOX Working Group Guidelines for CRS management (Neelapu, 
2018).  Siltuximab may be repeated if needed, in the event that CRS recurs after a subsequent infusion of 
tarlatamab.  Siltuximab may not be repeated in an individual subject that develops anaphylaxis to 
siltuximab, or gastrointestinal perforation after siltuximab.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 78 of 176 
CONFIDENTIAL    
Re-start of treatment after CRS:  
After a grade  3 CRS event, the next in fusion may be administered if all the following 
criteria are met:  
 The Amgen medical monitor must be consulted prior to re -starting treatment  
 If CRS occurred during tarlatamab  infusion, infusion has been interrupted for at least 
72 hours  
 The event has resolved to grade ≤ 1 prior to re -starting treatment  
If a subject experiences two separate grade  3 CRS events, tarlatamab  must be 
permanently discontinued.   
6.8.2  Immune -effector Cell -associated Neurologic Syndrome  
For this trial, ICANS will be using the criteria referenced in the publication by 
Lee et al, 2019.  While the grading system has been developed in large part from 
CAR -T therapies, symptoms of ICANS may be shared among immune  effector cell -
associated therapies such as BiTE molecules.  Although there may be a wide 
range of symptoms associated with ICANS, subjects may have a stereotypic 
course of a specific set of symptoms.  The earliest manifestations of ICANS are 
tremor, dysgr aphia, mild difficulty with expressive speech (especially in naming 
objects), impaired attention, apraxia, and mild lethargy.  
Immune effector cell -associated neurologic syndrome grade is determined by the 
most severe event (eg, depressed level of conscious ness, seizure, motor findings, 
raised intracranial pressure [ICP]/cerebral edema) not attributable to any other 
cause.  Refer to the immune effector cell -associated encephalopathy (ICE) score 
below for grading of ICANS.  
Immune Effector Cell -associated Ence phalopathy (ICE) Assessment Tool  
The ICE tool was designed to provide objectivity for the grading of multiple 
overlapping encephalopathy terms.  The tool includes an element for assessing 
the receptive aphasia seen in these subjects.  The total score that after assessing 
the following questions will be used as an input in the determination of the ICANS 
grade.  
 Orientation:  Orientation to year, month, city, hospital:  4  points  
 Naming:  ability to name 3  objects (eg, point to clock, pen, button):  3  points  
 Following commands:  ability to follow simple commands (eg, “Show me 
2 fingers” or “Close your eyes and stick out your tongue”):  1  point  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 79 of 176 
CONFIDENTIAL    
 Writing:  ability to write a standard sentence (eg, “Our national bird is the bald 
eagle”):  1 point  
 Attention:  abili ty to count backwards from 100 by 10:  1 point  
ICE Scoring  
 7-9, grade 1  
 3-6, grade 2  
 0-2, grade 3  
 0 due to subject unarousable and unable to perform ICE  
 Assessment, grade 4  
Table 6-5  ASBMT I mmune Effector Cell -associated Neurotoxicity Syndrome 
(ICANS) Consensus Grading for Adults  
Neurotoxicity 
Domaina Grade  1 Grade  2 Grade  3 Grade  4 
ICE scoreb 7-9 3-6 0-2 0 (subject is 
unarousable and 
unable to perform 
ICE) 
Depression level 
of 
consciousnessc Awakens 
spontaneously  Awakens 
to voice  Awakens only to 
tactile stimulus  Subject is 
unarousable or 
requires vigorous or 
repetitive tactile 
stimuli to arouse.  
Stupor or coma  
Seizure  N/A N/A Any clinical seizure 
focal or generalized 
that resolves 
rapidly or 
nonconvulsive 
seizures on EEG 
that resolve with 
intervention  Life-threatening 
prolonged seizure 
( 5 min); or repetitive 
clinical or electrical 
seizures without 
return to baseline in 
between  
Motor findingsd N/A N/A N/A Deep focal motor 
weakness such as 
hemiparesis or 
paraparesis  
Elevated 
ICP/cerebral 
edema  N/A N/A Focal/local edema 
on neuroimaginge Diffuse cerebral 
edema on 
neuroimaging; 
Decerebrate or 
decorticate posturing; 
or Cranial nerve VI 
palsy; or Papilledema; 
or Cushing’s triad  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 80 of 176 
CONFIDENTIAL    
ASBMT  American Society for Blood and Marrow Transplantation; CTCAE  Common Terminology 
Criteria for Adverse Events; EEG  electroencephalogram; ICANS  immune effector cell -associated 
neurologic syndrome; ICE  immune effector cell -associated encephalopathy; ICP  intracranial 
pressure; N/A  not applicable.  
a Other signs and symptoms such as headache, tremor, myoclonus, asterixis, and hallucinations 
may occur and could be attributable to immune effector -cell engaging therapies.  Although they 
are not included in this grading scale, careful attention and directed therapy may be warranted.  
b A subject with an ICE score of 0 may be classified as grade  3 ICA NS if awake with global aphasia, 
but a subject with an ICE score of 0 may be classified as grade  4 ICANS if unarousable.  
c Depressed level of consciousness should be attributable to no other cause (eg, no sedating 
medication).  
d Tremors and myoclonus asso ciated with immune effector cell therapies may be graded according to 
CTCAE  v5.0, but they do not influence ICANS grading.  
e Intracranial haemorrhage with or without associated edema is not considered a neurotoxicity 
feature and is excluded from ICANS grad ing.  It may be graded according to CTCAE v5.0.  
Source:  Lee et al, 2019  
 
Refer to the regional prescribing information or institutional guidelines (if not 
addressed in prescribing information) for additional information regarding 
standard of care therapy.  
6.8.3  Neurologic Events   
Please see  Table 6 -6 for the management of adverse events related to neurological 
events.  For subjects with suspected neurological  events, samples may be collected for 
analysis after discussion with the Medical Monitor.  
Table 6-6.  Management of Adverse Events Related to Neurologic Events   
Toxicity  Gradea Instructions for Treatment Interruption and Restart  
Neurologic 
Events  3b  Interrupt tarlatamab until the event improves to grade ≤ 1 and 
administer corticosteroids per local practice  
 Resume tarlatamab no less than 72 hours after the initial 
observation of the grade  3 adverse event at 1 dose level below  
 Permanently discontinue if:  
o Initial grade  3 neurologic event does not improve to grade 
≤ 1 within 7 days, OR 
o Grade  3 neurologic event reoccurs at the lower dose level 
within 7 days of re -initiation  
4  Permanently discontinue tarlatamab   
Seizure   Interrupt tarlatamab , administer corticosteroids and anti -seizure 
medication per local practice  
 For restart, refer to grade  3 neurologic events above for dose 
level rules for re -instituting infusion.  
 Do not re -initiate tarlatamab  until 7 days after the last seizure and 
after therapeutic levels of anti -seizure medication are likely to 
have been achieved.  
 Permanently discontinue if a second seizure occurs with 
re-initiation of tarlatamab at any dose  
a Per Common Terminology Criteri a for Adverse Events (CTCAE) Guidelines Version 4.0  
b For adverse events grade ≤ 2, please follow institutional guidelines for management.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024         Page 81 of 176 
CONFIDENTIAL    
6.8.4  Pituitary Dysfunction   
Based on the expr ession of DLL3 in the pituitary and observations in the cynomolgus 
monkey toxicology study, there is a key risk of pituitary dysfunction in humans with 
administration of tarlatamab . 
Early recognition of signs and symptoms and prompt intervention are essent ial.  
Symptoms may derive from hormonal deficiencies and by the mass effect due to the 
swelling of the gland.  The most common presentation includes headaches, asthenia, 
fatigue, nausea, weakness, lethargy, erectile dysfunction, and loss of libido.  
The diagnosis and management of pituitary gland dysfunction should be performed 
according to the guidelines provided in  Table 6 -7.  Adrenocorticotropic hormone 
(ACTH), cortisol, TSH, free thyroxine (FT4) will be evaluated at screening and monitored 
throughout the study.  Prolactin and follicle stimulating hormone (FSH)/ luteinizing 
hormone (LH), testosterone (in males) and estradiol (in females)  will also be evaluated 
at screening, end of therapy and as clinically indicated.  After a confirmed diagnosis, 
tarlatamab will be withheld, and corticosteroids and hormone replace ment administered 
if clinically indicated.  Please see Section 6.2.2.1.3  for guidelines for restarting 
tarlatamab .  This management recommendation ma y be revised based on emerging 
clinical data.
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 82 of 176 
CONFIDENTIAL    
Table 6-7  Monitoring and Management of Pituitary Gland Dysfunction (González -Rodríguez and Rodríguez -Abreu, 2016; 
Brahmer et al, 2018)  
 Monitor f or signs and symptoms of pituitary gland dysfunction, TSH, FT4, cortisol, and ACTH throughout study (prolactin, FSH, LH, test osterone [in males] and 
estradiol [in females] will be evaluated only at screening, EOT, and as clinically indicated)  
 Abnormal hormone monitoring result or clinical suspicion of pituitary gland dysfunction (headache, fatigue, asthenia, impaire d vision, vomiting, hypotension, 
amenorrhea, impotence)  
 Diagnostic tests:  consider brain MRI (if clinically indicated) with or wit hout contrast with pituitary/sellar cuts in subjects with multiple endocrine 
abnormalities and/or with new headache or vision changes.  Evaluate ACTH, AM Cortisol, TSH, FT4, electrolytes and consider ev aluating LH, FSH, and 
testosterone levels in males or estrogen females.  
 Obtain endocrinology consultation for hypophysitis or if clinically indicated  
 Once pituitary gland dysfunction is confirmed, hold further treatment with tarlatamab pending completion of evaluation.  Mana ge pituitary dysfunction according 
to NCCN or ASCO guidelines for Management of Immune -Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy (NCCN 
Guidelines, 2021; Brahmer et al, 2018).  
 Once stabilized on any replacement hormones and taking  mg or less of p rednisone or equivalent may consider restarting tarlatamab.  If subject experienced 
grade  3 or higher pituitary dysfunction, must discuss with medical monitor prior to restarting treatment.  
 Continue endocrinological surveillance  
ACTH  adrenocorticotropic hormone; ASCO  American Society of Clinical Oncology;  EOT  end of treatment; FSH  follicle stimulating hormone; FT4  free 
thyroxine; LH   luteinizing hormone; MRI  magnetic resonance imaging; NCCN  National Comprehensive Cancer N etwork;  TSH  thyroid stimulating hormone  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 83 of 176 
CONFIDENTIAL    
6.8.5  Neutropenia   
Neutropenia has been observed in patients receiving tarlatamab.  The risk mitigation 
plan includes monitoring of laboratory parameters (including, but not limited, to white 
blood cell [WBC] count and absolute neutrophil count) which will be evaluated at 
baseline and monitored throughout the study.  Specific recommendations for the 
management of neutropenia, and infusion interruption and stopping rules are fo und in 
the Table  6-8. 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 84 of 176 
CONFIDENTIAL    
Table  6-8.  Tarlatamab Dose Modification Guidelines for Neutropenia   
Grade  Interruption/ Delay  Specific Management  Re-start guidance  Permanent Discontinuation  
Non-febrile Neutropenia  
3 Interrupt tarlatamab until the 
event improves to grade  2 Assess for other potential etiologies of 
neutropenia, including concomitant 
medications and underlying infection  
Consider bone marrow biopsy, anti -neutrophil 
antibodies  
Granulocyte colony -stimulati ng factor (G -CSF) 
administration permitted  Resume tarlatamab no less than 
72 hours after the initial 
observation of the grade  3 
adverse event at the same dose 
level Initial grade  3 non -febrile 
neutropenia does not improve 
to  grade  2 in 3  weeks  
4 Interru pt tarlatamab until the 
event improves to grade  2 Assess for other potential etiologies of 
neutropenia, including concomitant 
medications and underlying infection  
Consider bone marrow biopsy, anti -neutrophil 
antibodies  
Consider G -CSF administration  Resume tarlatamab no less than 
72 hours after the initial 
observation of the grade  4 
adverse event and discuss with 
medical monitor the restarting 
dose  Initial grade  4 non -febrile 
neutropenia event that lasts 
 7 days  
G-CSF  granulocyte colony -stimulatin g factor  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   2020043 9 
Date:   05 June 2024         Page 85 of 176 
CONFIDENTIAL    
6.8.6  Tumor Lysis Syndrome   
Tumor lysis syndrome, a preventable complication of cancer therapies, is a result of 
rapid tumor necrosis with release of intracellular ions into the bloodstream.  It is 
characterized by hyperuricemia, hyperkalemia, and hyperphosphatemia.  Tumor lysis 
syndrome occurs primarily in hematological malignancies and high -grade lymphomas.  
The occurrence of TLS in solid tumors is rare but is more common in highly responsive 
tumor s with large tumor burdens.  Pretreatment elevation of serum lactate 
dehydrogenase (LDH) and uric acid, and pre -existing renal failure are risk factors for the 
development of TLS (Kallab and Jillella, 2001).  In light of the extremely low incidence of 
TLS in patients with solid tumors, routine prophylactic measures, such as allopurinol and 
alkaline hydration, cannot be recommended in all patients.  However, the potential for 
TLS in patients with bulky, SCLC who present with renal insufficiency, dehydration,  
hyperuricemia, and elevated serum LDH levels must be recognized, to allow for 
appropriate monitoring after treatment and early initiation of therapeutic measures if 
necessary (Kalemkerian et al, 1997).  Intravenous hydration and careful monitoring of 
fluid status is recommended.  Allopurinol or rasburicase can be considered for both 
prophylaxis and/or treatment of hyperuricemia.  
6.8.7  Vaccines   
Every effort should be made to fully vaccinate patients prior to  days from first dose of 
tarlatamab.  The use of vaccines except live and live -attenuated vaccines will be allowed 
during therapy per regional and institutional st andard of care.  However, SARS -CoV-2 
vaccinations should be avoided during screening (within a minimum of  days from first 
dose of tarlatamab) and should be also avoided in the first treatment cycle for better 
assessment of safety parameters.  Throughout  the trial, SARS -CoV-2 vaccination should 
be avoided within  days after the administration of tarlatamab.  In the event where a 
patient requires steroids for treatment of adverse events, vaccination should be avoided 
while on steroids.  
6.8.8  Management of SARS -CoV-2 Infection and COVID -19 Disease   
Management of SARS -CoV-2 infection and COVID -19 should be performed according to 
the guidelines provided in Table  6-9 (exceptions may be permitted with medical monitor 
approval).  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 86 of 176 
CONFIDENTIAL    
Table  6-9.  Infusion Interruptions/Delays/Withholding/Permanent Discontinuation and Management of SARS -CoV-2 Infection 
and COVID -19 Disease   
Grade  Interruption/ Delay  Specific 
Management  Re-start guidance  Permanent 
Discontinuation  
SARS -CoV-2 infection and COVID -19 disease  
Asympto
matic  Interruption required until 
at least 10 days since 
positive SARS -CoV-2 test 
UNLESS patient previously 
fully vaccinated against 
SARS -CoV-2.  If patient 
previously vaccinated and 
tests positive, then discuss 
with medical monitor.  Follow local 
guidelines and 
standard of care 
for COVID -19 
treatment and 
isolation  
Contact Amgen 
Medical Monitor 
within 
1 business day 
to ensure 
appropriate 
documentation 
and 
management of 
study activities   Re-start possible upon agreement between investigator and Amgen 
Medical Monitor provided:  
o There are no new findings on physical exam related to 
SARS -CoV-2, AND  
o Subject tests negative for SARS -CoV-2 by RT -PCR  
o Consider CT of the chest imaging, ECG, ECHO , and 
cardiology assessment prior to re -start of investigational 
product .  
OR 
o If subject continues to test positive for SARS -CoV-2 more 
than 10 days after initial positive test, or if subject  initially 
tests positive in the setting of prior COVID vaccination, 
resume investigational product only after discussion with 
patient and reassessment of individual risk/benefit and 
perform CT of chest imaging and ECG required prior to 
re-start of investi gational product.  Consider ECHO and 
cardiology assessment  
 Consider hospitalization for re -start of investigational product based 
on length of treatment interruption, risk of CRS at restart, and 
amount of time since patient was last treated  
 Dose modification:  resume at the same dose or reduce to next 
lower dose if clinically indicated  
 Premedication and assessments:  follow guidance in SOA tables  Immediately stop the 
infusion (if applicable) and 
permanently discontinue 
investigational product 
therapy if:  
Subject required 
treatment interruption 
greater than 28 days and 
upon discussion with 
Amgen medical monitor 
the decision is made to 
permanently discontinue 
treatment  
OR 
Initial benefit/risk 
assessment for individual 
patient is no longer 
favorable  
Page 1 of 2  
Footnotes defined on last page of this table.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 87 of 176 
CONFIDENTIAL    
Table  6-9.  Infusion Interruptions/Delays/Withholding/Permanent Discontinuation and Management of SARS -CoV-2 Infection 
and COVID -19 Disease  
Grade  Interruption/ Delay  Specific 
Management  Re-start guidance  Perm anent 
Discontinuation  
SARS -CoV-2 infection and COVID -19 disease  
Symptom
atic Interruption required 
until at least 10 days 
since complete 
resolution of acute 
symptoms  Follow local 
guidelines and 
standard of care for 
COVID -19 
treatment and 
isolation  
Contact Amgen 
Medical Monitor 
within 1 business 
day to ensure 
appropriate 
documentation and 
management of 
study activities   Re-start possible upon agreement between investigator and Amgen 
medical monitor provided:  
o There are no new findings on phys ical exam and chest 
imaging, related to SARS -CoV-2 
o Subject tests negative for SARS -CoV-2 by RT -PCR  
o Consider CT of the chest imaging and ECG, ECHO and 
cardiology assessment prior to re -start of investigational 
product .  
OR 
o If subject continues to test positive for SARS -CoV-2 more 
than 10 days after initial positive test, resume investigational 
product only after discussion with patient and reassessment 
of individual risk/benefit and perform CT of chest imaging 
and ECG required prior to re -start of inves tigational product.  
Consider ECHO and cardiology assessment  
 Consider hospitalization for re -start of investigational product based 
on length of treatment interruption, risk of CRS at restart, and amount 
of time since patient was last treated  
 Dose modification:  resume at the same dose or reduce to next lower 
dose if clinically indicated  
 Premedication and assessments:  follow guidance in SOA tables  Immediately stop the 
infusion (if applicable) and 
permanently discontinue 
investigational product 
therapy, if:  
Subject required 
treatment interruption 
greater than 28 days due 
to severe or 
life-threatening COVID -19 
OR 
Initial benefit/risk 
assessment for individual 
patient is no longer 
favorable  
Page 2 of 2  
COVID -19  coronavirus disease 2019; CRS  cytok ine release syndrome; CT  computed tomography; ECG  electrocardiogram; ECHO  echocardiogram; 
RT PCR   real time polymerase chain reaction; SARS -CoV-2  severe acute respiratory syndrome coronavirus 2; SOA   Schedule of Activities  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 88 of 176 
CONFIDENTIAL    
7. Discontinuation of Study Treatment and Subject 
Discontinuation/Withdrawal   
Subjects have the right to withdraw from investigational product and/or other 
protocol -required therapies, protocol procedures, or the study as a who le at any time 
and for any reason without prejudice to their future medical care by the physician or at 
the institution.  
The investigator and/or sponsor can decide to withdraw a subject(s) from investigational 
product, device, and/or other protocol -require d therapies, protocol procedures, or the 
study as a whole at any time prior to study completion for the reasons listed in  Section  1. 
7.1 Discontinuation of Study Treatment   
Subjects (or a legally acceptable representative) can decline to continue receiving 
investigational product and/or other protocol -required th erapies and/or procedures at any 
time during the study but continue participation in the study.  If this occurs, the 
investigator is to discuss with the subject the appropriate processes for discontinuation 
from investigational product or other protocol -required therapies and must discuss with 
the subject the possibilities for continuation of the Schedule of Activities (see 
Section  1.3) including different options of follow -up (eg, in person, by phone/mail, 
through family/friends, in correspondence/communication with other treating physicians, 
from the review of medical records) and collection of data, including endpoints, adverse 
events,  and must document this decision in the subject’s medical records.  Subjects who 
have discontinued investigational product , and/or other protocol -required therapies 
and/or procedures should not be automatically removed from the study.  Whenever safe 
and fe asible, it is imperative that subjects remain on -study to ensure safety surveillance 
and/or collection of outcome data.  
Reasons for early removal from protocol -required investigational product(s) or 
procedural assessments may include any of the following:  
 Decision by sponsor  
 Lost to follow -up 
 Death  
 Adverse event  
 Subject request  
 Ineligibility determined  
 Protocol deviation  
 Non-compliance  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 89 of 176 
CONFIDENTIAL    
 Confirmed disease progression as defined by modified RECIST 1.1 criteria 
(Section  11.9) or disease progression accompanied by worsening of symptoms or 
deterioration of the subject’s general condition  
*Note: Subjects with confirmed di sease progression per modified RECIST 1.1 criteria 
who have clinical benefit in the investigator’s judgment may be allowed to continue 
treatment after approval by the Medical Monitor as per Section 7.2 
 Requirement for alternative therapy  
 Protocol -specified criteria:  
Subjects who require more than 1 dose reduction  
7.2 Continuation on Study Treatment After Radiologic Disease 
Progression   
This section details the conditions necessary to allow continued treatment with 
tarlatamab after radiologic disease prog ression in subjects that continue to have clinical 
benefits in the investigator’s judgement, provided all of the following criteria are met at 
each occurrence:  
 Absence of threat to vital organs or critical anatomical sites (eg, respiratory failure 
due to tumor compression, spinal cord compression) requiring urgent alternative 
medical intervention with persistent immediate threat to vital organs after 
intervention.  The presence of brain metastases may be allowed, provided the 
lesions are amenable to radiat ion therapy or dexamethasone (or corticosteroid 
equivalent) and the subject is clinically stable as per investigator’s judgment.  
 No other treatment discontinuation criteria are met.  
 No significant, unacceptable, or irreversible toxicities related to any dose of the study 
treatment or treatment related adverse events of CTCAE grade  4 at the current dose 
at the time of progression.  
 The subject is willing to undergo biopsy of one of the new or progressing lesions.   If 
tumor biopsy is not clinically feasible  or advisable, the subject may continue only 
upon agreement with the investigator and the Amgen Medical Monitor.  
 Approval for continuation from the Amgen Medical Monitor.  
 Palliative radiation for new, progressive, or symptomatic lesions is permitted as p er 
Section 6.1.7 .  Tarlatamab must be held during treatment and radiation and must be 
completed at least  days before the subsequent dose of tarlat amab.  
 All protocol -mandated procedures must be performed as noted in the Schedule of 
Activities (Section 1.3) (imaging, labs, and clinic visits ma y be obtained earlier per 
clinical judgment and if clinically indicated).  
7.3 Subject Discontinuation/Withdrawal from the Study   
Withdrawal of consent for a study means that the subject does not wish to receive 
further protocol -required therapies or procedures, and the subject does not wish to or is 
unable to continue further study participation.  Subject data up to withdrawal of consent 
will be included in the analysis of the stu dy, and where permitted, publicly available data 
can be included after withdrawal of consent.  The investigator is to discuss with the 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 90 of 176 
CONFIDENTIAL    
subject appropriate procedures for withdrawal from the study and must document the 
subject’s decision to withdraw in the subject’s medical records.  
If a subject withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator must notify Amgen accordingly (see 
Section  11.6 for further details).  Refer to the Schedule of Activities (Section  1.3) for data 
to be collected at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed.  
7.3.1  Reasons for Removal from Study   
Reasons for removal of a subject from the study are:  
 Decision by sponsor  
 Withdrawal of consent from study  
 Death  
 Lost to follow -up 
7.4 Lost to Follow -up  
A subject will be considered lost to follow -up if they repeatedly fail to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions mus t be taken if a subject fails to return to the clinic for a required 
study visit:  
 The site must attempt to contact the subject and reschedule the missed visit as soon 
as possible and counsel the subject on the importance of maintaining the assigned 
visit s chedule and ascertain whether or not the subject wishes to and/or is able to 
continue in the study.  
 In cases in which the subject is deemed lost to follow -up, the investigator or 
designee must make every effort to regain contact with the subject (where pos sible, 
3 telephone calls and, if necessary, a certified letter to the subject’s last known 
mailing address or local equivalent methods).  These contact attempts are to be 
documented in the subject’s medical record.  
 If the subject continues to be unreachabl e, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  
 For subjects who are lost to follow -up, the investigator should search publicly 
available records where permitted to ascertain survival status.  This ensures that the 
data set(s) produced as an outcome of the study is/are as comprehensive as 
possible.  
8. Study Assessments and Procedures   
Study procedures and thei r time points are summarized in the Schedule of Activities 
(see Section  1.3).  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 91 of 176 
CONFIDENTIAL    
If an enrolled subject is subsequently determined to be ineligible for  the study, this must 
be discussed with the sponsor immediately upon occurrence or awareness to determine 
if the subject is to continue or discontinue study treatment.  
Adherence to the study design requirements, including those specified in the Schedule 
of Activities, is essential and required for study conduct.  
8.1 General Study Periods   
8.1.1  Screening, Enrollment and/or Randomization   
Informed consent must be obtained before completing any screening procedure or 
discontinuation of standard therapy for any disallowed therapy.  After the subject has 
signed the ICF, the site will register the subject manually and screen the subject in order 
to assess eligibility for participation.  The screening window is up to . 
All screening evaluations must be completed and reviewed to confirm that potential 
subjects me et all eligibility criteria.  The investigator will maintain a screening log to 
record details of all subjects screened and to confirm eligibility or record reasons for 
screening failure, (see Section 5.4) as applicable.  
If a subject has not met all eligibility criteria at the end of the screening period, the 
subject will be registered as a screen fail.  Screen fail subjects may be eligible for 
re-screening 1 time.  
Rescreen subjects must first be registered as screen failures and subsequently 
registered as rescreens.  Once the subject is registered as rescreened, a new  
screening window will begin.  Subjects will retain the same subject identific ation number 
assigned at the original screening.  If the rescreening period begins more than 30 days 
after the original signing of the ICF, all screening procedures, including informed 
consent, must be repeated.  
8.1.2  Treatment Period   
Treatment begins on cycle  1  when the first IV infusion of investigational product is 
administered to a subject.  The following procedures will be completed during the 
treatment period at the times de signated in the Schedule of Activities (Section  1.3).  The 
results of the cycle  1  laboratory tests must be available before starting treatment 
with tarlatamab .  Laboratory assessments that were done within 24 hours prior to 
infusion do not need to be repeated (except for cycle  1  dosing where laboratory 
assessments that were done within 48 hours prior to infusion do not need to be 
repeated).   Clinical evaluation should be completed within 6 hours prior to the first dose 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 92 of 176 
CONFIDENTIAL    
of tarlatamab .  All assessments and procedures should be collected at the exact nominal 
time point as noted in the Schedule of Activities (Section  1.3).  If unable to perform a 
procedure at the specified nominal time point, collect it as close as possible to the 
nominal time point and record the actual collection time.  
The end of treatment (EOT) visit will occur at the end of the last treatment cycle.  For 
subjects who prematurely discontinue investigational product treatment, the EOT visit 
should occur as soon as possible (within ) after the last dose of investigati onal 
product was administered.  
8.1.3  Safety Follow -up  
The procedures to be completed during SFU are indi cated in the Schedule of Activities 
(Section  1.3).  Upon permanent discontinuation from the study treatment for any reason, 
an SFU visit will be per formed approximately after the last dose 
(tarlatamab  or AMG  404) or prior to initiation of other therapy, whichever occurs first.  
The second safety follow -up visit will be performed approximately after 
the end of the last dose  of AMG  404 or prior to initiation of other therapy, whichever 
occurs first.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 93 of 176 
CONFIDENTIAL    
Subjects who discontinue AMG  404 but remain on treatment with AMG  757 will continue 
to have safety event collection at regularly scheduled study visits.  The second safety 
follow -up visit need only occur if  has not elapsed from the end of AMG  404 
treatment at the time of end of study treatment . 
8.1.4  Long -term Follow -up  
Long term follow -up will be conducted every 3  months ( 2 weeks)  up to 1 year from the 
first dose of tarlatamab  for all subjects who have not withdrawn consent by clinic visit, 
telephone, or chart review to assess for survival and/or the commencement of 
subsequent cancer therapy only.  
For subjects who discontinued treatment for any reason other than confirmed 
progressive disease, every effort should be made to perform radiographic imaging 
(computed tomography [CT]/MRI) of the chest, abdomen, pelvis, and all  other known 
sites of disease every 3 months until documentation of confirmed disease progression 
per modified RECIST 1.1, clinical progression, start of new anticancer therapy, or up to 
12 months after the first dose of tarlatamab, whichever occurs first.  
8.1.5  End of Study   
The End of Study visit is defined as the date of the final study visit (eg, final long -term 
follow -up visit) when assessments and/or procedures are performed.   
8.2 General Assessments   
8.2.1  Informed Consent   
All subjects or their legally authorized representative must sign and personally date the 
IRB/IEC approved informed consent before any study -specific procedures are 
performed.  
8.2.2  Demographics   
Demographic data collection including sex , age , race, and ethnicity will be collected in 
order to study their possible association with subject safety and treatment effectiveness .  
Additionally, demographic data will be used to study the impact on biomarkers variability 
and PK of the protocol -required therapies.  
8.2.3  Medical History   
The investigator or des ignee will collect a complete medical and surgical history that 
started prior to enrollment through the time of consent.  Medical history will include 
information on the subject's concurrent medical conditions.  Record all findings on the 
medical history C RF.  In addition to the medical history above, SCLC history must date 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 94 of 176 
CONFIDENTIAL    
back to the original diagnosis.  Relevant medical history, including antecedent 
hematologic or oncologic disease, other diseases/symptoms such as fatigue, bleeding, 
and infection (resolv ed and ongoing) will be collected.  The current toxicity grade will be 
collected for each condition that has not resolved.  Any unresolved medical history will 
be graded according to the CTCAE version 4.0 (See Section 11.4) unless specified 
otherwise.  
All prior cancer therapies will be collected.  
8.2.4  Physical Examination   
Physical examination will be performed as per standard of care.  Physical examination 
findings should be recorded on the appropriate CRF (eg, medical history, event).  
8.2.5  Physical Measurements   
Height (in centimeters) and weight (in kilograms) should be measured without shoes.  
8.2.6  Substance Abuse History   
Obtain a detailed history of prior and/or concurrent use of tobacco.  
8.2.7  Performance Status   
The subject’s performance status will be assessed using the ECOG performance scale 
(see Section 11.8). 
8.3 Efficacy Assessments   
8.3.1  Radiologic Imaging Assessment   
The extent of disease will be evaluated by contrast -enhanced MRI/computed 
tomography (CT) acc ording to modified RECIST 1.1 (Section 11.9).   

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 95 of 176 
CONFIDENTIAL    
Due to the mechanism of action of immune -enhancing therapies, subjects may 
experience delayed response or enhanced T -cell expansion and infiltratio n into tumors, 
leading to an apparent enlargement of existing lesions or the appearance of new lesions 
prior to maximal clinical benefit being observed.  
 
 
 
.  All brain scans on protocol are required to be MRI unless MRI is 
contraindicated, and  then CT with contrast is acceptable.  
 
. 
Determination of disease response for clinical management of subjects will be assessed 
at the clinical sites per modified RECIST 1.1.  Scans may be submitted to a central 
imaging core laboratory for archival, response assessment including modified 
RECIST  1.1, and/or  eg, volumetric and viable tumor measurements.  
Detailed information regarding submission of images to the central imaging core 
laboratory is found in the Imaging Procedural Manual.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 96 of 176 
CONFIDENTIAL    
8.4 Safety Assessments   
Planned time points for all safety assessments are listed in the Schedule of Activities 
see (Section  1.3). 
8.4.1  Vital Signs and Pulse Oximetry   
Vitals signs (blood pressure [BP], RR, HR, and temperature) and pulse oximet ry will be 
recorded by the investigator or designee at time points specified in the Schedule of 
Assessments ( Section  1.3). 
The following measurement s must be performed:  systolic/diastolic BP, HR, RR, and 
temperature.  Subject must be in a rested and calm state for at least 5 minutes before 
blood pressure assessments are conducted.  The position selected for a subject should 
be the same that is used t hroughout the study and documented on the vital sign CRF.  
The temperature location selected for a subject should be the same  as that used 
throughout the study and documented on the vital signs CRF.  Record all measurements 
on the vital signs CRF.  
In subjects with an initial blood pressure reading within the hypertensive range, a 
second  reading should be taken at least 1 minute after the initial reading, with the 
2 readings averaged to obtain a final blood pressure measurement.  The average value 
should be recorded in the eCRF.  
Oxygen saturation will be measured using a standard pulse oximeter.  The subject must 
be in a rested and calm state for at least 5 minutes before pulse oximetry assessments 
are completed.  
Vital signs will be taken pre -AMG  404 infusion and at AMG  404 EOI.  After each 
tarlatamab  infusion for the first 2 cycles (during the hospitalization period), vital signs will 
be assessed accordingly during the following timepoints:  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 97 of 176 
CONFIDENTIAL    
8.4.2  Neurological Examination   
A neurological examination will be performed as outlined in the Schedule of Activities 
(Section  1.3).  Subjects will be specifically queried for neurological symptoms observed 
in the interval since the last extended neurological examination.  Abnormalities of the 
following should be recorded:  level of consciousness, orientation, vision, cranial nerves 
and brain stem functions, pyramidal and extra pyramidal motor system, reflexes, musc le 
tone and trophic findings, coordination, sensory system, neuropsychological findings (eg, 
speech, cognition, and emotion).  
The individual performing the neurological examination will characterize the findings as 
either normal or abnormal.  Abnormal find ings found predose will be reported on the 
medical history page of the eCRF.  Abnormal findings found after the subject is dosed 
will be reported on the Event page of the eCRF.  
A more detailed neurological assessment may be performed in subjects at selecte d 
sites.  
8.4.3  Writing Test   
Subjects will be asked to provide writing tests in order to detect early cerebellar signs as 
outlined in the Schedule of Activities ( Section  1.3).  Subjects will write down the current 
date, location of the clinic, and the current time in a sentence.  The sentence format 
should be repeated each time thr oughout the study.  Interpretation of writing sample 
results will be based solely on the investigator’s assessment.  
8.4.4  Mini-Mental Status Examination   
The Mini Mental Status Examination (MMSE) Version 2 will be performed as outlined in 
the Schedule of Activities ( Section  1.3).  The MMSE is a 30 -point healthcare 
profession al (including study coordinators) administered questionnaire to assess 
potential subjects for cognitive impairment.  The assessment covers 8 categories, such 
as orientation to time, orientation to place or language, with a total score that ranges 
from 0 to  30 (30 indicates the best possible outcome).  The overall total score should be 
recorded on the appropriate eCRFs.  
8.4.5  Electrocardiograms (ECGs)   
Subject must be in supine positi on in a rested and calm state for at least 5 minutes 
before ECG assessment is conducted.  If the subject is unable to be in the supine 
position, the subject should be in most recumbent position as possible.  The ECG must 
include the following measurements:   Heart Rate, QRS, QT, QTc, and PR intervals.  The 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 98 of 176 
CONFIDENTIAL    
Principal Investigator will review all ECGs.  Once signed, the original ECG tracing will be 
retained with the subject's source documents.  At the request of the sponsor, a copy of 
the original ECG will be made available to Amgen.  See Section 1.3 for timing of ECG 
assessments.  
8.4.6  Clinical Laboratory Assessments   
Refer to Section  11.2 for the list of clinical laboratory tests to be performed and to the 
Schedule of Activities (Section  1.3) for the timing and frequency.  
The investigator is responsible for reviewing laboratory test results and recording any 
clinically relevant changes occurring during the study in the Event CRF.  The investigator 
must determine whether an  abnormal value in an individual study subject represents a 
clinically significant change from the subject’s baseline values.  In general, abnormal 
laboratory findings without clinical significance (based on the investigator's judgment) 
are not to be recor ded as adverse events.  However, laboratory value changes that 
require treatment or adjustment in current therapy are considered adverse events.  
Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded 
as the adverse event.  
All protocol -required laboratory assessments, as defined in Section  11.2, must be 
conducted in accordance with the laboratory manual and the Schedule of Activities 
(Section  1.3). 
8.4.7  Vital Status   
Vital status must be obtained for all subjects within the limits of local law.  This includes 
subjects who may have discontinued study visits with or without withdrawing consent 
and should include interrogation of public databases, if necessary.  If deceased, the date 
and reported cause of death should be obtained.  
8.4.8  Other Safety   
8.4.8.1  Echocardiogram (ECHO)/Multigated Acquisition (MUGA) Scan   
Echocardiogram  or MUGA will be performed t o assess cardiac ejection fraction and will 
occur at time points specified in the Schedule of Activities (Section  1.3). 
Echocardiography/MUGA should include an evaluation from left ventricular ejection 
fraction (LVEF).  Additional ECHO/MUGA assessments may be performed as clinically 
indicated.  For subjects developing COVID -19 during screening period and following 
screening imaging assessments, conside r repeating ECHO following resolution.   
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 99 of 176 
CONFIDENTIAL    
8.4.8.2  Hypersensitivity  
Hypersensitivity reactions have been reported in patients treated with tarlatamab 
including rare severe events.  Clinical signs and symptoms of hypersensitivity 
may include but are not limited to ra sh and bronchospasm.  Monitor patients for 
signs and symptoms of hypersensitivity during treatment with tarlatamab and 
manage as clinically indicated.  Withhold or consider permanent discontinuation 
of tarlatamab based on severity . 
8.4.9  Adverse Events and Ser ious Adverse Events   
8.4.9.1  Time Period and Frequency for Collecting and Reporting Safety 
Event Information   
8.4.9.1.1  Adverse Events   
The adverse event grad ing scale to be used for this study will be the C TCAE and is 
described in Section  11.4. 
The investigator is responsible for ensuring that all adverse events observed by the 
investigator or reported by the subject that occur after the first dose of investigational 
products through the second safety follow -up visit or 60 days after the last dose of 
investigational product(s), whichever is later,  are reported using the Events CRF.  
8.4.9.1.2  Serious Adverse Events   
The investigator is responsible for ensuring that all serious adverse events observed by 
the investigator or reported by the  subject that occur after signing of the informed 
consent through the second safety follow -up visit or  60 days after the last dose of 
investigational product(s), whichever is later,  are reported using the Events CRF . 
All serious adverse events will be collected, recorded, and reported to the sponsor or 
desig nee immediately and no later than 24 hours of the investigator’s awareness  of the 
event, as indicated in Section  11.4.  The investigator will submit any updated serious 
adverse event data to the sponsor immediately and no later than 24 hours of it being 
available.  
The criteria for grade  4 in the CTCAE gradin g scale differs from the regulatory criteria for 
serious adverse events.  It is left to the investigator’s judgment to also report these 
grade  4 abnormalities as serious adverse events.  For any adverse event that applies to 
this situation, comprehensive d ocumentation of the event’s severity must be recorded in 
the subject medical records.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 100 of 176 
CONFIDENTIAL    
8.4.9.1.3  Reporting Serious Adverse Events After the Protocol -required 
Reporting Period   
During the lon g-term follow -up period, if the investigator becomes aware of serious 
adverse events suspected to be related to investigational product and all fatal serious 
adverse events (regardless of causality), then these serious adverse events will be 
reported to Am gen.  The investigator will report serious adverse events  to Amgen 
immediately and no later than 24 hours after the investigator’s  awareness  of the event  
on the Events CRF . 
There is no requirement to actively monitor study subjects after the study has ended with 
regards to study subjects treated by the investigator.  However, if  the investigator 
becomes aware of  serious adverse events suspected to be related to investigational 
product  after the study has ended, then these serious adverse events  will be reported to 
Amgen immediately and no later than 24 hours after the investigator’s  awareness of the 
event.  
Serious adverse  events reported after the end of study  will be captured within the safety 
database as clinical trial cases and handled accordingly bas ed on relationship to 
investigational product.  
If further safety related data is needed to fulfill any regulatory reporting requirements for 
a reportable event, then additional information may need to be collected from the 
subject’s records if the subject ends the study.  
The method of recording, evaluating, and assessing causality of adverse events, and 
serious adverse events and the procedures for completing and transmitting serious 
adverse event reports are provided in Section  11.4. 
8.4.9.2  Method of Detecting Adverse Events and Serious Adverse Events   
Care will be taken not to introduce bias when detecting adverse events and/or serious 
adverse events.  Open -ended and non -leading verbal questioning of the subject is the 
prefer red method to inquire about adverse event  occurrence.  
8.4.9.3  Follow -up of Adverse Events and Serious Adverse Events   
After the initial adverse event/serious adverse event report, the inv estigator is required to 
proactively follow each subject at subsequent visits/contacts.  All adverse events and 
serious adverse events will be followed until resolution, stabilization, until the event is 
otherwise explained, or the subject is lost to follo w-up (as defined in Section  7.4).  
Further information on follow -up procedures is given in Section  11.4. 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 101 of 176 
CONFIDENTIAL    
All new information for previously reported serious adverse events must be sent to 
Amgen immediately and no later than 24 hours following awar eness of the new 
information.  If specifically requested, the investigator may need to provide additional 
follow -up information, such as discharge summaries, medical records, or extracts from 
the medical records.  Information provided about the serious adv erse event must be 
consistent with that recorded on the Events CRF.  
8.4.9.4  Regulatory Reporting Requirements for Serious Adverse Events   
If subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, this information must be submitted to Amgen.  
Prompt notification by the investigator to the sponsor of serious adverse events is 
essential so that legal obligations and ethical responsibilitie s towards the safety of 
subjects and the safety of a study treatment under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study treatm ent under clinical 
investigation.  The sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRBs/IECs, and investigators.  
Individual safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and sponsor policy and forwarded 
to investigators as necessary.  
An investigator who receives an individual safety report describing a serious adverse 
event or other s pecific safety information (eg, summary or listing of serious adverse 
events) from the sponsor , will file it along with the Investigator’s Brochure and will notify 
the IRB/IEC, if appropriate according to local requirements.    
Amgen will prepare a single Development Safety Update Report (DSUR) (also referred 
to as Annual Safety Report [ASR] in the European Union) for the Amgen Investigational 
Product.  In order to ensure that consolidated safety information for the trial is provided, 
this single DSUR will also include appropriate information on any other investigational 
products used in the clinical trial, if applicable.  
8.4.9.5  Safety Monitoring Plan   
Subject safety will be routinely moni tored as defined in Amgen’s safety surveillance and 
signal management processes.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 102 of 176 
CONFIDENTIAL    
8.4.9.6  Pregnancy and Lactation   
Details of all pregnancies and/or lactation in female subjects and female  partners of 
male subjects will be collected after the start of study treatment and until , after 
the last dose of tarlatamab and  days for female study subjects and  days for 
female partners of male study subjects  after the last dose of AMG  404. 
If a pregnancy is reported, the investigator is to inform Amgen immediately and no later 
than 24 hours of learning of the pregnancy and/or lactation and is to follow the 
procedures outlined in Section  11.5.  Amgen Global Patient Safety will follow -up with the 
investigator regarding additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneo us abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered serious adverse events.  
Further details regarding pregnancy and lactation are provided in Section  11.5. 
Pregnancy Testing  
A highly sensitive (urine or serum) pregnancy test should be completed at screening and 
within  days of initiation of investigational product for females of childbearing potential.  
Note:  Females who have undergone a bilateral tubal ligation/occlusion should have 
pregnancy testing per protocol requirements.  If a female subject, or the partner of a 
male subj ect, becomes pregnant it must be reported on the Pregnancy Notification 
Form, see  Figure  11-2.  Refer to Section 11.5 for contraceptive requirements.   
A pregnancy test should be performed  after the last dose of tarlatamab  and 
 days after the last dose of AMG  404. 
Additional on -treatment pregnancy testing may be performed at the investigator’s 
discretion or as required per local laws and regulations.  
8.5 Pharmacokinetic Assessments   
All subjects enrolled in the study will have PK samples assessed.  
Blood samples will be collected for measurement of serum concentrations of tarlatamab,  
and AMG  404 as specified in the Schedule of Activities ( Section  1.3).  Instructions for the 
collection and handling of biological samples will be provided by the sponsor.  The actual 
date and time (24 -hour clock time) of each sample will be recorded.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 103 of 176 
CONFIDENTIAL    

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 104 of 176 
CONFIDENTIAL    

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 105 of 176 
CONFIDENTIAL    
9. Statistical Considerations   
9.1 Statistical Hypotheses   
No formal statistical hypothesis will be tested.  
9.2 Sample Size Determination   
Approximately  subjects were anticipated to be enrolled in the study (up  to  subjects 
in a dose exploration  phase, and the remaining subjects enrolled in a dose expansion 
phase).  Study enrollment ended in .  A total of  subjects were enrolled, 
including  subjects in Part  1, and  subjects in Part  2. 
Dose Exploration Phase:  
Up to 6  planned dose cohorts  will be examined during dose exploration.  The planned 
dose levels for tarlatamab  with a fixed dose o f AMG  404 (  mg IV  are described 
in Section  4.1. 
Dose exploration will begin with  subjects treated at Dose Cohort Level 1.  The 
study DLT period is  days.  Once all subjects enrolled at a certain Dose Cohort Level 
are DLT evaluable , a DLRT meeting will be convened.  Depending on observed safety 
data, the following may occur:  1) dose de -escalation to the next lowest Dose Cohort 
Level, 2) additional enrollment to the current Dose Cohort Level, or 3) dose escalation to 
the next highes t Dose Cohort Level or initiation of enrollment in Part 2.  In order to 
consider a certain Dose Level as the recommended phase  2 dose , at least 
 DLT-evaluable subjects must be enrolled at that Dose Level.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 106 of 176 
CONFIDENTIAL    
These sample sizes are based on practical consider ations and are consistent with 
conventional oncology studies with the objective to estimate the recommended phase  2 
dose  and to evaluate initial safety and tolerability.  The probability of observing at least 
1 DLT if the true DLT rate is 10 to 30  is prov ided in Table 9 -1 for various number of 
subjects.  
Table 9-1.  Probability of Observing at Least 1 DLT   
Number of Subjects  10 DLT Rate  30 DLT Rate  
19 55 
27 70 
34 80 
47 91 
57 96 
65 98 
DLT  dose -limiting toxicity  
Dose Expansion Phase:  
If the sample size in the dose expansion phase of 10 (or  20).  There is 65  (88) 
probability of observing at least 1  adverse event with 10  incidence rate, and the 95  
exact confidence interval for 20  objective response (OR) is 3  to 56 (6 to 44). 
9.3 Populations for Analysis   
The following populations are defined:  
Population  Description  
Enrolled  All subjects who sign the ICF  
Safety  The Safety Analysis Set will consist of all subjects who 
received at least 1 dose of any Investigational Products.  
The analysis of all safety and efficacy endpoints, unless 
noted otherwise, will be conducted on the Safety Analysis 
Set. 
DLT For the dose exploration part of the study,  the analysis of 
DLT will be conducted on the DLT Analysis Set, defined as 
all subjects that are enrolled and received at least 1 dose of 
tarlatamab  and AMG  404 with an evaluable DLT endpoint.  
The DLT endpoint is evaluable if either:  1)  the subject 
exper iences a DLT, or 2) the subject does not experience a 
DLT and receives tarlatamab  and AMG  404 treatment as 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 107 of 176 
CONFIDENTIAL    
planned in cycle  1 and has been followed for safety events 
a minimum of  from start of treatment.  
OR The OR Analysis Set will consist of all subjects in the 
Safety Analysis Set who have had the opportunity to be 
followed for at least 8 weeks starting from day  1.  
PK The PK Analysis Set will contain all subjects who have 
received at least 1 dose of the Investigational Product and 
have at least 1 PK sample collected.  These subjects will 
be evaluated for PK analysis unless the number of data 
points required for analysis is not enough, or significant 
protocol deviations have affected the data, or if key dosing 
or sampling information is missing.  
 
9.3.1  Covariates   
The relationship between covariates and efficacy endpoints may be explored if 
appropriate.  
9.4 Statistical Analyses   
The statistical analysis  plan will be developed and finalized before database lock.  Below 
is a summary of the timing and methods for the planned statistical analyses.  To 
preserve study integrity, the final analysis will be conducted and reported following the 
end of study, as d efined in Section  4.5. 
9.4.1  Planned Analyses   
9.4.1.1  Interim Analysis and Early S topping Guidelines   
Safety data will be reviewed on an ongoing basis.  
During dose exploration (Part  1) and formally during DLRMs, Amgen, in consultation 
with the site investigators, will review all available cumulative data by cohort prior to 
making dose escalation or dose de -escalation recommendation.  Adverse events and 
DLTs observed in all subjects will be evaluated continually and fully integrated into all 
DLRMs and  considered in all enrolment and dosing decisions.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 108 of 176 
CONFIDENTIAL    
During dose expansion (Part 2), Amgen will conduct evaluations of the ongoing grade  4 
or higher treatment -related treatment emergent adverse events  to assess if the 
threshold for possible early trial termi nation has been reached. The safety interim will 
occur for every  subjects enrolled who have had opportunity to have at least  days 
of follow up since the first dose of tarlatamab . If this threshold is met, enrollment to dose 
expansion will be halted p ending review of safety data by the DLRT.  After receiving the 
DLRT recommendation, Amgen will choose to take one of the following actions.  
1) Terminate the trial  
2) Amend the protocol to potentially improve the benefit/risk for subjects (eg, increase 
safety monitoring, modify dose/schedule, mandate premedication)  
3) Continue dose expansion without any changes.  
The stopping rules use a Bayesian approach proposed by Thall (Thall et al, 1995) to 
terminate the study if the posterior probability that the grad e 4 or higher 
treatment -related treatment emergent adverse event  rate is greater than 20  is > 
80.  The stopping boundaries assume a prior distribution of Beta (0.40, 1.60) are 
presented in Table  9-2 and the operating characteristics with pre -specified batch size of 
 new subjects per batch are presented in Table 9 -3. 
Table  9-2.  Stopping Boundary for Dose Expansion with Posterior Probability of 
80 and Grade  4 or Higher Treatment -related Adverse Event Limit of 20   
Number of 
Subjects  Stop Subjects if Observing This Many Grade 4 or Higher 
Treatment -related Adverse Events  
≥ 4 
≥ 6 
≥ 9 
Dose Expansion Complete  
Table 9-3 Operating Characteristics with Batch Size of  Subjects   
True Grade 4 or Higher 
Treatment -related Adverse 
Event Rate  Probability of Early Stopping 
of Dose Expansion  Average Dose Expansion 
Sample Size  
0.10 2.0 39.5 
0.15 9.7 37.6 
0.20 25.8 33.9 
0.25 47.7 28.8 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 109 of 176 
CONFIDENTIAL    
0.30 69.2 23.4 
 
9.4.1.1.1  Criteria for Evaluating Treatment With Siltuximab   
Amgen will conduct evaluations of the treatment and outcome of the CRS events treated 
with siltuximab on an ongoing basis to assess if the threshold for evaluating siltuximab 
treatment has been reached as outlined in the Table  9-4.  If these criteria are met, an 
adhoc DLRM will be triggered to review safety data and available pharmacokinetic, 
pharmacodynamics, and efficacy data.  If recommended by DLRT, the use of siltu ximab 
will resume.  The criteria to trigger an adhoc DLRM to review siltuximab treatment use a 
Bayesian approach proposed by Thall  et al, 1995; an adhoc DLRM will be triggered if the 
posterior probability that the CRS progression to grade 3 rate of greater  than 20 is 
> 80 or the posterior probability that the CRS progression to grade 4 rate of greater 
than 7.5 is >80; or observation of any grade  5 CRS after the event has been treated 
with siltuximab.  The boundaries presented below assume a prior distri bution of Beta 
(0.4, 1.6) for progression to grade  3 CRS and a prior distribution of Beta (0.15, 1.85) for 
progression to grade  4 CRS.  The evaluations could occur more frequently if necessary 
to address emerging safety concerns.  If the triggered ad hoc D LRM coincide s with 
regular DLRM, they may be combined.  
Table  9-4.  The Criteria for Evaluating the Use of Siltuximab   
Number of 
subjects treated 
with siltuximab  Trigger DLRM if severity of any CRS event treated with siltuximab 
progresses to Grade 5   
Or this number of subjects with 
severity of CRS progressed to 
Grade 3 after being treated with 
siltuximab  Or this number of subjects with 
severity of CRS progressed to 
Grade 4 after being treated with 
siltuximab  
≥ 3 ≥ 2 
≥ 4 ≥ 2 
≥ 5 ≥ 3 
≥ 6 ≥ 3 
≥ 7 ≥ 4 
≥ 9 ≥ 4 
≥ 10 ≥ 5 
≥ 11 ≥ 5 
CRS   cytokine release syndrome; DLRM  Dose Level Review Meeting  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 110 of 176 
CONFIDENTIAL    
9.4.1.2  Primary Analysis   
The primary analysis for this study will occur when target enrollment is complete and 
each subject either completes at least 6 months on study or withdraws from the study.  
9.4.1.3  Final Analysis   
The final analysis will be performed after the last subject has had an opportunity to 
comp lete the corresponding EOT visit/procedures.  
9.4.2  Methods of Analyses   
9.4.2.1  General Considerations   
Descri ptive statistics will be provided for selected demographics, safety, 
pharmacokinetic, efficacy data by dose, dose schedule, and time as appropriate.  
Descriptive statistics on continuous data will include means, medians, standard 
deviations, and ranges, wh ile categorical data will be summarized using frequency 
counts and percentages.  Graphical summaries of the data may also be presented.  
Confidence intervals (CI) for proportions will be estimated using an exact method 
proposed by Clopper -Pearson (Clopper and Pearson, 1934).  Kaplan -Meier methods will 
be used to estimate the median and percentiles for time to event endpoints with CI 
calculated using the Brookmeyer and Crowley (Brookmeyer and Crowley, 1982) method.  
Kaplan -Meier methods will be used to estim ate landmarks for time to event endpoints 
(eg, 1 -year OS) with the Greenwood formula (Kalbfleisch and Prentice, 1980) used to 
estimate the standard error used in CI calculation.  
9.4.2.2  Efficacy Analyses   
 
Endpoint  Statistical Analysis Methods  
Primary  Not applicable  
Secondary  The proportion of subjects with an objective response and disease 
control (per modified RECIST v1.1) and 95  CI will be tabulated by 
planned dose level and schedule.  
 
For all subjects treated at the recommended phase  2 dose , 
Kaplan -Meier methods will be used to estimate for 1) duration of 
response (DOR), 2) OS, 3)  progression -free survival (PFS) wi th 95 
CI.  For all subjects treated at the recommended phase  2 dose , 
Kaplan -Meier methods will be used to estimate landmarks for time to 
event events (eg, 6 -month PFS and OS) with 95  CI. 
Exploratory  Will be described in the statistical analysis plan fin alized before 
database lock  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 111 of 176 
CONFIDENTIAL    
9.4.2.3  Safety Analyses   
9.4.2.3.1  Analyses of Primary Safety Endpoint(s)   
 
Endpoint  Statistical Analysis Methods  
Primary  The analysis of DLTs will be conducted on the DLT Analysis Set.  
Subject  incidence of DLT will be tabulated by planned dose level.    
Secondary  The statistical analysis methods for other safety endpoints are below . 
 
9.4.2.3.2  Adverse Events   
Subject incidence of all treatment -emergent adverse events will be tabulated by system 
organ class and preferred term.  Tables of fatal adverse events, serious adverse events, 
adverse events leading to discontinuation from investigational product or other 
protocol -required therapies, and significant treatment emergent adverse events will also 
be provided.   
 
9.4.2.3.3  Laboratory Test Results   
The analyses of safety laboratory endpoints will include summary statistics at selected 
time points by tre atment group.  Shifts in grades of safety laboratory values between the 
baseline and the worst on -study value will be tabulated by treatment group.  
9.4.2.3.4  Vital Signs   
The analyses o f vital signs will include  summary statistics at selected time points by 
treatment group.  Shifts in vital sign values between the baseline and the worst on -study 
value will be tabulated by treatment group.  
9.4.2.3.5  Physical Measurements   
The analyses  of physical measurements will include summary statistics at baseline by 
treatment group.  
9.4.2.3.6  Electrocardiogram   
The ECG measurements from this clinical study were performed as per standard of care 
for routine safety monitoring, rather than for purposes of assessment of potential QTc 
effect.  No statistical analyses of ECG measurements are planned.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 112 of 176 
CONFIDENTIAL    
9.4.2.3.8  Exposure to Investigational Product   
Subject exposure to investigational product and combination therapy will be summarized 
using descriptive sta tistics.  The number of cycles of protocol -specified therapy 
administered will be summarized with an additional breakdown of the number of cycles 
started.  In addition, the duration of therapy, the cumulative dose, and the average dose 
per administration a nd relative dose intensity will be summarized.  The number and 
percent of subjects with dose modifications (eg, dose reductions, dose interruptions) and 
reason for modification will be summarized as well.  Subject -level data may be provided 
instead of the summary if the subject incidence is low or single dose is given.  
9.4.2.3.9  Exposure to Concomitant Medication   
Number and proportion of subjects receiving therapies of interest will be summarized by 
preferred term for each treatment group as coded by the World Health Organization, 
2018.  
9.4.2.4  Other Analyses   
Pharmacokinetic parameters will be determined from the c oncentration -time profile using 
standard non -compartmental approaches and considering the profile over the complete 
sampling interval.   
 
 
 
9.4.2.5  Adaptive Design   
The guidelines described in Section 4.1 for dose escalation or de -escalation to the next 
dose level are determined by using a mTPI -2 algorithm (Guo et  al, 2017) with one 
practical modification.  Consistent with conventional oncology phase  1 study designs 
(eg, 3+3 design) and given the imprecision with making decisions using as few as 
 subjects, in the instance of 1 DLT in the initial  subjects at a do se level then, as 
appropriate, the design allows expansion at the dose level beyond  subjects.  All other 
dose escalation or de -escalation rules are determined strictly by the mTPI -2 algorithm as 
described below.  The mTPI -2 algorithm employs a simple bet a-binomial Bayesian 
model.  Let 𝑝𝑇 be the target toxicity level and ( 𝑝𝑇 − ϵ1, 𝑝𝑇 + ϵ 2) be the equivalence toxicity 
interval denoted as EI.  The unit toxicity interval (0, 1) is divided into subintervals with 
equal length given by (ϵ 1 + ϵ 2).  Let the under -dosing intervals (LI) denote for a set of 
intervals below EI, and the overdosing intervals (HI) for a set of intervals above EI.  The 
3 types of dosing intervals (EI, LI, HI) are associated with 3 different dose -escalation 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 113 of 176 
CONFIDENTIAL    
decisions.  The LI correspo nd to a dose escalation (E), the HI correspond s to a dose 
de-escalation (D), and proper dosing intervals (EI) correspond to staying at the current 
dose (S).  This study design uses a target toxicity level, 𝑝𝑇 of 30, and EI of (25 , 33). 
Decision rules are based on the unit probability mass (UPM) calculated on these 
equal -length intervals.  Given an interval and a probability distribution, the UPM of that 
interval is defined as the probability of the interval divided by the length of the i nterval.  
The mTPI -2 design calculates the UPMs for each of equal -length dosing intervals.  If the 
interval with the largest UPM is from LI, EI, or HI, then the corresponding dose decision 
would be E, S, or D, respectively.  
A dose level will be considered unsafe, with no additional subjects enrolled at that dose 
level, if it has an estimated 95  or more probability of exceeding the target DLT rate 𝑝𝑇 
(ie, P [DLT > 𝑝𝑇 | data] > 95 ).  Based on this rule, the following instances would result 
in a dose level being considered unsafe.  
 or more DLTs in ≤subjects  
 or more DLTs in ≤subjects  
 or more DLTs in ≤subjects  
 or more DLTs in  subjects  
After the escalation phase is completed, final DLT rates at each dose level will be 
estimate d by isotonic regression (Ji et al, 2010).  The weighted least squares regression 
model will assume monotonic non -decreasing DLT rates with increasing dose and use 
the empirical (observed) DLT rates at each dose level as responses and dose level 
sample siz es as weights, along with the pool adjacent violators algorithm (PAVA) to 
estimate the DLT rate at each dose level.  Given the DLT estimates for each dose level, 
the recommended phase  2 dose  will be selected from all tried dose levels that have not 
been pr eviously declared to be unsafe with a DU decision according to the mTPI 
decision table.  With this constraint, the recommended phase  2 dose  will be determined 
as the dose level with the DLT estimate closest to the target toxicity level of 30 . 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 114 of 176 
CONFIDENTIAL    
10. References   
AMG  404 Investigator’s Brochure.  Thousand Oaks, CA.  Amgen Inc.  
AMG  757 Investigator’s Brochure.  Thousand Oaks, CA.  Amgen Inc.  
Brahmer JR, Lacchetti C, Schneider  et al.  Management of Immune -Related Adverse 
Events in Patients Treated with Immune Checkpoint Inhibitor Therapy:  American 
Society of Clinical Oncology Clinical Practice Guideline.  J Clin Oncol .  
2018;36(17):1714 -1768.  
Bristol Myers Squibb.  Bristol Mye rs Squibb Statement on Opdivo (nivolumab) Small Cell 
Lung Cancer U.S. Indication.  2020.  https://news.bms.com/news/details/2020/Bristol -
Myers -Squibb -Statement -on-Opdivo -nivolumab -Small -Cell-Lung -Cancer -US-
Indication/default.aspx  
Brookmeyer R, Crowley J.  A confidence interval for the median survival time.  
Biometrics .  1982;38:29 -41. 
Byers LA, Rudin CM.  Small cell lung cancer:  where do we go from here?  Cancer.  
2015;121:664 672.  
Clopper CJ and Pearson ES.  The Use of Confidence or Fiducial Limits Illust rated in the 
Case of the Binomial.  Biometrika .  1934;26:404 -413. 
Coiffier B, Altman A, Pui C -H, et al.  Guidelines for the Management of Pediatric and 
Adult Tumor Lysis Syndrome:  An Evidence -Based Review.  J Clin Oncol .  
2008;26(16):2767 -2678.  
Eisenhauer  EA, Therasse P, Bogaerts J, et al.  New response evaluation criteria in solid 
tumors:  revised RECIST guideline (version 1.1).  Eur J Cancer .  2009;45:228 -247. 
Friberg G, Reese D.  Blinatumomab (Blincyto):  lessons learned from the bispecific t -cell 
engag er (BiTE) in acute lymphocytic leukemia (ALL). Annals of Oncology . 2017;28:2009.  
González -Rodríguez E, Rodríguez -Abreu D; Spanish Group for Cancer Immuno 
Biotherapy (GETICA).  Immune Checkpoint Inhibitors:  Review and Management of 
Endocrine Adverse Events .  Oncologist . 2016 Jul;21(7):804 -816. 
doi:10.1634/theoncologist.2015 -0509. Epub 2016 Jun 15  
Guo W, Wang SJ, Yang S, Lynn H, Ji Y.  A Bayesian interval dose -finding design 
addressing Ockham’s razor:  mTPI -2.  Contemp Clin Trials . 2017;58:23 -33. 
Gustafsson BI, Kidd M,  Chan A, Malfertheiner MV, Modlin IM .  Bronchopulmonary 
neuroendocrine tumors.  Cancer .  2008;113:5 -21. 
IMFINZI United States Prescribing Information  
https://www.azpicentral.com/imfinzi/imfinzi.pdf#page 1 
Ji Y, Liu P, Li Y, Bekele BN.  A modified toxicity probability interval method for 
dosefinding trials.  Clin Trials.   2010;7:653 -663. 
Kalbfleisch JD, Prentice RL.  The statistical analysis of failure t ime data. John Wiley & 
Sons, Inc., New York, 1980. xi + 321 pp  
Kalemkerian GP, Darwish B, Varterasian ML.  Tumor lysis syndrome in small cell 
carcinoma and other solid tumors.  Am J Med .  1997 Nov;103(5):363 -367. 
Kallab AM, Jillella AP.  Tumor lysis syndro me in small cell lung cancer.  Med Oncol .   
2001;18(2):149 -151. 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 115 of 176 
CONFIDENTIAL    
Keytruda United States Prescribing Information, 2020.  
https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf  
Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M.  Increase  of PD -L1 expressing 
B-precursor ALL cells in a patient resistant to the CD19/CD3 -bispecific T cell engager 
antibody blinatumomab.   J Hematol Oncol.  2015;8:111.  Published 2015 Oct 8. 
doi:10.1186/s13045 -015-0213 -6 
Koinis F, Kotsakis A, Georgoulias V.  Sma ll cell lung cancer (SCLC):  no treatment 
advances in recent years.  Transl Lung Cancer Res.  2016;5:39 -50 
Lee DW, Gardner R, Porter DL, et al.  Current concepts in the diagnosis and 
management of cytokine release syndrome.  Blood 2014;124(2):188 -195 
Lee DW, Santomasso BD, Locke FL, et al.  ASTCT Consensus Grading for 
Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune 
Effector Cells.  Biol Blood Marrow Transplant .  2019;25:625 -638. 
Merck.  Merck Provides Update on KEYTRUDA (pembrolizumab) Indication in 
Metastatic Small Cell Lung Cancer in the US.  2021.  
https://www.merck.com/news/merck -provides -update -on-keytruda -pembrolizumab -
indication -in-metastatic -small -cell-lung-cancer -in-the-us/. 
NCCN Guid elines.  Immunotherapy.  2021.  
https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf.  
Neelapu SS, Tummala S, Kebriaei P, et al.  Chimeric antigen receptor T -cell therapy - 
assessment and management of toxicities.  Nat Rev Clin Oncol .  201 8;15(1):47 -62. 
Nishino M, Giobbie -Hurder A, Gargano M, et al.  Developing a common language for 
tumor response to immunotherapy:  immune -related response criteria using 
unidimentional measurements.  Clin Cancer Res .  2013;19:3936 -3943.  
Offner S, Hofmeister  R, Romaniuk A, Kufer P, Baeuerle PA.  Induction of regular 
cytolytic T cell synapses by bispecific single -chain antibody constructs on MHC class I 
negative tumor cells.  Mol Immunol.  2006;43:763 -771. 
Oken MM, Creech RH, Tormey DC, et al.  Toxicity and re sponse criteria of the Eastern 
Cooperative Oncology Group.  Am J Clin Oncol .  1982;5:649 -655. 
Opdivo United States Prescribing Information 2019.  
https://packageinserts.bms.com/pi/pi_opdivo.pdf  
Owen DH, Giffin MJ, Bailis J, et al.  DLL3:  an emerging targe t in small cell lung cancer.  
J Hematol Oncol .  2019;12:61.  
Rudin CM, Ismaila N, Hann CL, et al.  Treatment of small -cell lung cancer:  American 
Society of Clinical Oncology endorsement of the American College of Chest Physicians 
guideline.  J Clin Oncol.   2015;33:4106 -4111.  
Sylvant United States Prescribing Information, 2014. 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125496s013lbl.pdf  
TECENTRIQPrescribing Information 2019. 
https://www.gene.com/download/pdf/tecentriq_prescribing.pdf  
Thall PF, Simon RM, Estey EH.  Bayesian sequential monitoring designs for single -arm 
clinical trials with multiple outcomes.  Statistics in Medicine .  1995;14:357 -379. 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 116 of 176 
CONFIDENTIAL    
Trigo J, Subbiah V, Besse B, et al.  Lurbinectedin as second -line treatment for patients 
with small -cell lung cancer:  a single -arm, open -label, phase 2 basket trial.  Lancet 
Oncol .  2020;21:645 -654. 
Webster J, Luskin MR, Prince GT, et al.  Blinatumomab in  combination with immune 
checkpoint inhibitors of PD -1 and CTLA -4 in adult patients with relapsed/refractory (R/R) 
CD19 positive B -Cell acute lymphoblastic leukemia (ALL): preliminary results of a 
phase  I study.   Blood .  2018; 132(Suppl 1):557. doi: 10.1182 /blood -2018 -99-111845.  
Wolchok JD, Hoos A, O’Day S, et al.  Guidelines for the evaluation of immune therapy 
activity in solid tumors:  immune -related response criteria.  Clin Cancer Res .  
2009;15:7412 -7420.  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 117 of 176 
CONFIDENTIAL    
11. Appendices   
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 118 of 176 
CONFIDENTIAL    
11.1 Appendix 1.  List of Abbreviations   
 
Abbreviation  Explanation  
ACTH  adrenocorticotropic hormone  
ADA-IC anti-drug antibody related immune complexes  
ADAs  anti-drug antibodies  
ADCC  antibody -dependent cellular cytotoxicity  
ADL activities of daily living  
ADR  adverse drug reaction  
ALL acute lymphoblastic leukemia  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
aPTT  activated partial thromboplastin time  
ASBMT  American Society for Blood and Marrow Transplantation  
ASCO  American Society of Clinical Oncology  
AST 
ASR aspartate aminotransferase  
Annual Safety Report  
AUC  area under the concentration -time curve  
BCG  bacille Calmette -Guerin  
BiTE® 
BNP  bi-specific T -cell engager  
B-Natriuretic Peptide  
BP blood pressure  
CAR -T cells  chimeric antigen receptor T cells  
CBC  complete blood count  
CD3 cluster of differentiation 3  
CFR Code of Federal Regulations  
CI confidence intervals  
Cmax maximum serum concentration  
Cmin minimum serum concentration  
CNS  central nervous system  
COVID -19 coronavirus disease 2019  
CR complete response  
CRF case report form  
CRO  contract research organization  
CRP  C-reactive  protein  
CRS  cytokine release syndrome  
CSF cerebral spinal fluid  
CT computed tomography  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 119 of 176 
CONFIDENTIAL    
Abbreviation  Explanation  
CTCAE  Common Terminology Criteria for Adverse Events  
D dose de -escalation  
DCR  disease control rate  
DILI drug induced liver injury  
DLL3  delta -like ligand 3  
DLRM  dose level review meeting  
DLRT  dose level review team  
DLT 
DNA  dose -limiting toxicity   
deoxyribonucleic acid  
DSUR  
DOR  Development Safety Update Report  
duration of response  
E dose escalation  
ECG  electrocardiogram  
ECHO  echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
ED extensive disease  
EI dosing interval  
EDC  electronic data capture  
EOI end of infusion  
EOT End of treatment  
EP platinum -etoposide  
EpCAM  epithelial cell adhesion molecule  
eSAE  electronic Serious Adverse Event  
EU European Union  
Fc fragment crystallizable  
FDA Food and Drug Administration  
FFPE  formalin -fixed  paraffin -embedded  
FIH first-in-human  
FSH follicle stimulating hormone  
FT4 free thyroxine  
GCP  Good Clinical Practice  
G-CSF granulocyte colony stimulating factor  
GSO  Global Safety Officer  
GLP Good Laboratory Practice  
HBcAb  anti-hepatitis B antibody  
HBsAg  hepatitis B antigen  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 120 of 176 
CONFIDENTIAL    
Abbreviation  Explanation  
HCV  hepatitis C  
HCV  Ab Hepatitis C virus antibody  
HI overdosing intervals  
HIV human immunodeficiency virus  
HLE half-life extended  
HNSTD  Highest Non -Severely Toxic Dose  
HR heart rate  
HUVECs  human endothelial cells  
IC50 half maximal inhibitory concentration  
ICANS  immune effector cell -associated neurotoxicity syndrome  
ICE immune effector cell -associated encephalopathy  
ICF informed consent form  
ICH International Council for Harmonisation  
ICP intracranial pressure  
IEC Independent Ethics Committee  
IFN- interferon gamma  
Ig immunoglobulin  
IHC immunohistochemistry  
IL-2 interleukin -2 
INN International Nonproprietary Name  
INR international normalized ratio  
IRB Institutional Review Board  
IRT interactive response technology  
IV intravenous(ly)  
LD limited disease  
LDH  lactate dehydrogenase  
LH luteinizing hormone  
LI under -dosing intervals  
LVEF  left ventricular ejection fraction  
MDRD  Modification of Diet in Renal Disease  
MMSE  Mini Mental Status Examination  
MRI magnetic resonance imaging  
mTPI  modified toxicity probability interval  
MUGA  multigated acquisition  
NCCN  National Comprehensive Cancer Network  
NCT National Clinical Trials  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 121 of 176 
CONFIDENTIAL    
Abbreviation  Explanation  
ND not done  
NSAIDs  non-steroidal anti -inflammatory drugs  
OR Objective response  
OS overall survival  
PAVA  pool adjacent violators algorithm  
PBL peripheral blood leukocytes  
PCR  polymerase chain reaction  
PD pharmacodynamic(s)  
PD-1 programmed cell death -1 
PD-L1 programmed death ligand -1 
PFS progression -free survival  
PK pharmacokinetic(s)  
PO orally  
PPP Platelet Poor Plasma  
PR partial response  
Pre pre-infusion  
PT prothrombin time  
PTT partial thromboplastin time  
PTU propylthiouracil  
RBC  red blood cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
RO receptor occupancy  
RP2D  recommended phase  2 dose  
RR 
RNA  respiratory rate  
ribonucleic acid  
S current dose  
SARS -CoV-2 severe acute respiratory syndrome -coronavirus -2 
SC subcutaneous  
scFC  single chain fragment crystallizable  
SCLC  Small Cell Lung Cancer  
SD stable disease  
SFU safety follow -up 
SGOT  serum glutamic -oxaloacetic transaminase  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 122 of 176 
CONFIDENTIAL    
Abbreviation  Explanation  
SGPT  serum glutamic -pyruvic transaminase  
SJS Stevens -Johnson syndrome  
SLD sum of the longest diameters  
SOI start of infusion  
SSKI  saturated solution of potassium iodide  
TBL total bilirubin  
TEN toxic epidermal necrolysis  
TLS tumor lysis syndrome  
TNF tumor necrosis factor  
TSH thyroid stimulating hormone  
ULN upper limit of normal  
UPM  
US 
USFDA  unit probability mass  
United States  
United States food and drug administration  
USPI  United States Prescribing Information  
WBC  white blood cell  
 
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 123 of 176 
CONFIDENTIAL    
11.2 Appendix 2.  Clinical Laboratory Tests   
The tests detailed in Table 11 -1 will be performed by the central labora tory and/or by the 
local laboratory .  
Protocol -specific requirements for inclusion or exclusion of subjects are detailed in 
Sections 5.1 to 5.2 of the protocol.  
Additional tests may be performed at any time during the study as determined necessary 
by the investigator or required by local regulations.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 124 of 176 
CONFIDENTIAL    
Table 11-1.  Analyte Listing   
LOCAL/SAFETY LABS  CENTRAL LABS  
Chemistry  
 Sodium  
 Potassium  
 Chloride  
 Bicarbonate or 
CO2  
 Total protein  
 Albumin  
 Calcium  
 Glucose  
 BUN (Blood Urea 
Nitrogen) or 
Serum Urea  
 Creatinine  
 Total bilirubin  
 Direct bilirubin  
 Alkaline phos  
 AST (SGOT)  
 ALT (SGPT)  
 Estimated CrCl, 
GFR, MDRD 
calculation  
 
 CBC with differential  
 RBC  
 Hemoglobin  
 MCV  
 Platelets  
 WBC  
 
Differentials  
5-part differential:  
 Lymphocytes  
 Monocytes  
 Eosinophilsa 
 Basophilsa 
 Total Neutrophilsa 
or (Segmented 
neutrophils and 
bands/stabs]  
3-part differential if 
unable to perform 
5-part: 
 Lymphocytes  
 Granulocytes  
 Monocytes  
OR 
 Lymphocytes  
 Neutrophils  
 Mid-cell fraction  Coagulation  
 PT/INR  
 Partial 
Thromboplastin 
Time (PTT) or 
Activated Partial 
Thromboplastin 
Time (aPTT)  
 
Urinalysis  
 Blood  
 Protein  
 Glucose  
 Bilirubin  
 
Endocrine safety  
 Cortisol (AM 
sample preferred)  
 TSH 
 FT4 
 ACTH (AM sample 
preferred)  
Only collected at 
screening and EOT  
 Prolactin  
 FSH 
 LH 
 Estradiol (in 
females)  
 Testosterone (in 
Males)  
  
Other Labs:  
 Tarlatamab PK  
 AMG  404 PK  
 Pre-dose tumor 
tissue (archival or 
fresh tumor biopsy)  
Other safety labs  
 CRP  
 Ferritin  
 LDH 
 Uric Acid  
 Phosphorus  
 HIV antibody 
testing  
  Pregnancy test 
(serum or urine)  
 Amylase  
 Lipase  
 Hepatitis Serology 
Testing  
 Hep B surface 
antigen  
 Hep C antibody  
 Hep B total core 
antibody   
a Local lab may report Granulocytes instead of Neutrophils, Eosinophils, and Basophils individually.  
ACTH  adrenocorticotropic hormone; ALT  alanine aminotransferase; AM  ante-meridiem; aPTT  
activated partial thromboplastin time; AST  aspartate aminot ransferase; BUN  blood urea nitrogen; 
CBC   complete blood count; CO 2  carbon dioxide; CrCL  creatine clearance; CRP  c-reactive protein; 
ctDNA = circulating tumor DNA;  EOT  end of treatment;  FSH  follicle stimulating hormone; FT4  free 
thyroxine; Hep B  hepatitis B; Hep  C  hepatitis C; GFR  glomerular filtration rate;  HIV  human 
immunodeficiency virus; INR  international normalized ratio; LDH   lactate dehydrogenase; LH   luteinizing 
hormone ; MCV   mean corpuscular volume; MDRD   modification of diet in renal disease;  PT  prothrombin 
time; PTT  partial thromboplastin time;  PK  pharmacokinetics; 
RBC  red blood cell; SGOT  serum glutamic -oxaloaceti c transaminase; SFU   safety follow -up; SGPT  
serum glutamic -pyruvic transaminase; TSH  thyroid stimulating hormone; WBC  white blood cell  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 125 of 176 
CONFIDENTIAL    
If the subject is being followed for possible drug induced liver injury (DILI), the following 
analytes may be test ed at the local laboratory depending on the clinical situation (see 
Section 11.7): 
Table 11-2.  DILI Potential Analyte Listing   
Chemistry  Total bilirubin, direct bilirubin, ALP, LDH, AST (SGOT), ALT (SGPT), 
creatine kinase, ferritin, gamma -glutamyl transferase, haptoglobin  
Hematology  Hemoglobin, Platele ts, RBC Morphology, WBC Count, WBC Differential  
Coagulation  PT, INR  
Immunology  5 Prime Nucleotidase, Alpha -1 Antitrypsin, Antinuclear Antibodies, Anti -
Smooth Muscle Antibody, Anti -Soluble Liver Ag/Liver -Pancreas Ag, 
Cytomegalovirus IgG Antibody, Cytomega lovirus IgM Antibody, Endomysial 
IgA Antibody, Epstein -Barr Virus EDA IgG Antibody, Epstein -Barr Virus NA 
IgG Antibody, Epstein -Barr Virus VCA IgG Antibody, Epstein -Barr Virus 
VCA IgM Antibody, Hepatitis A Virus IgG Antibody, Hepatitis A Virus IgM 
Antibody , Hepatitis B Core Antibodies, Hepatitis B Core IgM Antibody, 
Hepatitis B Surface Antigen, Hepatitis B Virus DNA Genotyping, Hepatitis B 
Virus Surface Antibody, Hepatitis C Antibodies, Hepatitis C Virus RNA 
Genotyping, Hepatitis D Virus Antibody, Hepatitis  E IgG Antibody, Hepatitis 
E IgM Antibody, Herpes Simplex Virus Type 1_2 IgG AB, Herpes Simplex 
Virus Type 1_2 IgM AB, Human Herpes Virus 6 DNA, Human Herpes Virus 
7 DNA, Human Herpes Virus 8 DNA, Immunoglobulin G, Liver Kidney AB 1,  
Parvovirus IgM/IgG An tibody, Serum Caeruloplasmin, Tissue 
Transglutaminase IgA Antibody, Toxoplasma IgM/IgG, Varicella Zoster 
Virus Antibody  
Toxicology  Acetaminophen  
ALP  alkaline phosphatase; ALT  alanine aminotransferase; AST  aspartate aminotransferase; 
Ig  immunoglobulin; INR  international normalized ratio; LDH  lactate dehydrogenase; PT  prothrombin 
time; RBC  red blood cell; SGOT  serum glutamic -oxaloacetic transaminase; SGPT  serum 
glutamic -pyruvic transaminase; WBC  white blood cell  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 126 of 176 
CONFIDENTIAL    
11.3 Appendix 3.  Study Governance Considerations   
Dose Level Review  Meetings (DLRM)   
A dose level review meeting (DLRM) is conducted to review and interpret safety data for 
the purposes of making recommendations about dose -level escalation (either to the next 
planned dose or to an intermediate dose), dose level de -escalation, cohort  continuation, 
or cohort expansion; making recommendations about non -dose escalation cohorts  (eg, 
expanded, highest dose and/or final cohort ); and evaluating safety signa ls for purposes 
of applying Dose Cohort Stopping Rules.  Based on emerging safety data, the dose level 
review team (DLRT) will make recommendations on the day of AMG  404 administration 
in cycle  1 as well as the dose of tarlatamab  administered.  The DLRT wi ll make 
recommendations on additional premedications, including the recommendation to 
implement additional corticosteroids (dexamethasone  mg orally [PO] 6 to 16 hours 
prior to the first step dose and step dose[s] in cycle  1) based on emerging results fro m 
Part D in the ongoing first -in-human (FIH) study (20160323), as well as emerging data 
from the current study (20200439).   The DLRT will also make any recommendations on 
adjustments to the step -dosing schedule if necessary.  Additionally, based on emergin g 
safety data, the DRLT may make recommendations on the hospitalization requirements, 
including reducing or eliminating the required hospitalization time in cycle  1 or cycle  2.  
The required DLRT members are the Medical Monitor, Global Safety Officer (GSO) , and 
Site investigators.  The DLRT will include actively screening and enrolling Site 
investigators.  The Medical Monitor, GSO, and Site  investigators are the only voting 
DLRT members.  The following non -voting Amgen representatives may also be part of 
the DLRT:  as appropriate other functional area representatives (eg, clinical study 
manager, biostatistician, or pharmacokinetic [PK] scientist).  
The Medical Monitor must be in attendance and cannot be represented by a voting 
designee or delegate.  Voting designees can be identified as appropriate by the GSO or 
Site investigator(s).  A Site investigator may identify a delegate (eg, sub -investigator) 
who is listed in the Delegation of Authority.  If a Site investigator does this, the Site 
investigator must p rovide written agreement with the designee or delegate’s vote.  
For a DLRM to occur, the Medical Monitor must attend, and the GSO or delegate must 
attend.  In addition, a quorum of Site investigators must be present.  A quorum is defined 
as greater than or equal to 50  of the participating investigators or their qualified 
designee.  The DLRM will be rescheduled if these requirements are not met.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 127 of 176 
CONFIDENTIAL    
All available study data, including demographics, investigational product administration, 
medical history, concomi tant medications, adverse events, electrocardiogram (ECG), 
vital signs, and laboratory results will be reviewed.  Data will not need to be source data 
verified and queries will not need to be resolved prior to the DLRM.  
DLRM voting will occur as follows:  there will be a total of 3 votes, 1 for the Medical 
Monitor, 1 for the GSO or delegate, and 1 for all the Site investigators or delegates 
combined.  Regardless of how many Site investigators there are, all the Site 
Investigators combined will have a total of 1 vote decided by a majority of the 
investigators (defined as greater than or equal to 50 ). 
DLRM recommendations to escalate to the next planned cohort , or to an intermediate 
cohort , must be by unanimous vote.  If the voting members of the DLRT are not  able to 
reach a unanimous recommendation on whether to escalate to the next planned cohort  
or to an intermediate cohort , then this should be reflected in the DLRM Memo.  Other 
recommendations, such as expanding a cohort  or lowering a dose will be made by a 
majority vote . 
Regulatory and Ethical Considerations   
This study will be conducted in accordance with the protocol and with:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
 Applicable International Council for Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines  
 Applicable ICH laws and regulations  
The protocol, protocol amendments, informed consent form (ICF), Investigator’s 
Brochure, and other relevant documents (eg, subject recruitment advertisements) must 
be submitted to an Institutional Review Board (IRB)/Ind ependent Ethics Committee (IEC)  
by the investigator and reviewed and approved by the IRB/IEC .  A copy of the written 
approval of the protocol and ICF must be received by Amgen before recruitment of 
subjects into the study and shipment of Amgen investigatio nal product.  
Amgen may amend the protocol at any time.  The investigator must submit and, where 
necessary, obtain approval from the IRB/IEC  for all subsequent protocol amendments 
and changes to the informed consent document.  The investigator must send a c opy of 
the approval letter from the IRB/IEC  and amended protocol Investigator’s Signature 
page to Amgen prior to implementation of the protocol amendment at their site.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 128 of 176 
CONFIDENTIAL    
During the course of the study, if new information becomes available that alters the 
benefit-risk of the study or the study drug, Amgen will follow applicable regulations to 
notify investigators, the IRB/IEC, and regulatory authorities, as appropriate.  
The investigator will be responsible for the following:  
 Providing written summaries of the  status of the study to the IRB/IEC  annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC  
 Obtaining annual IRB/IEC  approval/renewal throughout the duration of the study.  
Copies of the investig ator’s reports and the IRB/IEC  continuance of approval must be 
sent to Amgen  
 Notifying the IRB/IEC  of serious adverse events occurring at the site, deviations from 
the protocol or other adverse event reports received from Amgen, in accordance with 
local pr ocedures  
 Overall conduct of the study at the site and adherence to requirements of Title  21 of 
the U.S. Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC , and all 
other applicable local regulations  
Informed Consent Process   
An initial sample ICF is provided for the investigator to prepare the informed consent 
document to be used at his or her site.  Updates to the sample ICF are to be 
communicated formally in writing f rom the Amgen  Trial Manager to the investigator.  The 
written informed consent form is to be prepared in the language(s) of the potential 
patient population.  
The investigator or his/her delegated representative will explain to the subject, or his/her 
legally authorized representative, the aims, methods, anticipated benefits, and potential 
hazards of the study before any protocol -specific screening procedures or any 
investigational product(s) is/are administered and answer all questions regardin g the 
study.  
Subjects must be informed that their participation is voluntary.  Subjects or their legally 
authorized representative defined as an individual or other body authorized under 
applicable law to consent, on behalf of a prospective subject, to the  subject’s 
participation in the clinical study  will then be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
Health Insurance Portability and Accountability Act requirements, wher e applicable, and 
the IRB/IEC  or study site.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 129 of 176 
CONFIDENTIAL    
The medical record must include a statement that written informed consent was obtained 
before the subject was enrolled in the study and the date the written consent was 
obtained.  The authorized person obtaining the informed consent must also sign the ICF. 
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed 
of the subject’s participation in the clinical study unless it is a local req uirement.  The 
investigator shall then inform the primary care physician.  If the subject agrees to such 
notification, the investigator is to inform the subject’s primary care physician of the 
subject’s participation in the clinical study.  If the subject does not have a primary care 
physician and the investigator will be acting in that capacity, the investigator is to 
document such in the subject’s medical record.  
The acquisition of informed consent and the subject’s agreement or refusal of his/her 
notific ation of the primary care physician  is to be documented in the subject’s medical 
records, and the informed consent form is to be signed and personally dated by the 
subject or a legally acceptable representative  and by the person who conducted the 
informed consent discussion.  Subject withdrawal of consent or discontinuation from 
study treatment and/or procedures must also be documented in the subject’s medical 
records; refer to Section 1. 
If important new information becomes available that may be relevant to the subject’s 
consent during their participation in the study, subjects will be reconsented.  
The original signed ICF is to be retained in accordance with institutional policy, and a 
copy of the ICF(s) must be provided to the subject or the subject’s legally authorized 
representative.  
If a potential subject is illiterate or visually impaired and does not have a legally 
acceptable representative, the investigator must provide an impartial witness to read the 
ICF to the subject and must allow for questions.  Thereafter, both the subject and the 
witness must sign the ICF to attest that informed consent was freely given and 
understood.  (Refer to ICH GCP guideline, Section  4.8.9.)  
A subject who is rescreened is not required to sign another ICF if the rescreening occurs 
within 30 days from the previous ICF signature date . 
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional future research.  The investigator or authorized designee will 
explain to each subject the objectives of the future research.  Subjects will be told that 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 130 of 176 
CONFIDENTIAL    
they are free to refuse to participate a nd may withdraw their specimens at any time and 
for any reason during the storage period.  A separate signature will be required to 
document a subject’s agreement to allow any remaining specimens to be used for future 
research.  Subjects who decline to par ticipate will not provide this separate signature.  
Data Protection/Subject Confidentiality   
The investigator must ensure that the subject’s confidentiality is maintained for 
docum ents submitted to Amgen.  
The subject will be assigned a unique identifier by the sponsor.  Any subject records or 
datasets that are transferred to the sponsor will contain the identifier only; subject names 
or any information which would make the subject i dentifiable will not be transferred.  
On the case report form (CRF) demographics page, in addition to the unique subject 
identification number, include the age at time of enrollment.  
For serious adverse events reported to Amgen, subjects are to be identifie d by their 
unique subject identification number, initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations).  
Documents that are not submitted to Amgen (eg, signed informed consent fo rms) are to 
be kept in confidence by the investigator, except as described below.  
Subject data should be kept in a secure location.  Access to subject data will be limited 
to authorized individuals, as described below.  
In compliance with governmental regul ations/ICH GCP Guidelines , it is required that the 
investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the IRB/IEC  direct access to review the subject’s original 
medical records for verification o f study -related procedures and data.  Direct access 
includes examining, analyzing, verifying, and reproducing any records and reports that 
are important to the evaluation of the study.  
The investigator is obligated to inform and obtain the consent of the s ubject to permit 
such individuals to have access to his/her study -related records, including personal 
information.  
Amgen complies with all relevant and applicable laws and regulations that protect 
personal information in order to ensure subject confidentia lity and privacy.  Subjects are 
designated by a unique subject identification number in the sponsor’s systems.  The 
sponsor uses access -controlled systems to house, review and analyze subject data.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 131 of 176 
CONFIDENTIAL    
These systems are backed -up regularly to minimize the ris k of loss of subject data; 
procedures are also defined for data recovery in the event of data loss.  The sponsor 
has standard operating procedures in place that restrict access to subject data to those 
who require access to this data based on their role an d have also completed the 
required training.  These procedures also outline the process for revoking access to 
such data when it is no longer needed.  In the event of a security breach, the sponsor 
has procedures in place for notification of privacy incide nts and to address these 
incidents, via its Business Conduct Hotline.  
Publication Policy   
To coordinate dissemination of data from this study, Amgen may facilitate the formation 
of a publication committee consisting of several investigators and appropriate Amgen 
staff, the governance and responsibilities of which are set forth in a Publication Charter.  
The committee is expected to solicit input and assistance from other investigat ors and to 
collaborate with authors and Amgen staff, as appropriate, as defined in the Publication 
Charter.  Membership on the committee (both for investigators and Amgen staff) does 
not guarantee authorship.  The criteria described below are to be met for  every 
publication.  
All publications (eg, manuscripts, abstracts, oral/slide presentations, book chapters) 
based on this study must be prepared in accordance with Amgen’s publications policy 
and submitted to Amgen for review.  Authorship of any publication s resulting from this 
study will be determined on the basis of the Uniform Requirement for Manuscripts 
Submitted to Biomedical Journals International Committee of Medical Journal Editors 
Recommendations for the Conduct of Reporting, Editing, and Publicatio ns of Scholarly 
Work in Medical Journals, which states:  Authorship credit is to be based on:  (1) 
substantial contributions to conception and design, acquisition of data, or analysis and 
interpretation of data; (2) drafting the article or revising it crit ically for important 
intellectual content; (3) final approval of the version to be published; and (4) agreement 
to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are approp riately investigated and resolved.  
Authors need to meet conditions 1, 2, 3, and 4.  
When a large, multicenter group has conducted the work, the group is to identify the 
individuals who accept direct responsibility for the manuscript.  These individuals mus t 
fully meet the criteria for authorship defined above.  Acquisition of funding, collection of 
data, or general supervision of the research group, alone, does not justify authorship.  All 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 132 of 176 
CONFIDENTIAL    
persons designated as authors must qualify for authorship, and all t hose who qualify are 
to be listed.  Each author must have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content.  All publications (eg, manuscripts, 
abstracts, oral/slide presentations, book chapters) b ased on this study must be 
submitted to Amgen for review.  The Clinical Trial Agreement among the institution, 
investigator, and Amgen will detail the procedures for, and timing of, Amgen’s review of 
publications.  
Investigator Signatory Obligations   
Each clinical study report is to be signed by the investigator or, in the case of multicenter 
studies, the coordinating investigator.  
The coordinating investigator, i dentified by Amgen, will be any or all of the following:  
 A recognized expert in the therapeutic area  
 An investigator who provided significant contributions to either the design or 
interpretation of the study  
 An investigator contributing a high number of el igible subjects  
Data Quality Assurance   
All subject data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data, centrally or 
adjudicated data).  The investigator is responsible for verifying that data entries are 
accurate and correct by physically or electronically signing the CRF.  
The investigator must maintain accurate document ation (source data) that supports the 
information entered in the CRF.  
The investigator must permit study -related monitoring,  audits, IRB/IEC  review, and 
regulatory agency inspections and provide direct access to source data documents.  
The sponsor or design ee is responsible for the data management of this study including 
quality checking of the data.  
Clinical monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, a nd verifiable 
from source documents; that the safety and rights of subjects are being protected; and 
that the study is being conducted in accordance with the currently approved protocol and 
any other study agreements, ICH GCP, and all applicable regulatory  requirements per 
the sponsor’s monitoring plan.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 133 of 176 
CONFIDENTIAL    
The investigator agrees to cooperate with the clinical monitor to ensure that any 
problems detected in the course of these monitoring visits, including delays in 
completing CRFs, are resolved.  
The Amgen repr esentative(s) and regulatory authority inspectors are responsible for 
contacting and visiting the investigator for the purpose of inspecting the facilities and, 
upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinen t data) provided that subject confidentiality is respected.  
In accordance with ICH GCP and the sponsor’s audit plans, this study may be selected 
for audit by representatives from Amgen’s Global Research and Development 
Compliance and Audit function (or des ignees).  Inspection of site facilities (eg, 
pharmacy, protocol -required therapy storage areas, laboratories) and review of 
study -related records will occur to evaluate the study conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
Retention of study documents will be governed by the Clinical Trial Agreement.  
Case report forms (CRF) must be completed in English.  TRADENAMES® (if used) for 
concomitant medications may be entered in the local language.  Consult the 
country -specific language requirements.  
All written information and other material to be used by subjects and investigative staff 
must use vocabulary and language that are clearly understood.  
Source Documents   
The investigator is to maintain a list of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or corrections 
on CRFs will be included on the Amgen Delegation of Auth ority Form.  
Source documents provide evidence for the existence of the subject and substantiate 
the integrity of the data collected.  Source documents are filed at the investigator’s site.  
Source documents are original documents, data, and records from whi ch the subject’s 
CRF data are obtained.  These include but are not limited to hospital records, clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, 
and correspondence.  Source documents may also include data capt ured in the 
interactive response technology (IRT) system (if used, such as subject ID and 
randomization number) and CRF entries if the CRF is the site of the original recording 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 134 of 176 
CONFIDENTIAL    
(ie, there is no other written or electronic record of data, such as paper ques tionnaires 
for a clinical outcome assessment or certain demographic information).  
Data reported on the CRF or entered in the electronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies 
must be  explained.  The investigator may need to request previous medical records or 
transfer records, depending on the study.  Also, current medical records must be 
available.  
The investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation, suitable for 
inspection at any time by representatives from Amgen and/or applicable regulatory 
authorities.  
Elements to include:  
 Subject files containing completed CRFs, informed consent forms, and subject 
identification list  
 Study files containing the protocol with all amendments, Investigator’s Brochure, 
copies of prestudy documentation, and all correspondence to and from the IRB/IEC 
and Amgen  
 Investigational produ ct-related correspondence including [Proof of Receipts, 
Investigational Product Accountability Record(s), Return of Investigational Product 
for Destruction Form(s), Final Investigational Product Reconciliation Statement, as 
applicable  
 Non-investigational p roduct(s), and/or medical device(s) or combination product(s) 
documentation, as applicable  
Retention of study documents will be governed by the Clinical Trial Agreement.  
Study and Site Closure   
Amgen or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable 
laws, regulations, and GCP.  
Both Amgen and the investigator reserv e the right to terminate the investigator’s 
participation in the study according to the Clinical Trial Agreement.  The investigator is to  
notify the IRB/IEC  in writing of the study’s completion or early termination and send a 
copy of the notification to Am gen. 
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
by a separate protocol or as provided for by the local country’s regulatory mechanism.  
However, Amgen reserves the unilateral right, at its sole discretion, to det ermine 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 135 of 176 
CONFIDENTIAL    
whether to supply Amgen investigational product(s) and by what mechanism, after 
termination of the study and before the product(s) is/are available commercially.  
Compensation   
Any arrangements for compensation to subjects for injury or illness that arises in the 
study are described in the Compensation for Injury section of the Informed Consent that 
is available as a separate document.  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 136 of 176 
CONFIDENTIAL    
11.4 Appendix 4.  Safety Events:  Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting   
Definition of Adverse Event   
Adverse Event Definition  
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the study treatment.  
 Note:  An adverse event can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease (new or 
exacerbated) temporally associated with the use of a treatment, combination 
product, medical device, or procedure.  
 Note:  Treatment -emergent adverse events will be defi ned in the SAP.  
 
Events Meeting the Adverse Event Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, electrocardiogram [ECG], radiological scans, vital 
signs measurements), including those that worsen from baseline, that are 
considered clinically significant in the medical and scientific judgment of the 
investigator (ie, not related to progression of underlying disease).  
 Exacerbation of a chronic or intermitten t pre-existing condition including either an 
increase in frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study treatment administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication.  Overdose per se will not be reported as an 
adverse event/seri ous adverse event unless it is an intentional overdose taken with 
possible suicidal/self -harming intent.  Such overdoses are to be reported 
regardless of sequelae.  
 For situations when an adverse event or serious adverse event is due to small cell 
lung canc er (SCLC)  report all known signs and symptoms.  Death due to disease 
progression in the absence of signs and symptoms should be reported as the 
primary tumor type (eg, metastatic pancreatic cancer).  Note:  The term “disease 
progression” should not be used  to describe the adverse event.  
 “Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an adverse event or serious adverse event.  Such instances will be 
captured in the efficacy assessments.  However, the signs, symptoms, and/or 
clinical sequelae resulting from lack of efficacy will be reported as adverse event or 
serious adverse event if they fulfill the definition of an adverse event or serious 
adverse event.  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 137 of 176 
CONFIDENTIAL    
Events NOT Meeting the Adverse Event Definition  
 Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that 
leads to the procedure is the adverse event.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 Anticipated day-to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Definition of Serious Adverse Event   
A Serious Adverse Event is defined as any untoward medical occurrence that, 
meets at least 1 of the following serious criteria:  
Results in death (fatal)  
Immediately life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event.  It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
Requires in -patient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting.  Complications that occur during hospitalization are an adverse 
event.  If a complication prolongs hospitalization or fulfills any other serious criteria, 
the event is serious.  When in doubt as to whether “hospitalization” occurred or wa s 
necessary, the adverse event is to be considered serious.  Hospitalization for elective 
treatment of a pre -existing condition that did not worsen from baseline is not 
considered an adverse event.  
Results in persistent or significant disability/incapacit y 
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  This definition is not intended to include experiences of relatively 
minor medical significance such as uncomplicated headache, nausea, vomiting, 
diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere 
with or prevent everyday life functions but do not constitute a substantial disruption.  
Is a congenital anomaly/birth defect  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 138 of 176 
CONFIDENTIAL    
Other medically important serious event  
Medical or scientific judgment is to be exercised in deciding whether serious adverse 
event reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospitalization but  may 
jeopardize the subject or may require medical or surgical intervention to prevent 1 of 
the other outcomes listed in the above definition.  These events are typically to be 
considered serious.  
Examples of such events include invasive or malignant cance rs, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug dependency 
or drug abuse.  
Recording Adverse Events and Serious Adverse Events   
Adverse Event and Serious Adverse Event Recording  
 When an adverse event or serious adverse event occurs, it is the responsibility of 
the investigator to review all docume ntation (eg, hospital progress notes, 
laboratory, and diagnostics reports) related to the event.  
 The investigator will then record all relevant adverse event/serious adverse event 
information in the Event case report form (CRF).  
 The investigator must assig n the following mandatory adverse event attributes:  
o Adverse event diagnosis or syndrome(s), if known (if not known, signs or 
symptoms);  
o Dates of onset and resolution (if resolved);  
o Did the event start prior to first dose of investigational product, other p rotocol -
required therapies;  
o Assessment of seriousness;  
o Severity (or toxicity defined below);  
o Assessment of rela tedness to investigational product(s) and other 
protocol -required therapies .  
o Assessment of relatedness to study -required activity and/or procedures is only 
required for serious adverse events.  
o Action taken; and  
o Outcome of event.  
 If the severity of an adverse event changes from the date of onset to the date of 
resolution, record as a single event with the worst severity on the Event CRF.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 139 of 176 
CONFIDENTIAL    
 It is not acceptable for the investigator to send photocopies of the subject’s medical 
records to sponsor/responsible contract research organization (CRO)  in lieu of 
completion of the Event CRF page.  
 If specifically requested, the investigator may need to pro vide additional follow -up 
information, such as discharge summaries, medical records, or extracts from the 
medical records.  In this case, all subject identifiers, with the exception of the 
subject number, will be blinded on the copies of the medical record s before 
submission to Amgen . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the adver se event/serious 
adverse event.  
Evaluating Adverse Events and Serious Adverse Events   
Assessment of Severity  
The investigator will make an assessment of severity for each adverse event and 
serious adverse event reported during the study.  The assessment of severity will be 
based on:   
The Common Terminology Criteria for Adverse Events  (CTCAE) , version 4 which is 
available at the following location:  
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
Assessment of Causality  
 The investigator is obligated to assess the relationship between investigational 
product(s) protocol -required therapies  and each occurrence of each adverse event.  
 The investigator is obligated to assess the relationship between investigational 
product(s) p rotocol -required therapies, study -required activity and/or procedures 
and each occurrence of each serious adverse event .  
 Relatedness means that there are facts or reasons to support a relationship 
between investigational product and the event.  
 The investi gator will use clinical judgment to determine the relationship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study treatment 
administration will be cons idered and investigated.  
 The investigator will also consult the Investigator’s Brochure and/or Product 
Information, for marketed products, in his/her assessment.  
 For each adverse event/serious adverse event, the investigator must document in 
the medical no tes that they have reviewed the adverse event/serious adverse 
event and has provided an assessment of causality.  For sites reporting serious 
adverse events via electronic data capture (EDC), the investigator or sub 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 140 of 176 
CONFIDENTIAL    
investigator must confirm causality in ED C within 72 hours of the serious adverse 
event being entered on the Events CRF.  
 There may be situations in which a serious adverse event has occurred and the 
investigator has minimal information to include in the initial report.  However, it is 
very import ant that the investigator always make an assessment of causality for 
every event before the initial transmission of the serious adverse event data.  
 The investigator may change his/her opinion of causality in light of follow -up 
information and send a seriou s adverse event follow -up report with the updated 
causality assessment.  In this case, for sites reporting serious adverse events via 
EDC, the investigator or sub -investigator must reconfirm causality in the EDC 
system within 72 hours of the serious adverse event being entered on the Events 
CRF.  
 The causality assessment is 1 of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of Adverse Event and Serious Adverse Event  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by 
Amgen  to elucidate the nature and/or causality of the adverse event or serious 
adverse event as fu lly as possible.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health 
care professionals.  
 If a subject is permanently withdrawn from protocol -required therapies because of 
a seri ous adverse event, this information must be submitted to Amgen.  
 If a subject dies during participation in the study or during a recognized follow -up 
period, the investigator will provide Amgen with a copy of any post -mortem 
findings including histopatholog y. 
 New or updated information will be recorded in the originally completed Event 
CRF.  
 The investigator will submit any updated serious adverse event data to  Amgen  
immediately and no later than  24 hours of receipt of the information.  
Reporting of Serious A dverse Event   
Serious Adverse Event Reporting via Electronic Data Collection Tool  
 The primary mechanism for reporting serious adverse event will be the electronic 
data capture (EDC) system.  
 If the EDC system is unavailable, then the site will report the information to Amgen 
using a paper -based Serious Adverse Event Contingency Report Form (also 
referred to as the electronic Serious Adverse Event [eSAE ] Contingency Report  
Form) (see Figure  11-1) immediately and no later than 24 hours of the 
investigator’s awareness  of the event.  
 The site will enter the serious adverse event data into the electronic system as 
soon as it becomes avail able.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 141 of 176 
CONFIDENTIAL    
 After the study is completed at a given site, the EDC system will be taken off -line to 
prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new serious adverse event from a study subject or 
receives updated data  on a previously reported serious adverse event after the 
EDC system has been taken off -line, then the site can report this information on 
the paper -based Serious Adverse Event Contingency Report Form (see 
Figure  11-1). 
 Once the study has ended, serious adverse event(s) suspected to  be related to 
investigational product will be  reported to Amgen immediately and not later than 24 
hours  of the investigator's awareness  of the event.  The investigator should use the 
paper -based Serious Adverse Event Contingency Report Form to report the event.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 142 of 176 
CONFIDENTIAL    
Figure  11-1.  Sample Electronic Serious Adverse Event Contingency Report Form 
(paper -based form)   
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 143 of 176 
CONFIDENTIAL    
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 144 of 176 
CONFIDENTIAL    
 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 145 of 176 
CONFIDENTIAL    
11.5 Appendix 5.  Contraceptive Guidance and Collection of Pregnancy 
and Lactation Information   
Study -specific contraception requirements for males and  females of childbearing 
potential  are outlined in Section  5.2.  Contraceptive use and methods should be 
consistent with local regulations for subjects participating in clinical studies.  
Male and  female subjects of childbearing potential should be advise d of the pregnancy 
prevention requirements and the potential risk to the fetus if they become pregnant (or 
father a child)  during treatment and for , after the last dose of tarlatamab .  
Additionally, subjects will have pregnancy prevention requirem ents  following 
the last dose of AMG  404 (females), and an additional  following the last dose 
of AMG  404 (males) . 
Definition of Females of Childbearing Potential   
A female is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile.  Permanent sterilization methods include documented 
hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.  F emales with 
documente d permanent infertility due to an alternate medical cause 
(eg, Mullerian  agenesis, androgen insensitivity, gonadal dysgenesis), can be considered 
not of childbearing potential.  
Note:  Bilateral tubal ligation/occlusion is not considered a permanent sterili zation 
method.  
Note:  Documentation from the following sources is acceptable to provide confirmation of 
each sterilization method:  1) review of subject’s medical records; 2) subject’s medical 
examination; or 3) subject’s medical history interview.  
A postm enopausal female is defined as:  
 A woman of ≥ 55 years with no menses for 12 months without an alternative medical 
cause OR   
 A woman  age < 55 years with no menses for at least 12 months and with a 
follicle -stimulating hormone (FSH) level within the definition of “postmenopausal 
range” for the laboratory involved.  I n the absence of 12 months of amenorrhea, 
confirmation with more than one FSH measurement is required.  
Contraception Methods for Female Subjects  
Highly Effective Contraceptive Methods  
 Comb ined (estrogen and progestogen containing) hormonal contraception 
associated with inhibition of ovulation (oral, intravaginal, or transdermal)  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 146 of 176 
CONFIDENTIAL    
 Progestogen -only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implantable)  
 Intrauterine device  
 Intrauterine hormonal -releasing system  
 Female barrier methods like a diaphragm, cervical cap or a contraceptive 
sponge  
 Bilateral tubal ligation/occlusion  
 Vasectomized partner (provided that partner is the sole sexual partner of the female 
subject of childbearing potential and that the vasectomized partner has received 
medical assessment of the surgical success)  
 Sexual abstinence (defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study treatments; the reliability of sexual 
abstinence must be evaluated in relation to the duration of the trial and the preferred 
and usual lifestyle of the subject)  
Contraception Methods for Male Subjects  
 Sexual abstinence (defined as refraining from he terosexual intercourse during the 
entire period of risk associated with protocol -required therapies; the reliability of 
sexual abstinence must be evaluated in relation to the duration of the trial and the 
preferred and usual lifestyle of the subject)  
 Use a condom with spermicide  during treatment and for an additional  
following the last dose of tarlatamab , and  days  following the last dose of 
AMG  404 
The female partner should be made aware of the male subject’s participation in the 
study  and should consider using a method of contraception for female subjects stated 
above (a female condom should not be used because there is a risk of tearing when 
both partners use a condom).  
Note:  A male subject is not required to use additional forms of contrace ption during the 
study:  
 If the male’s sole female partner is post -menopausal as confirmed by her 
healthcare provider  or has had a bilateral tubal ligation/occlusion or hysterectomy 
or bilateral oophorectomy  or bilateral salpingectomy . 
 If the male has had a vasectomy and has been medically assessed to be sterile 
(absence of sperm in semen).  
Collection of Pregnancy Information   
Female Subjects Who Become Pregnant  
 Investigator wi ll collect pregnancy information on any female subject who becomes 
pregnant while taking protocol -required therapies through after the last 
dose of tarlatamab , and after the last dose of AMG  404. 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 147 of 176 
CONFIDENTIAL    
 Information will be recorded on the Pregnancy Notification Form (see  Figure  11-2).  
The form must be submitted to Amgen Global Patient Safety immediately and no 
later than  24 hours of the s ite’s awareness of a subject’s pregnancy.  (Note:  Sites 
are not required to provide any information on the Pregnancy Notification Form that 
violates the country or regions local privacy laws).  
 After obtaining the female subject’s signed consent for releas e of pregnancy and 
infant health information, the investigator will collect pregnancy and infant health 
information and complete the pregnancy questionnaire for any female subject who 
becomes pregnant while taking protocol -required therapies through  
following the last dose of tarlatamab  and  following the last dose of 
AMG  404.  This information will be forwarded to Amgen Global Patient Safety.  
Generally, infant follow -up will be conducted up to 12  months after the birth of the 
child (if ap plicable).  
 Any termination of pregnancy will be reported to Amgen Global Patient Safety, 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
 While pregnancy itself is not considered to be an adverse event or serious adverse 
event, any pregnancy complication or elective termination of a pregnancy for 
medical reasons will be reported as an adverse event or serious adverse event.  
Abnormal pregnancy outcomes (eg, spontaneous abortions, stillbirth, fetal death, 
congenital anomalies) will be reported as an adverse event or serious adverse 
event.  Note that an elective termination with no information on a fetal congenital 
malformation or maternal complication is generally not considered an adverse 
event, but still mu st be reported to Amgen as a pregnancy exposure case.  
 Any serious adverse event occurring as a result of a post -study pregnancy which is 
considered reasonably related to the study treatment by the investigator, will be 
reported to Amgen Global Patient Safety as described in Section  11.4.  While the 
investigator is not obligated to actively seek this information in former study 
subjects, he or she may learn of a serious adverse event through spontaneous 
reporting.  
 Any female subject who becomes pregnant while participating will discontinue study 
treatment while pregnant  (see Section 7.1 for details ). 
Male Subjects with Partners Who Become Pregnant  
 In the event a male subject fathers a child during treatment, and for an additional 
 following the last dose of tarlatamab , and  following the last 
dose of AMG  404 after discontinuing protocol -required therapies, the information 
will be recorded on the Pregnancy Notification Form.  The form (see Figure  11-2) 
must be submitted to Amgen Global Patient Safety immediately and no later than  24 
hours of the site’s awareness of the pregnancy.  (Note:  Sites are not required to 
provide any information on the Pregnancy Notification Form tha t violates the country 
or regions local privacy laws).  
 Males  whose partners become pregnant during treatment and for an ad ditional  
 after the last dose of tarlatamab , and  after the last dose of 
AMG  404 must practice sexual abstinence or use a condom through   after 
the last dose of tarlatamab , and  after the last dose of AMG  404. 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 148 of 176 
CONFIDENTIAL    
 The investigator will attempt to obtain a signed consent for release of pregnancy 
and infant health information directly from the pr egnant female partner to obtain 
additional pregnancy information.  
 After obtaining the female partner’s signed consent for release of pregnancy and 
infant health information, the investigator will collect pregnancy outcome and infant 
health information on t he pregnant partner and her baby and complete the 
pregnancy questionnaires.  This information will be forwarded to Amgen Global 
Patient Safety.  
 Generally, infant follow -up will be conducted up to 12 months after the birth of the 
child (if applicable).  
 Any termination of the pregnancy will be reported to Amgen Global Patient Safety 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
Collection of Lactation Information   
 Investigator will collect lactation information on any fema le subject who breastfeeds 
while taking protocol -required therapies through after the last dose of 
tarlatamab , and after the last dose of AMG  404. 
 Information will be recorded on the Lactation Notification Form (see below) and 
submitted to Amgen Global Patient Safety immediately and no later than 24 hours 
of the investigator’s awareness of the event.  
 Study treatment will be discontinued if female subject breastfeeds during the study 
as described in exclusion criterion 226. (See Section 5.2). 
 With the female subjects signed consent for release of mother a nd infant health 
information, the investigator will collect mother and infant health information and 
complete the lactation questionnaire on any female subject who breastfeeds while 
taking protocol -required therapies through after the last dose of 
tarlatamab  and after the last dose of AMG  404. 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 149 of 176 
CONFIDENTIAL    
Figure  11-2.  Pregnancy and Lactation Notification Forms   
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 150 of 176 
CONFIDENTIAL    
 
 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 151 of 176 
CONFIDENTIAL    
11.6 Appendix 6.  Sample Storage and Destruction   
When permitted by local regulations, any bloo d, biomarker, pharmacokinetic (PK ) 
sample collected according to the Schedule of Activities (Section  1.3) can be analyzed 
for any of the tests outlined in the protocol and for any te sts necessary to minimize risks 
to study subjects.  This includes testing to ensure analytical methods produce reliable 
and valid data throughout the course of the study.  This can also include, but is not 
limited to, investigation of unexpected results, i ncurred sample reanalysis, and analyses 
for method transfer and comparability.  
All samples and associated results will be coded prior to being shipped from the site for 
analysis or storage.  Samples will be tracked using a unique identifier that is assigne d to 
the samples for the study.  Results are stored in a secure database to ensure 
confidentiality.  
When permitted by local regulations and i f informed consent is provided by the subject, 
Amgen can do additional testing on remaining samples (ie, residual a nd back -up) to 
investigate and better understand the small cell lung c ancer, the dose response and/or 
prediction of response to Amgen investigational product(s) or other protocol -specified 
therapy , characterize antibody response , and characterize aspects o f the molecule (eg, 
mechanism of action/target, metabolites).  Results from this analysis are to be 
documented and maintained but are not necessarily reported as part of this study.  
Samples can be retained for up to 20  years.  
Since the evaluations are not  expected to benefit the subject directly or to alter the 
treatment course, the results of pharmacogenetic, biomarker development  or other 
exploratory studies are not placed in the subject’s medical record and are not to be 
made available to the subject, m embers of the family, the personal physician, or other 
third parties, except as specified in the informed consent.  
The subject retains the right to request that the sample material be destroyed by 
contacting the investigator.  Following the request from the subject, the investigator is to 
provide the sponsor with the required study and subject number so that any remain ing 
sample types (eg, blood, tumor)  samples and any other components from the cells can 
be located and destroyed.  Samples will be destroyed once all protocol -defined 
procedures are completed.  However, information collected from samples prior to the 
reque st for destruction, will be retained by Amgen.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 152 of 176 
CONFIDENTIAL    
The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the 
request of the subject through the investigator, at the end of the storage period,  or as 
appropriate (eg, the scientific rationale for experimentation with a certain sample type no 
longer justifies keeping the sample).  If a commercial product is developed from this 
research project, the sponsor owns the commercial product.  The subject  has no 
commercial rights to such product and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample.  See 
Section  11.3 for subject confidentiality.  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 153 of 176 
CONFIDENTIAL    
11.7 Appendix 7.  Hepatotoxicity Stopping Rules:  Suggested Actions and 
Follow -up Assessments and Study Treatment Rechallenge 
Guidelines   
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin [TBL]) 
and/or international normalized ratio (INR) and/or signs/s ymptoms of hepatitis (as 
described below) may meet the criteria for withholding or permanent discontinuation of 
Amgen investigational product or other protocol -required therapies, as specified in the 
Guidance for Industry Drug -Induced Liver Injury:  Premar keting Clinical Evaluation, 
July 2009 . 
Criteria for Withholding and/or Permanent Discontinuation of Amgen 
Investigational Product and Other Protocol -required Therapies Due to 
Potential Hepatotoxicity   
The following stopping and/or withholding rules apply to subjects for whom another 
cause of their changes in liver biomarkers (TBL, INR and transaminases) has not been 
identifie d.  
Important alternative causes for elevated AST/ALT and/or TBL values include, but are 
not limited to:  
 Hepatobiliary tract disease  
 Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein -Barr Virus, cytomegalovirus, herpes 
simplex virus, varicella, toxoplasmos is, and parvovirus)  
 Right sided heart failure, hypotension or any cause of hypoxia to the liver causing 
ischemia  
 Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
supplements, plants and mushrooms  
 Heritable disorders causin g impaired glucuronidation (eg, Gilbert’s syndrome, 
Crigler -Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir)  
 Alpha -one antitrypsin deficiency  
 Alcoholic hepatitis  
 Autoimmune hepatitis  
 Wilson’s disease and hemochr omatosis  
 Nonalcoholic fatty liver disease including steatohepatitis  
 Non-hepatic causes (eg, rhabdomyolysis, hemolysis)  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 154 of 176 
CONFIDENTIAL    
If investigational product(s) is/are withheld, the subject is to be followed for possible drug 
induced liver injury (DILI) according to r ecommendations in the last section of this 
appendix.  
Rechallenge may be considered if an alternative cause for impaired liver tests (ALT, 
AST, ALP) and/or elevated TBL, is discovered and the laboratory abnormalities resolve 
to normal or baseline (see next  section in this appendix).  
Table  11-3.  Conditions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -required Therapies Due to 
Potential Hepatot oxicity   
Analyte  Temporary Withholding  Permanent Discontinuation  
TBL > 3 x ULN  
at any time  > 2 x ULN  
  OR 
INR -- > 1.5  x (for subjects not on 
anticoagulation therapy)  
 OR AND  
AST/ALT  > 8 x ULN at any time  
> 5 x ULN but < 8  x ULN for ≥ 2 weeks  
> 5 x ULN but < 8  x ULN and unable to 
adhere to enhanced monitoring schedule  
> 3 x ULN with clinical signs or symptoms 
that are consistent with hepatitis (such as 
right upper quadrant pain/tenderness, 
fever, nausea, vomiting, and jaundice)  In the presence of no important 
alternative causes for elevated 
AST/ALT and/or TBL values  
> 3 x ULN (when baseline was <  ULN)  
 OR  
ALP > 8 x ULN at any time  -- 
ALP  alkaline phosphatase; ALT  alanine aminotransferase; AST  aspartate aminotransferase; INR  
international normalized ratio; TBL  total bilirubin; ULN  upper limit of normal  
Criteria for Rechallenge of Amgen Investigational Product and Other 
Protocol -required Therapies After Potential Hepatotoxicity   
The decision to rechallenge the subject is to be discussed and agreed upon 
unan imously by the subject, investigator, and Amgen.  
If signs or symptoms re cur with rechallenge, then tarlatamab  and other protocol -required 
therapies are  to be permanently discontinued.  Subjects who clearly meet the criteria for 
permanent discontinuation (a s described in Table  11-3) are never to be rechallenged.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 155 of 176 
CONFIDENTIAL    
Drug -induced Liver Injury Reporting and Additional Assessments   
Reporting  
To facili tate appropriate monitoring for signals of DILI, cases of concurrent AST or ALT 
and TBL and/or INR elevation, according to the criteria specified in the above, require 
the following:  
 The event is to be reported to Amgen as a serious adverse event immediate ly and 
no later than 24  hours of discovery or notification of the event (ie, before additional 
etiologic investigations have been concluded)  
 The appropriate case report form (CRF) (eg, Events CRF) that captures information 
necessary to facilitate the evaluation of treatment -emergent liver abnormalities is to 
be completed and sent to Amgen  
Other events of hepatotoxicity and potential DILI are to be reported as serious adve rse 
events if they meet the criteria for a serious adverse event defined in Section  11.4. 
Additional Clinical Assessments and Observation  
All subjec ts in whom investigational product(s) or protocol -required therapies is/are 
withheld (either permanently or conditionally) due to potential DILI as specified in 
Table  11-3 or who experience AST or ALT elevations >  3 x upper limit of normal (ULN) 
or 2-fold increases above baseline values for subjects with elevated values before drug 
are to undergo a period of “c lose observation” until abnormalities return to normal or to 
the subject’s baseline levels.  
Assessments that are to be performed during this period include:  
 Repeat AST, ALT, ALP, bilirubin (BIL) (total and direct), and INR within 24 hours  
 In cases of TBL > 2x ULN or INR > 1.5, retesting of liver tests, BIL (total and direct), 
and INR is to be performed every 24 hours until laboratory abnormalities improve  
Testing frequency of the above laboratory tests may decrease if the abnormalities 
stabilize or the  investigational product(s) or protocol -required therapies has/have been 
discontinued AND the subject is asymptomatic.  
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL.  
The following are to be considered depending o n the clinical situation:  
 Complete blood count with differential to assess for eosinophilia  
 Serum total immunoglobulin (Ig)G, anti -nuclear antibody anti -smooth muscle 
antibody, and liver kidney microsomal antibody -1 to assess for autoimmune hepatitis  
 Serum  acetaminophen (paracetamol) levels  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 156 of 176 
CONFIDENTIAL    
 A more detailed history of:  
o Prior and/or concurrent diseases or illness  
o Exposure to environmental and/or industrial chemical agents  
o Symptoms (if applicable) including right upper quadrant pain, 
hypersensitivity -type re actions, fatigue, nausea, vomiting and fever  
o Prior and/or concurrent use of alcohol, recreational drugs and special diets  
o Concomitant use of medications (including non -prescription medicines and 
herbal and dietary supplements), plants, and mushrooms  
 Viral serologies  
 Creatine phosphokinase, haptoglobin, lactate dehydrogenase (LDH), and peripheral 
blood smear  
 Appropriate liver imaging if clinically indicated  
 Appropriate blood sampling for PK analysis if this has not already been collected  
 Hepatology consult (liver biopsy may be considered in consultation with a 
hepatologist)  
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or considered stable by the investigator.  The 
“close observation period” is to continue for a minimum of 4  weeks after discontinuation 
of all investigational product(s) and protocol -required therapies.  
The potential DILI event and additional information such as medical history, concomitant 
medications an d laboratory results must be captured in the corresponding CRFs.  
 
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 157 of 176 
CONFIDENTIAL    
11.8 Appendix 8.  Performance Status According to Eastern Cooperative 
Oncology Group (ECOG)   
 
ECOG Performance Status Scale  
Grade  Descriptions  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, eg, light house work, office work  
2 Ambulatory and capable of all selfcare but unable to carry out any work activities.  
Up and about more than 50  of waking hours  
3 Capable of only limited selfcare, confined to bed or chair more than 50  of 
waking hours  
4 Completely disabled.  Cannot carry on any selfcare.  Totally confined to bed or 
chair  
5 Dead  
ECOG  Eastern Cooperative Oncology Group.  
Source:  Oken et al, 1982
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 158 of 176 
CONFIDENTIAL    
11.9 Appendix 9.  Modified Response Evaluation Criteria in Solid Tumors 
Version 1.1 (Modified RECIST 1.1)   
Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) are guidelines 
for assessing tumor burden changes in response to treatment (Eisenhauer et al, 2009) .  
Addit ional patterns of response have been observed with immune -enhancing therapies, 
including delayed clinical response, leading to criteria modifications to capture treatment 
responses more accurately (Nishino et al, 2013; Wolchok et al, 2009).  This study 
utilizes modified RECIST 1.1 criteria which applies aspects of the immune -related 
response criteria (including requiring confirmation of disease progression) to RECIST 1.1 
as outlined below.  
Modified RECIST 1.1 tumor response assessment  
 All measurable and non -measurable lesions should be assessed at screening, all 
defined tumor assessment time points (Schedule of Assessment), and any 
unscheduled imaging visits.  
Measurable lesions:  
 Non-nodal lesions with clear borders that can be measured accurately and 
seriall y in one dimension in the axial plane (longest diameter ≥ 10 mm measured 
by magnetic resonance imaging/computed tomography [MRI/CT ] with scan slice 
thickness ≤ 5 mm).  
 Nodal lesions with the longest diameter perpendicular to the long axis (short axis) 
≥ 15 mm on MRI/CT.  
 Must exclude simple cysts, pleural/pericardial effusions and ascites.  
Non-measurable lesions:  
 All other lesions, including small lesions (longest diameter < 10 mm or 
pathological lymph nodes with ≥ 10 mm but < 15 mm short axis) are considered  
non-measurable and characterized as non -index lesions.   
 Other examples of non -measurable lesions include:  
 Lesions with prior local treatment:  
▪ Tumor lesions situated in a previously irradiated area, or an area 
subject to other loco -regional therapy, should not be considered 
measurable unless there has been demonstrated progression in 
the lesion.  
 Biopsied lesions  
 Categorically, clusters of small lesions, bone lesions, inflammatory breast 
disease, and leptomeningeal disease are non -measurable.  See Imaging 
Procedural Manual provided by the central imaging core laboratory for 
additional guidance.  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 159 of 176 
CONFIDENTIAL    
Index lesions and measurable tumor burden:  
 Index lesions:  
 Measurable lesions (≤ 5 lesions per organ, ≤ 10 total) selected at baseline 
on the basis of  
▪ Size and suitability for accurate repeated measurements by 
imaging.  
▪ Representative  of the subject’s tumor burden, all organs involved 
and overall disease status  
Non-index lesions:  
 All measurable  lesions not selected as index lesions and non -measurable les ions   
 Non-index  lesions will be qualitatively evaluated  
 Values: ‘Present’, ‘absent’ or ‘unequivocal progression’.   
 Other  definitions  
 Unable to evaluate (UE):  Any lesion present at baseline which was not 
assessed or was unable to be evaluated leading to  an inability to 
determine the status of that particular tumor for that time point  
 Not Available (NA):  Scan not available  
 Not Done (ND):  Radiologic imaging was not performed at this time point 
to evaluate the index lesions  
Index lesion  response:  
 At basel ine and all subsequent tumor assessments, measurable tumor burden is 
the sum of the longest diameters (SLD) of all index lesions  
 Complete  Response (CR) – disappearance of all measurable lesions  
 Pathologic lymph nodes must have reduction in short axis to < 10 mm  
 Partial  Response (PR) – decrease of 30  or greater in tumor burden compared 
with baseline  
 Stable  Disease (SD) - not meeting the criteria for CR, PR, or progressive disease  
 Progressive Disease – increase of 20  or greater in tumor burden compared 
with nadir, or the appearance of one or more new lesions  
Non-index lesion response:  
 CR – disappearance  of all non -index lesions  
 Pathologic lymph nodes must have reduction in short axis to < 10 mm  
 SD – persistence  of one or more non -index lesions, not meeting the criteria for 
CR or progressive disease  
 Progressive  disease – unequivocal progression of existing non -index lesions, or 
the appearance of one or more new lesions  
Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 160 of 176 
CONFIDENTIAL    
Overall response:  
 CR 
o Complete disappearance of all lesions  
▪ Pathologic lymph nodes must have reduction in short axis to 
< 10 mm 
o Confirmation scan required - repeat, consecutive assessment no less 
than 4 weeks from the date of the first documented response  
o CR is dated at time of confirmation scan  
 PR 
o Decrease in tumor burden ≥ 30  relative to baseline, or  
o Complete disappearance of all index lesions with presence of non -index 
lesions  
o Confirmation scan required - repeat, consecutive assessment no less 
than 4 weeks from the date of the first documented re sponse  
o PR is dated at time of confirmation scan  
 SD 
o Index lesions not meeting criteria for CR, PR or progressive disease, or  
o In subjects with only non -index disease, persistence of one or more 
non-index lesions  
 Progressive  Disease  
o Radiologic detection of ≥  20 increase in tumor burden relative to nadir 
and at least 5 mm absolute increase, or  
o Unequivocal progression of non -index lesions, or  
o The presence of new lesions  
 Confirmation scan required - repeat, consecutive assessment  
 from the date of  the first documented response  
▪ Radiographic progressive disease is confirmed at repeat 
imaging
 if: 
 Tumor burden remains increased by ≥ 20  and at least 
5 mm absolute increase relative to nadir, or  
 Unequivocal progression of non -index lesions is observed, 
or 
 New lesions are present  
 Subjects with a global deterioration of health status requiring discontinuation of 
treatment prior to radiolog ic confirmation of disease progression should have the 
reason for treatment discontinuation classified as ‘clinical disease progression’ 
not ‘radiographic progressive disease’.  Every effort should be made to 
radiologically confirm progression even after d iscontinuation of treatment.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 161 of 176 
CONFIDENTIAL    
Summary of Measurement and Tumor Response Assessment Based on Modified 
RECIST 1.1  
Measurable lesions   Non-nodal  lesions : ≥ 10 mm (unidimensional 
measurement)  
 Pathologic  lymph nodes:  longest diameter short axis 
≥ 15 mm 
Measurement of each 
lesion   Non-nodal lesions:  The longest diameter (mm) in the axial 
plane  
 Pathologic  lymph nodes:  short axis (mm)  
Tumor burden   Sum of the longest  diameters (SLD) of all index lesions  
 Up to 5 lesions  per organ, up to 10 total  
Response assessment:  
index lesions  
(calculated from  change 
in tumor burden)   CR:  Disappearance  of all lesions  
 Pathologic  lymph nodes short axis < 10 mm  
 PR:  ≥  30 decrease from baseline  
 SD:  Does not meet criteria for CR, PR or progressive 
disease.  
 Progressive  disease : ≥ 20 increase (and ≥  5 mm 
absolute increase) from nadir  
Response assessment:  
non-index lesions   CR:  Disappearance  of all lesions  
 Pathologic  lymph nodes short axis < 10 mm  
 SD:  Persistence  of one or more non -index lesion(s)  
 Progressive  disease:  Unequivocal progression of existing 
non-index lesions  
New Lesions  The presence of new lesion(s) defines progression   
Confirmation  Confirmation  by subsequent assessment after ≥4  weeks 
required for CR, PR and progressive disease.  
Summary of Modified RECIST 1.1 Overall Response Assessment  
Index lesions (tumor 
burden)a,  Non-Index lesions  New 
lesions  Overall Response 
using modified 
RECIST 1.1  
↓ 100 Absent  Absent  CRb 
Noned Absent  Absent  CRb 
↓ 100 Present  Absent  PRb 
↓ ≥ 30 Absent/Present  Absent  PRb 
↓ < 30 to ↑ <  20 Absent/Present  Absent  SD 
Noned Present  Absent  SD 
↑ ≥ 20 Any Any Progressive diseasec 
Any Unequivocal 
progression  Any Progressive diseasec 
Any Any Present  Progressive diseasec 
NA/ND/UE  Absent/Present  Absent  UE 
Noned NA/ND/UE  Absent  UE 
CR  complete response; NA  not available; ND  not done; PR  partial response; RECIST  Response 
Evaluation Criteria in Solid Tumors; SD = stable disease;  UE  unable to evaluate  
a Decrease assessed relative to baseline.  Increase assessed relative to nadir.  
b Response:  CR and PR require a confirmation assessment after ≥  4 weeks, may also wait until the next 
scheduled imaging  
c Progression:  Progressive disease requires a confirmation assessment  
 
d Subjects with non -index lesions only

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 162 of 176 
CONFIDENTIAL    
11.10  Appendix 10.  Schedule of Activities:   
Table 11-4.  List of Schedule of Activities Tables   
Quick link to 
Schedule of 
Activities  Table Title  
Table 11 -5 One-Step Dosing – Cycle 1 only (AMG 404 Administered  
Table 11 -6 One-Step Dosing – Cycle 1 only (AMG 404 Administered  
Table 11 -7 One-Step Dosing – Cycle 1 only (AMG 404 Administered  
Table 11 -8 Cycle 2 and Beyond (AMG 404 Administered on  in Cycle 1)  
Table 11 -9 Cycle 2 and Beyond (AMG 404 Administered on  in Cycle 1)  
 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 163 of 176 
CONFIDENTIAL    
Table 11-5.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only (AMG  404 Administered   
STUDY PERIOD/ 
TREATMENT 
CYCLE  SCRa Cycle 1 only  
WEEKb -3 
to -1 1 2 3 4 
DAYb 
HOUR (relative to 
infusion)d  Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 96 Pre 757  EOI 757  2 6 24 48 Pre 757  EOI 757  2 6 24 48 168 
General/Safety Assessments  
Informed consent  X                       
Clinical Evaluatione X X      X X X X    X X X    X X X 
Vital signs, pulse 
oxf X X X X X Xf   X X Xf X X X Xf X X 
12-lead ECGg X   X X       X      X      
ECHO or MUGA  X                       
Adverse event 
review    ======================================================================================================= ➔ 
Serious adverse 
event review  ===================================================================================================================== ➔ 
Prior/concomitant 
medication  ===================================================================================================================== ➔ 
Local Laboratory Assessments  
CBC with 
differential  X X      X X X X    X X X    X X X 
Coagulation  X X      X  X X    X  X    X   
Chemistry panelh X X     X X X X X    X X X    X X X 
Lipase and 
Amylase  X X                      
Urinalysis  X                       
Serum/urine 
pregnancy testi X X                      
Safety endocrine 
panelj X                       
CRP   X     X X X  X   X X X X   X X X X 
Ferritin   X     X X X  X   X X X X   X X X X 
HBsAg, HBcAb, 
HCV Ab, HIV  X                       
Page 1 of 3  
Footnotes described after Table 11 -9 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 164 of 176 
CONFIDENTIAL    
Table 11 -5.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only (AMG  404 Administered  
STUDY PERIOD/ 
TREATMENT 
CYCLE  SCRa Cycle 1 only  
WEEKb -3 
to -1 1 2 3 4 
DAYb 
HOUR (relative to 
infusion)d  Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 96 Pre 757  EOI 757  2 6 24 48 Pre 757  EOI 757  2 6 24 48 168 
Central and Biomarker Laboratory Tests  
Study Drug Administration  
Tarlatamab  IV 
infusiont 
AMG  404 IV 
infusiont 
Page 2 of 3  
Footnotes described after Table 11 -9 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 165 of 176 
CONFIDENTIAL    
Table 11 -5.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only (AMG  404 Administered  
STUDY PERIOD/ 
TREATMENT 
CYCLE  SCRa Cycle 1 only  
WEEKb -3 
to -1 1 2 3 4 
DAYb 
HOUR (relative to 
infusion)d  Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 96 Pre 757  EOI 757  2 6 24 48 Pre 757  EOI 757  2 6 24 48 168 
Study Drug Administration (continued)  
Dexamethasone or 
equivalentu     X       X      X       
IV Hydrationv     X       X      X      
Hospital stayw  ============================= ➔   =================== ➔  ======================= ➔   
Other Assessments  
MRI Brainx X                       
Radiological 
imaging and tumor 
burden 
assessmenty X                       
Page 3 of 3  
Footnotes described after Table 11 -9 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 166 of 176 
CONFIDENTIAL    
Table 11-6.  Schedule of Activities:  One -Step Dosing – Cycle  1 Only (AMG  404 Administered   
STUDY PERIOD/ 
TREATMENT 
CYCLE  SCRa  Cycle  1 only  
WEEKb -3 
to -1 1 2c 3 4 
DAYb 
HOUR (relative to 
infusion)d  Pre 757   EOI 757  2 6 24 48 96 Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 Pre 757  EOI 757  2 6 24 48 168 
General/Safety Assessments  
Informed consent  X                       
Clinical Evaluatione X X    X X X X      X X X    X X X 
Vital signs, pulse 
oxf X X X Xf   X X X X Xf X X X Xf X X 
12-lead ECGg X X X         X      X      
ECHO or MUGA  X                       
Adverse event 
review    ======================================================================================================= ➔ 
Serious adverse 
event review  ===================================================================================================================== ➔ 
Prior/concomitant 
medication  ========================================================================================================= ============➔ 
Local Laboratory Assessments  
CBC with 
differential  X X    X X X X      X X X    X X X 
Coagulation  X X    X  X X      X  X    X   
Chemistry panelh X X   X X X X X      X X X    X X X 
Lipase and 
Amylase  X X                      
Urinalysis  X                       
Serum/urine 
pregnancy Testi X X                      
Safety endocrine 
panelj X                       
CRP   X   X X X  X     X X X X   X X X X 
Ferritin   X   X X X  X     X X X X   X X X X 
HBsAg, HBcAb, 
HCV Ab, HIV  X                       
Central and Biomarker Laboratory Tests  
Page 1 of 3  
Footnotes described after Table 11 -9 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 167 of 176 
CONFIDENTIAL    
Table 11 -6.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only (AMG  404 Administered Day 8)  
STUDY PERIOD/ 
TREATMENT 
CYCLE  SCRa  Cycle 1 only  
WEEKb -3 
to -1 1 2c 3 4 
DAYb 
HOUR (relative to 
infusion)d  Pre 757   EOI 757  2 6 24 48 96 Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 Pre 757  EOI 757  2 6 24 48 168 
Central and Biomarker Laboratory Tests (continued)  
Study Drug Administration  
Tarlatamab  IV 
infusiont 
AMG  404 IV 
infusiont 
Dexamethasone or 
equivalentu   X       X      X       
IV Hydrationv   X         X      X      
Hospital stayw  ================== ➔   ============================= ➔  ===================== ➔   
Page 2 of 3  
Footnotes described after Table 11 -9 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 168 of 176 
CONFIDENTIAL    
Table 11 -6.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only (AMG  404 Administered Day 8)  
STUDY PERIOD/ 
TREATMENT 
CYCLE  SCRa  Cycle 1 only  
WEEKb -3 
to -1 1 2c 3 4 
DAYb 
HOUR (relative to 
infusion)d  Pre 757   EOI 757  2 6 24 48 96 Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 Pre 757  EOI 757  2 6 24 48 168 
Other Assessments  
MRI Brainx X                       
Radiological 
imaging and tumor 
burden 
assessmenty X                       
Page 3 of 3  
Footnotes described after Table 11 -9 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 169 of 176 
CONFIDENTIAL    
Table 11-7.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only (AMG  404 Administered   
STUDY PERIOD/ 
TREATM ENT CYCLE  SCRa  Cycle 1 only  
WEEKb -3 to -1 1 2c 3 
4 
DAYb 
HOUR (relative to 
infusion)d  Pre 757  EOI 757  2 6 24 48 96 Pre 757  EOI 757  2 6 24 48 Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 168 
General/Safety Assessments  
Informed consent  X                       
Clinical Evaluatione X X    X X X X    X X X      X X X 
Vital signs, pulse oxf X X X Xf X X X X Xf X X X X X Xf X X 
12-lead ECGg X X X       X        X      
ECHO or MUGA  X                       
Adverse event review    ======================================================================================================= ➔ 
Serious adverse event 
review  ==================================================================================================================== ➔ 
Prior/concomitant 
medication  ==================================================================================================================== ➔ 
Local Laboratory Assessments  
CBC with differential  X X    X X X X    X X X      X X X 
Coagulation  X X    X  X X    X  X      X   
Chemistry panelh X X   X X X X X    X X X      X X X 
Lipase and Amylase  X X                      
Urinalysis  X                       
Serum/urine 
pregnancy Testi X X                      
Safety endocrine 
panelj X                       
CRP   X   X X X  X   X X X X     X X X X 
Ferritin   X   X X X  X   X X X X     X X X X 
HBsAg, HBcAb, HCV 
Ab, HIV  X                       
Central and Biomarker Laboratory Tests  
Page 1 of 2  
Footnotes described after Table 11 -9 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 170 of 176 
CONFIDENTIAL    
Table 11 -7.  Schedule of Activities:  One -Step Dosing – Cycle 1 Only (AMG  404 Administered Day 15)  
STUDY PERIOD/ 
TREATMENT CYCLE  SCRa  Cycle 1 only  
WEEKb -3 to -1 1 2c 3 
4 
DAYb 
HOUR (relative to 
infusion)d  Pre 757  EOI 757  2 6 24 48 96 Pre 757  EOI 757  2 6 24 48 Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 168 
Central and Biomarker Laboratory Tests (continued)  
Study Drug Administration  
Tarlatamab  IV infusiont 
AMG  404 IV infusiont 
Dexamethasone or 
equivalentu   X       X        X       
IV Hydrationv   X       X        X      
Hospital stayw  ================== ➔   =================== ➔  ================================ ➔   
Other Assessments  
MRI Brainx X                       
Radiological imaging 
and tumor burden 
assessmenty X                
  
     
Page 2 of 2  
Footnotes described after  Table 11 -9

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 171 of 176 
CONFIDENTIAL    
Table 11-8.  Schedule of Activities:  Cycle 2 and Beyond (If AMG 404 was Administered on  or 8 in Cycle 1)   
STUDY P ERIOD/ 
TREATMENT CYCLE  
Cycle 2  Q cycbb Q2 cyc  EOThh SFU-1ee SFU-2ff LTFUaa 
WEEKb 1 2c 3 4 1 3 1     
DAYb 
HOUR (relative to 
infusion)d Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 96 168 Pre 757  EOI 757  2 6 24 48 168        
General/Safety Assessments  
Clinical Evaluatione X      X X X X X    X X X X X  X X X  
Vital signs, pulse oxf X X X X Xf X X X X X Xf X X X X  X X X  
12-lead ECGg    X        X      Xcc Xcc      
ECHO or MUGA                          
Adverse event review   ======================================================================================================== ➔  
Serious adverse event 
review  =================================================================================================================== ➔ 
Prior/concomitant 
medication  =================================================================================================================== ➔ 
Local Laboratory Assessments  
CBC with differential  X      X X  X X    X X X X X  X X X  
Coagulation  X      X    X    X   X   X X X  
Chemistry panelh X     X X X X X X    X X X X X  X X X  
Lipase and Amylase  X                 X    X   
Urinalysis                     X     
Serum/urine pregnancy 
Testi X                 X    X X  
Safety endocrine panelj X                 X   X X   
CRP  X     X X X  X X   X X X X X   X X   
Ferritin  X     X X X  X X   X X X X X   X X   
Central and Biomarker Laboratory Tests  
Page 1 of 2  
Footnotes described after Table 11 -9 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 172 of 176 
CONFIDENTIAL    
Table 11-8.  Schedule of Activities:  Cycle 2 and Beyond (If AMG 404 was Administered on  in Cycle 1)  
STUDY PERIOD/ 
TREATMENT CYCLE  
Cycle 2  Q cycbb Q2 cyc  EOThh SFU-1ee SFU-2ff LTFUaa 
WEEKb 1 2c 3 4 1 3 1     
DAYb 
HOUR (relative to 
infusion)d Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 96 168 Pre 757  EOI 757  2 6 24 48 168        
General/Safety Assessments  
Tarlatamab  PK 
collectionp   X X  X X X  X X X  X X X X Xq       
AMG  404 PK collectionp X X         X       Xr     X  
Study Drug Administration  
Tarlatamab IV infusiont 
AMG  404 IV infusiont 
Hospital stayw ============================= ➔    ================= ➔          
Other Assessments  
MRI Brainx                         
Radiological imaging 
and tumor burden 
assessmenty             
       X Xz Xz  
Xdd 
Survival Status and 
subsequent cancer 
therapyaa             
           
X 
Page 2 of 2  
Footnotes described after Table 11 -9 
 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 173 of 176 
CONFIDENTIAL    
Table 11-9.  Schedule of Activities:  Cycle 2 and Beyond (If AMG 404 was Administered on  in Cycle 1)   
STUDY PERIOD/ 
TREATMENT CYCLE  
Cycle 2  Q cycbb Q2 cyc  EOThh SFU-1ee SFU-2ff LTFUaa 
WEEKb 1 2c 3 4 1 3 1     
DAYb 
HOUR (relative to 
infusion)d Pre 757  EOI 757  2 6 24 48 96 168 Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 168        
General/Safety Assessments  
Clinical Evaluatione X    X X X X X      X X X X X  X X X  
Vital signs, pulse oxf X X Xf X X X X X X X Xf X X X X  X X X  
12-lead ECGg  X          X      Xcc Xcc      
ECHO or MUGA                          
Adverse event review   ======================================================================================================== ➔  
Serious adverse event 
review  =================================================================================================================== ➔ 
Prior/concomitant 
medication  =================================================================================================================== ➔ 
Local Laboratory Assessments  
CBC with differential  X    X X  X X      X X X X X  X X X  
Coagulation  X    X    X      X   X   X X X  
Chemistry panelh X   X X X X X X      X X X X X  X X X  
Lipase and Amylase  X                 X    X   
Urinalysis                     X     
Serum/urine pregnancy 
Testi X                 X    X X  
Safety endocrine panelj X                 X   X X   
CRP  X   X X X  X X     X X X X X   X X   
Ferritin  X   X X X  X X     X X X X X   X X   
Central and Biomarker Laboratory Tests  
Page 1 of 2  
Footnotes described after Table 11 -9 

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 174 of 176 
CONFIDENTIAL    
Table 11 -9.  Schedule of Activities:  Cycle 2 and Beyond (If AMG 404 was Administered on  in Cycle 1)  
STUDY PERIOD/ 
TREATMENT CYCLE  
Cycle 2  Q cycbb Q2 cyc  EOThh SFU-1ee SFU-2ff LTFUaa 
WEEKb 1 2c 3 4 1 3 1     
DAYb 
HOUR (relative to 
infusion)d Pre 757  EOI 757  2 6 24 48 96 168 Pre 404  EOI 404  Pre 757  EOI 757  2 6 24 48 168        
Tarlatamab PK 
collectionp X X  X X X  X   X X  X X X X Xq       
AMG  404 PK collectionp         X X         Xr    X  
Study Drug Administration  
Tarlatamab IV infusiont 
AMG  404 IV infusiont 
Hospital stayw =================== ➔    =========================== ➔          
Other Assessments  
MRI Brainx                         
Radiological imaging 
and tumor burden 
assessmenty             
       X Xz Xz  
Xdd 
Survival Status and 
subsequent cancer 
therapyaa             
           
X 
Page 2 of 2  
Abbreviations used:  0  Hour zero; when Tarlatamab is infused; ACTH  adrenocorticotropic hormone; BP  blood pressure; C   cycle; C1   cycle  1  
CBC   complete blood count; CNS  central nervous system; CRP   C-reactive  protein; CT   computed tomography; ctDNA   cell-free tumor DNA; CTC  circulating 
ECG  electrocardiogram; ECHO   echocardiogram; ECOG   Easter n Cooperative Oncology Group; eCRF  electronic case report form; 
EOI  end of infusion; EOT  end of treatment; FFPE   formalin -fixed  paraffin -embedded; FSH   follicle  stimulating  hormone; FT4  free thyroxine; 
HBcAb   anti-hepatitis B antibody; HBsAg  hepatitis B antigen; HCV  hepatitis C; HIV   human immunodeficiency virus; HR  heart rate; IGF -1  insulin -like growth 
factor 1; IV   intravenous; LH  luteinizing hormone; MUGA   multigated acquisition; LDH  lactate dehydrogenase; LTFU  long-term follo w-up; MRI  magnetic 
resonance imaging; PD  progressive disease; PK  pharmacokinetic; Pre  pre-infusion; Q cyc  every cycle; Q2 
Cyc  every 2 cycles; RECIST  response evaluation criteria in solid tumors; RR   respiratory rate; SCR  screening; SFU  safety follow -up; SOI  start of infusion; 
TLS  tumor lysis syndrome; TSH  thyroid stimulating hormone  
a All screening procedures should be performed within  prior to cycle  1  dosing.   
b Each visit week and day is relative to  of each cycle.  cycle  1 and 2 visits have a  1-day window from designated time point unless otherwise specified.  All 
subsequent visits beginning in cycle  3 will have a  3-day window.  
c See Section  6.2.1.3  for more details regarding Step Dosing.  
d  End of infusion (EOI) assessments or procedures are to be completed immediately after infusion of tarlatamab.  EOI indicates the time when the 
investigational product infusion and saline flush is completed.  Assessments after EOI indicate the time relative to EOI.  In vestigational product infusions are 
marked in the EOI column.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 175 of 176 
CONFIDENTIAL    
 Assessments are done pre -infusion unless specified.  
 Laboratory assessments that were done within 24 hours prior to infusion do not need to be repeated (except for cycle  1  dosing where laboratory 
assessments that were done within 48 hours prior to infusion do not need to be  repeated).  
 All assessments and procedures should be collected at the exact nominal time point as noted in the Schedule of Assessments.  If unable to perform a 
procedure at the specified nominal time point, collect it as close as possible to the nominal ti me point and record the actual collection time.  
e Clinical evaluation including physical exam, ECOG, weight and neurological exams, writing test, and mini -mental status exams (neurology specialty consultation 
service as clinically indicated).  Mini mental  status exams and writing test are required on (if  clinical evaluation required per dosing regimen), 
(may be performed if clinically indicated on ) in cycle  1.  Mini mental status exam and writin g test may be performed in 
cycle  2 and beyond at the investigator’s discretion.  Performed at screening only:  demographics, medical history, and height.  Cli nical evaluation should be 
completed within 6  hours prior to the first dose of tarlatamab.  
f Vital signs (BP, HR, RR, temp) and pulse oximetry will be assessed.  Vitals will be taken pre -AMG  404 infusion and at AMG  404 EOI.  
  For each 
tarlatamab -infusion for the first 2 cycles (during the hospitalization period) vital signs should be assessed as detailed in Section  8.4.1 . 
g ECGs will be collected once and considered safety ECGs.  ECGs should be collected prior to blood draws when assessments are conducted at the same 
nominal time point (pre -infusion timepoint s for tarlatamab and AMG  404 may be collected 15 minutes prior to infusion, post -infusion time points for tarlatamab 
may be collected ± 15 minutes of indicated time point).  See Section  8.4.5 . 
h For cycles  1 and 2 only, please collect LDH, phosphorus, and uric acid along with the chemistry panel for TLS monitoring.  
i Serum pregnancy test at screening; serum or urine pregnancy test monthly until  from the last investigational product (tarlatamab or AMG  404) dose.  
Additionally, a pregnancy test at  after last dose of AMG  404. 
j Safety endocrine panels:  ACTH, cortisol, TSH, and FT4 will be evaluated at screening,  of every cycle starting with cycle  2, EOT, and SFU -1.  Prolactin, 
FSH, LH, testosterone (in males) and estradiol (in females) will be evaluated only at screening, EOT, and as clinically in dicated.  
m A tumor biopsy is required at screening if patient has received any treatment prior to participating into this study and biop sy can be performed safely as 
determined by the investigators.  Tumor tissue (archival or fresh biopsy) must be available.  Subject s must consent to allow the acquisition of FFPE material 
(block or unstained slides) by study personnel.   
q For cycles  3 and 4, collect tarlatamab PK samples at pre - and post -infusion.  For all remaining cycles beginning with cycle  5, collect at pre -infusion only.  
tarlatamab PK samples to be collected until end of cycle  12 only  
r AMG  404 PK samples to be collected at pre-infusion and end of infusion in cycles  3, 5, 7, 9, and 11 and at pre -infusion in cycles  4, 6, 8, 10, and 12.  

Product:   Tarlatamab (AMG  757), AMG  404 
Protocol Number:   20200439  
Date:   05 June 2024  Page 176 of 176 
CONFIDENTIAL    
u Dexamethasone  mg IV (or equivalent dose of other corticosteroids) will be administered within 1 hour prior to all tarlatama b doses, in week 1 and step doses of 
tarlatamab in cycle  1 only.  
v Refer to Section  6.1.4  for administration details.  
x All subjects must have MRI/CT of the brain performed within 21 days prior to the first dose of tarlatamab.  All brain scans on protocol are required to be MRI 
unless MRI is contraindicated, then CT with contrast is acceptable.  Subsequently, MRI brain can be performed at any time if clinically indicated per standar d of 
care.  
y 
 Tumor burden assessments will be performed based on modified RECIST 1.1  guidelines (see Section  11.9).  
 
 
aa LTFU will be conducted every 3 months (  2 weeks) for 1 year from the first dose of tarlatamab on all subjects who have not withdrawn consent by clinic visit, 
telephone, or chart review to assess for survival and/or the commencement of subsequent cancer therapy only. If the investiga tor becomes aware of serious 
adverse events suspected to be related to investigational product or any fatal adverse event (regardless of causality) after the protocol -required reporting period 
(as defined in Section 8.4.9.1.3 ) is complete, then these serious adverse events will be reported to Amgen immediately and no later than 24 hours following t he 
investigator’s awareness of the event on the Event eCRF.  
bb Assessments to be completed at specified timepoint beginning with cycle  3 and at each subsequent cycle unless otherwise specified.  
cc For cycles  3 and 4 only:  please collect ECG post -tarlatamab infusion.  No further ECG’s are collected after cycle  4.   
dd For subjects who discontinued treatment for any reason other than confirmed PD, every effort should be made to perform radiog raphic imaging (CT/MRI) of the 
chest, abdomen, pelvis, and all other known sites of disease every 3 months until documentation o f confirmed PD per modified RECIST 1.1, clinical 
progression, start of new anticancer therapy, or up to 12 months after the first dose of tarlatamab, whichever occurs first.   
ee The first safety follow -up visit should be completed  from the last dose (tarlatamab or AMG  404).  
ff The second safety follow -up visit should be completed after the last dose of AMG  404 or prior to initiation of other therapy, whichever occurs first.  
hh After end of study, serious adverse events suspected to be related to investigational product will be reported to Amgen.  Ple ase refer to Section  8.4.9.1.3  for 
additional details.  
 
 

Product:  Tarlatamab (AMG 757), AMG 404  
Protocol Number:  20200439  
Date:  05 June  2024 Page 1 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0   
 Amendment 5  
Protocol Title:  A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in 
Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)   
 
Amgen Protocol Number AMG 757, AMG 404, 20200439  
EudraCT number:  2020 -005957 -26 
Study ID: [REMOVED]  
 
Amendment Date:  05 June  2024 
 
Rationale:  
This protocol is primarily being amended to align with the latest  updates to the Core 
Risks and Discomforts section of the informed consent form (ICF) . 
The following changes were also incorporated into the protocol:  
 Updated the version number and date of the amendment.  
 Updated the safety follow -up period for tarlatamab  throughout the protocol , to 
 (previously ) following  the last dose . 
 Updated the second safety follow -up period for AMG 404 throughout the protocol, to 
 (previously ) following the last dose.  
 Updated the timeframe for using contraception following the last dose of tarlatamab  
throughout the protocol , which has now been updat ed to  for female 
subjects (previously )  and male subjects and their female partners 
(previously ).  
 Added new Section 2.3.3.1.1.2 , Immune Effector Cell -Associated Neurotoxicity 
Syndrome (ICANS)  and its support care and risk management guidelines in the new 
Section 6.8.2 , since ICANS has been ident ified as a common side -effect of 
tarlatam ab in the Core Risks and Discomforts section of the informed consent form 
(ICF) . 
 Added language to  Sections 8.4.9.1.1 , Adverse Events  and 8.4.9.1.2, Serious 
Adverse Events, to clarify that investigator is responsibl e for collection of adverse 

Product:  Tarlatamab (AMG 757), AMG 404  
Protocol Number:  20200439  
Date:  05 June  2024 Page 2 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0   
 events and serious adverse events, 30 days after the last dose of investigational 
product (s) or after the second safety follow -up, whichever is later . 
 Updated Section 11.5 , Appendix 5, Contraceptive Guidance and Collection of 
Pregnancy and Lactation Information  for: 
 barrier contraceptive methods  for female subjects and female partners of 
male subjects . 
 condoms with spermicide for male subjects  
 conditions for  not using additional forms of contraception for male subjects 
during the study . 
 Administrative, abbreviations, numbering, grammatical and  editorial changes have 
been made throughout the protocol for clarification.  
Product:  Tarlatamab (AMG 757), AMG 404  
Protocol Number:  20200439  
Date:  10 Novem ber 2023  Page 1 of 1 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0   
 Amendment 4   
Protocol Title:  A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in 
Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)   
 
Amgen Protocol Number AMG 757, AMG 404, 20200439  
EudraCT number:  2020 -005957 -26 
Study ID: [REMOVED]  
 
Amendment Date:  10 November  2023  
 
Rationale:  
This protocol is mainly being amended to specify the conditions to be met for the 
continuation of tarlatamab treatment in subjects with radiologic disease progression, who 
continue to have clinical benefits as per the in vestigator’s judgement.  A new section 
(Section 7.2) has been added to elaborate the conditions to be met and language is 
being included throughout to update/clarify the protocol.  The following changes were 
also incorporated into the protocol:  
 Updated the key sponsor contact as  MD and also updated the relevant 
contact details.  
 Added language to the rationale in Section 1.1 and Section 2.1 to clarify that 
AMG  404 has been evaluated as a monotherapy agent.  
 Added footnotes in the schedule  of assessment tables (Table 1 -2, Table 11 -8 and 
11-9) to clarify the reporting requirements of serious adverse events.  
 Removed sucrose -mediated renal impairment as a potential safety concern for 
tarlatamab and deleted language related to this throughout t he protocol.  
 Deleted language related to first -in-human study in Section 4.4.1.1.  
 Clarified the requirements for recording and reporting of serious adverse events in 
Section  8.4.9.1.2 and Section  8.4.9.1.3 and changes associated with this were 
updated thro ughout the protocol.  
 Clarified the timing for collecting pregnancy and lactation details for female subjects 
and female partners of male subjects after tarlatamab treatment in Section  8.4.9.6 
and associated changes were updated throughout the protocol.  
 Administrative, grammatical and editorial changes have been made throughout the 
protocol for clarification.  

Product:  Tarlatamab (AMG  757), AMG  404 
Protocol Number:  20200439  
Date:  04 April  2023  Page 1 of 22 
 
Amendment 3 
Protocol Title:  A Phase  1b Study Evaluating the Safety and Efficacy of AMG  757 in 
Combination with AMG  404 in Subjects with Small Cell Lung Cancer (SCLC)  
 
Amgen Protocol Number Tarlatamab  20200439  
  
Amendment Date:  04 April 2023  
 

Product:  Tarlatamab ( AMG 757 ), AM G 404  
Protocol Number:  20200439  
Date:  28 January 2022  Page 1 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0   
 Amendment 2  
Protocol Title:  A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in 
Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)  
 
Amgen Protocol Number AMG 757, AMG 404, 20200439  
EudraCT number:  2020 -005957 -26 
Study ID: [REMOVED]  
 
Amendment Date:  28 January 2022  
 
Rationale:  
This protocol is being amended to address site shortages of tocilizumab.  Applicable 
sections of the protocol are being  modified to clarify the use of siltuximab in place of 
tocilizumab for the treatment of potential cytokine release syndrome (CRS) during a 
treatment -related adverse event.  Language is being included throughout to 
update/clarify the protocol.  Changes incl uding, but not limited to, the following were 
incorporated into the protocol:  
 Added language to include neutropenia as a risk following study treatment 
administration and guidance for treatment of neutropenia  
 Criteria for use of siltuximab in place of tocilizumab, justification for the proposed 
dose and schedule, and safety stopping rules were included  
 Updated schedule of assessment (SOA) to exclude antineutrophil cytoplasmic 
antibodies (ANCA)/antinuclear antibody (ANA) testing as a clinical test; to mo dify 
fresh tumor biopsies language to allow biopsies on subjects who provide consent at 
the end of cycle 2 and end of treatment (EOT) ; and to clarify that safety endocrine 
panels are to be evaluated day 1 of every cycle starting with cycle 2  
 Updated the SOA timepoint s for the electrocardiogram ( ECG ), Coagulation, Lipases 
and amylase, C reactive protein ( CRP), and ferritin  assessments   
 Updated AMG  757 and AMG  404 background clinical experience and key safety 
information sections , and  AMG  757 toxicology section  to reflect latest version of the 
Investigator’s Brochure (IB)  
 Updated restarting AMG 757 dosing rules to allow resuming of dosing if the toxicities 
resolve to grade  1 or return to subjects’ baseline values within 3 weeks, instead of 
4 weeks  
 Update end of study section to increase the total study duration from 12 to 
24 months  
Product:  Tarlatamab ( AMG 757 ), AM G 404  
Protocol Number:  20200439  
Date:  28 January 2022  Page 2 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0   
  Update table for monitoring and management of pituitary gland dysfunction to align 
with latest approved AMG 757 protocol  
 Updated long -term follow -up language to continue radiographic imaging for subjects 
that discontinued treatment for any reason  
 Updated language in dosage formulation and dosing instructions in  Table  6-1 of 
investigational products   
 Updated language in vital signs and pulse oximetry section to exclude supine 
position ing as a requirement for vital signs to be measured  
 Updated language on recording and reporting of serious adverse events.  
 Updated contraception and pregnancy language  
 Added vaccine and COVID -19 language  
 Included hypothyroidism, colit is, myasthenia gravis, and other additional risks as 
potential safety risk to AMG 404 based on recent available clinical data   
 Administrative and editorial changes have been made throughout the protocol for 
clarification  
Product:  AMG 757, AMG 404  
Protocol Number:  2020043 9 
Date:  26 July 2021  Page 1 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Amendment 1  
Protocol Title:  A Phase 1b Study Evaluating the Safety and Efficacy of 
AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung 
Cancer (SCLC)  
 
Amgen Protocol Number:  AMG 757, AMG 404 20200439  
 
Amendment Date:  26 July  2021  

Product:  AMG 757, AMG 404  
Protocol Number:  2020043 9 
Date:  26 July 2021  Page 2 of 2 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 

Approval Signatures
Document Name: Protocol Amendment tarlatamab 20200439 5
Document Description: 20200439 Protocol Amendment
Document Number: CLIN-000259408
Approval Date: 06 Jun 2024
Type of Study Protocol: Amendment
Protocol Amendment No.: 5
Document Approvals
Reason for Signing: ManagementName: 
Date of Signature: 05-Jun-2024 23:30:10 GMT+0000
Reason for Signing: ManagementName: 
Date of Signature: 06-Jun-2024 03:55:59 GMT+0000
